<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003804.pub2" GROUP_ID="DEMENTIA" ID="796202051716121960" MERGED_FROM="" MODIFIED="2017-06-15 11:20:32 +0100" MODIFIED_BY="Sue Marcus" REVIEW_NO="" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.0">
<COVER_SHEET MODIFIED="2017-06-13 12:08:50 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2017-02-21 11:59:55 +0000" MODIFIED_BY="Sue Marcus">Effect of the treatment of Type 2 diabetes mellitus on the development of cognitive impairment and dementia</TITLE>
<CONTACT>
<PERSON ID="12995" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Almudena</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Areosa Sastre</LAST_NAME>
<SUFFIX/>
<POSITION>Geriatrician</POSITION>
<EMAIL_1>almudena.areosa2@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Geriatric Unit</DEPARTMENT>
<ORGANISATION>Hospital Universitario de Getafe</ORGANISATION>
<ADDRESS_1>Carretera de Toledo (Km 12,500)</ADDRESS_1>
<ADDRESS_2/>
<CITY>Madrid</CITY>
<ZIP>28905 Getafe (Madrid)</ZIP>
<REGION/>
<COUNTRY CODE="ES">Spain</COUNTRY>
<PHONE_1>+34 91 683 93 60</PHONE_1>
<PHONE_2>+34 620 876 659</PHONE_2>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2017-06-13 12:07:50 +0100" MODIFIED_BY="Sue Marcus">
<PERSON ID="12995" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Almudena</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Areosa Sastre</LAST_NAME>
<SUFFIX/>
<POSITION>Geriatrician</POSITION>
<EMAIL_1>almudena.areosa2@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Geriatric Unit</DEPARTMENT>
<ORGANISATION>Hospital Universitario de Getafe</ORGANISATION>
<ADDRESS_1>Carretera de Toledo (Km 12,500)</ADDRESS_1>
<ADDRESS_2/>
<CITY>Madrid</CITY>
<ZIP>28905 Getafe (Madrid)</ZIP>
<REGION/>
<COUNTRY CODE="ES">Spain</COUNTRY>
<PHONE_1>+34 91 683 93 60</PHONE_1>
<PHONE_2>+34 620 876 659</PHONE_2>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="z1402250931410462437091445028514" ROLE="AUTHOR">
<PREFIX>Mr</PREFIX>
<FIRST_NAME>Robin</FIRST_NAME>
<MIDDLE_INITIALS>WM</MIDDLE_INITIALS>
<LAST_NAME>Vernooij</LAST_NAME>
<SUFFIX/>
<POSITION>Research associate</POSITION>
<EMAIL_1>rwmvernooij@cochrane.es</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Iberoamerican Cochrane Centre</ORGANISATION>
<ADDRESS_1>&#8203;C/ Sant Antoni Maria Claret 167</ADDRESS_1>
<ADDRESS_2/>
<CITY>Barcelona</CITY>
<ZIP>08025</ZIP>
<REGION>Barcelona</REGION>
<COUNTRY CODE="ES">Spain</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="30202201467708740415110824145416" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Magali</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>González-Colaço Harmand</LAST_NAME>
<SUFFIX/>
<POSITION>Geriatric Physician</POSITION>
<EMAIL_1>magaligch@hotmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>00 34 655 45 70 75</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>UCICEC</DEPARTMENT>
<ORGANISATION>University hospital of Canary Islands</ORGANISATION>
<ADDRESS_1>C/ Ofra s/n</ADDRESS_1>
<ADDRESS_2/>
<CITY>La Laguna</CITY>
<ZIP>38320</ZIP>
<REGION>Santa Cruz de Tenerife</REGION>
<COUNTRY CODE="ES">Spain</COUNTRY>
<PHONE_1>00 34 922 67 8115</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="z1411101445529436440705715292412" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Gabriel</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Martínez</LAST_NAME>
<SUFFIX>MD</SUFFIX>
<POSITION>Researcher</POSITION>
<EMAIL_1>gmartinez@cochrane.es</EMAIL_1>
<EMAIL_2>gmartinezfuentes@gmail.com</EMAIL_2>
<URL/>
<MOBILE_PHONE>(+34)625713253</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Iberoamerican Cochrane Centre</ORGANISATION>
<ADDRESS_1>C/ Sant Antoni Maria Claret 167</ADDRESS_1>
<ADDRESS_2>Pavelló 18 Planta 0</ADDRESS_2>
<CITY>Barcelona</CITY>
<ZIP>08025</ZIP>
<REGION>Barcelona</REGION>
<COUNTRY CODE="ES">Spain</COUNTRY>
<PHONE_1>+34935537814</PHONE_1>
<PHONE_2/>
<FAX_1>+34935537809</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2017-02-14 14:22:00 +0000" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="15" MONTH="10" YEAR="2016"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="15" MONTH="10" YEAR="2016"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="15" MONTH="4" YEAR="2018"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2002"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2002"/>
<LAST_CITATION_ISSUE ISSUE="6" YEAR="2017"/>
</DATES>
<WHATS_NEW MODIFIED="2017-06-13 12:08:50 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2017-06-13 12:08:46 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="14" MONTH="6" YEAR="2017"/>
<DESCRIPTION>
<P>An update search was performed for this review on 15 October 2016. New studies found for inclusion. Conclusions unchanged. Authors changed.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2017-06-13 12:08:50 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="14" MONTH="6" YEAR="2017"/>
<DESCRIPTION>
<P>An update search was performed for this review on 15 October 2016. Review updated. New studies found for inclusion. Conclusions remained unchanged. Author team has changed.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2017-05-31 23:14:46 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2017-05-31 23:14:43 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="24" MONTH="5" YEAR="2011"/>
<DESCRIPTION>
<P>An update search was performed for this review on 24 May 2011.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-10-10 14:44:06 +0100" MODIFIED_BY="Helen Collins">
<DATE DAY="10" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2017-05-31 23:14:40 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="10" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>An update search was run in January 2008, which retrieved some studies for consideration by the authors.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2017-05-31 23:14:37 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="21" MONTH="7" YEAR="2008"/>
<DESCRIPTION>
<P>Substantive amendment.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2017-05-31 23:14:46 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="16" MONTH="11" YEAR="2005"/>
<DESCRIPTION>
<P>An update search was run in August 2005 but no new studies for inclusion or exclusion were retrieved.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2017-02-14 14:20:46 +0000" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES MODIFIED="2017-02-14 14:20:46 +0000" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2017-02-14 14:20:46 +0000" MODIFIED_BY="[Empty name]">
<NAME>NIHR</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>This update was supported by the National Institute for Health Research (NIHR), via a Cochrane Programme Grant to the Cochrane Dementia and Cognitive Improvement group. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, National Health Service or the Department of Health</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2017-06-06 13:42:16 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2017-05-31 21:21:16 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2017-02-02 13:02:31 +0000" MODIFIED_BY="[Empty name]">Effect of the treatment of Type 2 diabetes mellitus on the development of cognitive impairment and dementia</TITLE>
<SUMMARY_BODY MODIFIED="2017-05-31 21:21:16 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Background</B>
</P>
<P>Dementia is a global healthcare concern. Type 2 diabetes mellitus &#8212; a form of diabetes which becomes commoner with older age &#8212; increases the risk of developing dementia. Type 1 diabetes, which typically begins earlier in life, is always treated with insulin; but there are a variety of different ways of treating Type 2 diabetes, including lifestyle changes and different medications. We wanted to find out if some ways of treating Type 2 diabetes were better than others in terms of preventing either dementia or less serious decline in cognition (memory and other thinking skills).</P>
<P>
<B>What we did</B>
</P>
<P>We searched medical databases for clinical trials in which participants had been assigned at random to different treatments for Type 2 diabetes and in which cognition had been measured at the beginning and end of the trial. We were only interested in treatments for Type 2 diabetes which are recommended by international clinical practice guidelines (CPGs). We analysed data from the studies we found, looking for effects on dementia and cognition, death rates and the side effect of hypoglycaemia, which is when blood glucose levels fall too low and which can be a result of treatment.</P>
<P>
<B>Key results</B>
</P>
<P>We found seven randomised trials suitable for inclusion in this review, but we could only get data on cognition from four of them. Of these, the two larger studies had a total of 13,934 participants and compared a standard treatment strategy with a more intensive strategy which aimed to keep blood glucose lower. Two smaller studies, which each had approximately 150 participants, compared different drug treatments, but in both studies one of the treatments was a drug which is not generally considered suitable for older patients. We found no good evidence that any of the treatments in these studies was clearly superior to any other for preventing dementia or cognitive decline. An intensive treatment strategy was more likely than standard treatment to cause hypoglycaemia, but there were no differences in death rates.</P>
<P>
<B>Quality of evidence</B>
</P>
<P>We judged the quality of the evidence for all outcomes to be low or moderate due to risk of bias in the included studies, small sample sizes, and imprecise estimates of the effects. This means that our confidence in the results is limited.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2017-06-06 08:45:55 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2017-04-25 20:42:11 +0100" MODIFIED_BY="[Empty name]">
<P>Prevention of cognitive impairment and dementia is an important public health goal. Epidemiological evidence shows a relationship between cognitive impairment and Type 2 diabetes mellitus. The risk of dementia increases with duration of disease. This updated systematic review investigated the effect on cognitive function of the type of treatment and level of metabolic control in people with Type 2 diabetes.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2017-02-13 19:42:36 +0000" MODIFIED_BY="[Empty name]">
<P>To assess the effects of different strategies for managing Type 2 diabetes mellitus on cognitive function and the incidence of dementia.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2017-06-03 20:04:02 +0100" MODIFIED_BY="[Empty name]">
<P>We searched ALOIS (the Specialized Register of the Cochrane Dementia and Cognitive Improvement Group (CDCIG)), the Cochrane Library, MEDLINE, Embase, PsycINFO, CINAHL and LILACS on 15 October 2016. ALOIS contains records from all major health care databases, (CENTRAL, MEDLINE, Embase, PsycINFO, CINAHL, LILACS), as well as from many trials' registers and grey literature sources.<BR/>
</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2017-04-25 20:42:22 +0100" MODIFIED_BY="[Empty name]">
<P>We included randomised controlled trials (RCTs) which compared two or more different treatments for Type 2 diabetes mellitus and in which cognitive function was measured at baseline and after treatment.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2017-02-13 19:46:04 +0000" MODIFIED_BY="[Empty name]">
<P>Two review authors independently extracted data and assessed the quality of the included RCTs. We pooled data for comparable trials and estimated the effects of treatment by using risk ratios (RRs) and mean differences (MDs), according to the nature of the outcome. We assessed the quality of the evidence using GRADE methods.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2017-06-06 08:45:55 +0100" MODIFIED_BY="[Empty name]">
<P>We identified seven eligible studies but only four provided data we could include in efficacy analyses. Two of these studies compared intensive versus standard glycaemic control and two compared different pharmacological treatments. All studies were at unclear risk of bias in at least two domains and one large study was at high risk of performance and detection bias.</P>
<P>(a) Two studies with 13,934 participants at high cardiovascular risk provided efficacy data on intensive versus standard glycaemic control. A third study with 1791 participants provided additional data on hypoglycaemic episodes and mortality. There is probably no difference between treatment groups in the number of participants who decline by at least 3 points on the Mini&#8211;Mental State Examination (MMSE) over five years (RR 0.98, 95% CI 0.88 to 1.08; 1 study; n = 11,140; moderate-quality evidence); and there may also be little or no difference in the incidence of dementia (RR 1.27, 95% CI 0.87 to 1.85; 1 study; n = 11,140; low-quality evidence). From another study, there was probably little or no difference in MMSE score after 40 months (MD &#8722;0.01, 95% CI &#8722;0.18 to 0.16; 1 study; n = 2794; moderate quality evidence). Participants exposed to the intensive glycaemic control strategy probably experience more episodes of severe hypoglycaemia than those who have standard treatment (RR 2.18, 95% CI 1.52 to 3.14; 2 studies; n = 12,827; moderate-quality evidence). The evidence from these trials suggests that the intensity of glycaemic control may have little or no effect on all-cause mortality (RR 0.99, 95% CI 0.87 to 1.13; 3 studies; n = 15,888; low-quality evidence).</P>
<P>(b) One study with 156 participants compared glibenclamide (glyburide) with repaglinide. There may be a small advantage of glibenclamide on global cognitive function measured with the MMSE after 12 months (MD &#8722;0.90, 95% CI &#8722;1.68 to &#8722;0.12; low-quality evidence). No data were reported on the incidence of dementia, hypoglycaemic events or all-cause mortality.</P>
<P>(c) One study with 145 participants compared rosiglitazone plus metformin to glibenclamide (glyburide) plus metformin over 24 weeks. It reported only on cognitive subdomains and not on global cognitive function, incidence of MCI or dementia, hypoglycaemic events or all causes of mortality.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2017-06-03 15:52:35 +0100" MODIFIED_BY="[Empty name]">
<P>We found no good evidence that any specific treatment or treatment strategy for Type 2 diabetes can prevent or delay cognitive impairment. The best available evidence related to the comparison of intensive with standard glycaemic control strategies. Here there was moderate-quality evidence that the strategies do not differ in their effect on global cognitive functioning over 40 to 60 months.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2017-06-06 13:42:16 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2017-06-06 12:59:26 +0100" MODIFIED_BY="[Empty name]">
<P>According to the World Health Organization (WHO), dementia affects 47 million people worldwide. Every year there are 9.9 million new cases. The world total is expected to increase to 75.6 million in 2030 and 135.5 million in 2050 (<LINK REF="REF-WHO-2017" TYPE="REFERENCE">WHO 2017</LINK>). Also according to the WHO, 422 million people worldwide have diabetes, a number likely to more than double in the next 20 years (<LINK REF="REF-WHO-2016b" TYPE="REFERENCE">WHO 2016b</LINK>). Both dementia and diabetes mellitus represent major public health problems since both are associated with long-term disability.</P>
<CONDITION MODIFIED="2017-06-06 12:59:26 +0100" MODIFIED_BY="[Empty name]">
<P>Diabetes mellitus can be divided into two major categories. Type 1 diabetes mellitus is an autoimmune disorder in which the insulin-producing beta cells in the pancreas are destroyed. It typically begins in childhood or early adulthood (<LINK REF="REF-Atkinson-1994" TYPE="REFERENCE">Atkinson 1994</LINK>), although it can occur in adults as well (<LINK REF="REF-ADA-2017a" TYPE="REFERENCE">ADA 2017a</LINK>). Type 2 diabetes mellitus is characterised by insulin resistance in peripheral tissues and progressive dysfunction of beta pancreatic cells (<LINK REF="REF-Kahn-2014" TYPE="REFERENCE">Kahn 2014</LINK>). It usually affects adults, its prevalence increasing with age.</P>
<P>Diabetes may be diagnosed based either on the fasting plasma glucose (FPG) or the plasma glucose two hours after a 75 g oral glucose tolerance test (2-h PG) &#8212; the plasma glucose criteria; or on the level of glycated haemoglobin in the blood &#8212; the HbA1c criteria (<LINK REF="REF-ADA-2017a" TYPE="REFERENCE">ADA 2017a</LINK>).</P>
<P>There are a number of serious complications associated with diabetes. These have traditionally been divided into microvascular complications (retinopathy, neuropathy, and nephropathy) and macrovascular complications (cardiovascular and cerebrovascular disease) (<LINK REF="REF-Wright-2016" TYPE="REFERENCE">Wright 2016</LINK>).</P>
<P>Cognition is a term used to describe a set of higher cerebral functions, including memory, language, executive function, attention, perception and social behaviour. Dementia is a condition of cognitive impairment, usually progressive and irreversible, which involves a significant decline from a previous level of function and which interferes with independence in everyday activities (<LINK REF="REF-DSM_x002d_5-2013" TYPE="REFERENCE">DSM-5 2013</LINK>). The greatest risk factor for dementia is increasing age. The most common diseases that lead to dementia are Alzheimer's disease (AD) and cerebrovascular diseases (<LINK REF="REF-Morris-2003" TYPE="REFERENCE">Morris 2003</LINK>).</P>
<P>In recent years, important epidemiological evidence has been gathered regarding the relationship between diabetes, cognitive dysfunction and dementia. No evidence of a substantial long-term decline in cognitive function has been found in a large group of patients with Type 1 diabetes followed for an average of 18 years (<LINK REF="REF-DCCT_x002f_EDIC-2007" TYPE="REFERENCE">DCCT/EDIC 2007</LINK>), although this remains somewhat controversial (<LINK REF="REF-Kodl-2008" TYPE="REFERENCE">Kodl 2008</LINK>). Cognitive changes have been described in Type 2 diabetes, affecting mainly learning and memory, mental flexibility and mental speed (<LINK REF="REF-Kodl-2008" TYPE="REFERENCE">Kodl 2008</LINK>). People with Type 2 diabetes mellitus have been reported to have a risk of developing dementia 1.5 to 2 times higher than people without diabetes (<LINK REF="REF-Ott-1999" TYPE="REFERENCE">Ott 1999</LINK>; <LINK REF="REF-Gregg-2000" TYPE="REFERENCE">Gregg 2000</LINK>; <LINK REF="REF-Cukierman-2005" TYPE="REFERENCE">Cukierman 2005</LINK>). A more recent meta-analysis by <LINK REF="REF-Cheng-2012" TYPE="REFERENCE">Cheng 2012</LINK> found the relative risk of developing dementia in people with diabetes versus those without diabetes to be 1.46 for dementia due to Alzheimer's disease and 2.48 for vascular dementia. Diabetes mellitus and pre-diabetes have also been found to accelerate the rate of progression from mild cognitive impairment to dementia (<LINK REF="REF-Xu-2010" TYPE="REFERENCE">Xu 2010</LINK>). Patients with Type 2 diabetes and established dementia have been found to be less likely to receive adequate diabetic care compared with those who have diabetes alone (<LINK REF="REF-Bunn-2014" TYPE="REFERENCE">Bunn 2014</LINK>). The relationship between diabetes and dementia is likely to be complex and multifactorial.</P>
<P>Patients with Type 2 diabetes mellitus often have other cardiovascular risk factors and conditions, including high blood pressure, dyslipidaemia, cardiovascular disease, and cerebrovascular diseases that may contribute to cognitive impairment (<LINK REF="REF-Prince-1996" TYPE="REFERENCE">Prince 1996</LINK>; <LINK REF="REF-Kilander-1998" TYPE="REFERENCE">Kilander 1998</LINK>; <LINK REF="REF-Rockwood-2002" TYPE="REFERENCE">Rockwood 2002</LINK>). Macrovascular disease, both peripheral and cerebral, is associated with dementia risk in patients with Type 2 diabetes mellitus (<LINK REF="REF-Bruce-2008" TYPE="REFERENCE">Bruce 2008</LINK>). Cerebrovascular disease underlies vascular and mixed dementia and it has also been suggested that it triggers a series of events that lead to Alzheimer's disease (<LINK REF="REF-De-la-Torre-2000" TYPE="REFERENCE">De la Torre 2000</LINK>; <LINK REF="REF-Kalaria-2000" TYPE="REFERENCE">Kalaria 2000</LINK>; <LINK REF="REF-Shi-2000" TYPE="REFERENCE">Shi 2000</LINK>).</P>
<P>Patients with diabetes may develop microvascular disease, manifested as diabetic nephropathy and retinopathy. Albuminuria, an indicator of nephropathy, is associated with accelerated cognitive impairment (<LINK REF="REF-Barzilay-2013" TYPE="REFERENCE">Barzilay 2013</LINK>). It has also been shown that diabetic retinopathy is associated with dementia risk in patients with Type 2 diabetes mellitus (<LINK REF="REF-Exalto-2014" TYPE="REFERENCE">Exalto 2014</LINK>).</P>
<P>Diabetes has a bidirectional association with depression, which is associated with dementia (<LINK REF="REF-Hugo-2014" TYPE="REFERENCE">Hugo 2014</LINK>; <LINK REF="REF-Tab_x00e1_k-2014" TYPE="REFERENCE">Tabák 2014</LINK>).</P>
<P>Insulin receptors are widely distributed in the brain, especially on neurons in areas concerned with memory and learning, such as the hippocampus and parts of the cerebral cortex (<LINK REF="REF-Wickelgren-1998" TYPE="REFERENCE">Wickelgren 1998</LINK>). It is possible that insulin disorders may affect the utilisation of glucose in these areas. Type 2 diabetes also causes extensive disturbances in brain insulin and insulin-like growth factor signalling mechanisms, which could promote molecular, biochemical, and histopathological lesions in AD (<LINK REF="REF-de-la-Monte-2008" TYPE="REFERENCE">de la Monte 2008</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2017-06-03 16:11:14 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment for a patient with Type 2 diabetes should be individualised, taking into account the patient's characteristics and comorbidities (<LINK REF="REF-NICE-2016" TYPE="REFERENCE">NICE 2016</LINK>; <LINK REF="REF-AACE_x002f_ACE-2017" TYPE="REFERENCE">AACE/ACE 2017</LINK>; <LINK REF="REF-ADA-2017b" TYPE="REFERENCE">ADA 2017b</LINK>). International clinical practice guidelines (CPGs) and consensus standards vary, but all agree that the first line of treatment should include lifestyle changes, such as exercise and weight loss. Counselling may be provided to support these goals (<LINK REF="REF-NICE-2016" TYPE="REFERENCE">NICE 2016</LINK>; <LINK REF="REF-AACE_x002f_ACE-2017" TYPE="REFERENCE">AACE/ACE 2017</LINK>; <LINK REF="REF-ADA-2017c" TYPE="REFERENCE">ADA 2017c</LINK>). Additional pharmacological treatment may also be offered at the time of diagnosis (<LINK REF="REF-AACE_x002f_ACE-2017" TYPE="REFERENCE">AACE/ACE 2017</LINK>); and is recommended if lifestyle recommendations do not achieve glycaemic goals (<LINK REF="REF-NICE-2016" TYPE="REFERENCE">NICE 2016</LINK>; <LINK REF="REF-ADA-2017b" TYPE="REFERENCE">ADA 2017b</LINK>).</P>
<P>There are many different drugs available to treat Type 2 diabetes, including metformin, sulphonylureas, thiazolidinediones, dipeptidyl-peptidase 4 (DPP-4) inhibitors, sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide 1 (GLP-1) agonists and insulin (<LINK REF="REF-NICE-2016" TYPE="REFERENCE">NICE 2016</LINK>; <LINK REF="REF-AACE_x002f_ACE-2017" TYPE="REFERENCE">AACE/ACE 2017</LINK>; <LINK REF="REF-ADA-2017b" TYPE="REFERENCE">ADA 2017b</LINK>). Depending on the level of HbA1c, treatment may start with a single agent, commonly metformin, or a combination of drugs. The treatment becomes more complex if satisfactory glycaemic control is not achieved over time. Important factors influencing the choice of drug treatment relate to the overall health condition of the patient, especially considering the risk of hypoglycaemia, comorbidities, functional status, remaining life expectancy, renal disease, and macrovascular complications (<LINK REF="REF-NICE-2016" TYPE="REFERENCE">NICE 2016</LINK>; <LINK REF="REF-AACE_x002f_ACE-2017" TYPE="REFERENCE">AACE/ACE 2017</LINK>; <LINK REF="REF-ADA-2017b" TYPE="REFERENCE">ADA 2017b</LINK>); and the presence and degree of cognitive impairment or dementia (<LINK REF="REF-ADA-2017d" TYPE="REFERENCE">ADA 2017d</LINK>).</P>
<P>In recent years, intensive treatment strategies have been proposed to reduce the risk of micro- and macrovascular complications. However, the more intensive the treatment, the greater the risk of adverse effects such as hypoglycaemia and higher mortality. Therefore, intensive treatment might be not suitable in those at high risk of treatment complications (<LINK REF="REF-ADA-2017d" TYPE="REFERENCE">ADA 2017d</LINK>; <LINK REF="REF-ADA-2017e" TYPE="REFERENCE">ADA 2017e</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2017-06-03 16:15:39 +0100" MODIFIED_BY="[Empty name]">
<P>Different drug treatments may have differential effects on dementia risk due to different actions on pathophysiological processes at the molecular level or different effects on other risk factors for cognitive decline. Hyperglycaemia is a risk factor for dementia (<LINK REF="REF-Crane-2013" TYPE="REFERENCE">Crane 2013</LINK>). Haemoglobin A1c levels reflect average glycaemia over several months. High levels have a strong predictive value for general diabetic complications and are related to the risk of developing cognitive impairment (<LINK REF="REF-Yaffe-2006" TYPE="REFERENCE">Yaffe 2006</LINK>). Hence, glycaemic control seems to be related to cognitive dysfunction in patients with Type 2 diabetes and tight glycaemic control may lower the risk of cognitive decline and dementia. On the other hand severe hypoglycaemia, which can be caused by pharmacological treatment of diabetes, may have permanent neurological consequences which may accelerate dementia. There are studies demonstrating that episodes of serious hypoglycaemia which require hospitalisation or visits to the emergency room are associated with a higher risk of dementia, and a greater number of episodes increases the risk (<LINK REF="REF-Whitmer-2009" TYPE="REFERENCE">Whitmer 2009</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2017-05-31 22:29:06 +0100" MODIFIED_BY="[Empty name]">
<P>There is a very high level of interest in any interventions which could prevent or delay the onset of dementia. Since diabetes is a risk factor for dementia and is very common in the older population at risk of dementia, its treatment offers considerable potential for prevention. This review aims to identify and synthesise high-quality evidence to determine whether different management strategies for Type 2 diabetes have any effect on cognitive function and the incidence of dementia. Given the prevalence of both conditions, even small effects of a particular management strategy could have consequences for public health.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2017-02-01 14:11:55 +0000" MODIFIED_BY="[Empty name]">
<P>To assess the effects of different strategies for managing Type 2 diabetes mellitus on cognitive function and the incidence of dementia.</P>
</OBJECTIVES>
<METHODS MODIFIED="2017-06-06 08:51:39 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2017-06-06 08:49:58 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2017-06-01 20:19:43 +0100" MODIFIED_BY="[Empty name]">
<P>We included randomised controlled trials (RCTs) of treatments approved by international clinical practice guidelines for Type 2 diabetes in which objective measures of participants' cognitive function were made at baseline and after treatment.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2017-05-31 22:30:45 +0100" MODIFIED_BY="[Empty name]">
<P>We included people over 18 years old suffering from Type 2 diabetes diagnosed by accepted international criteria &#8212; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1610250739037713180787518930694&amp;format=REVMAN#REF-ADA-Diagnosis-2016">ADA Diagnosis 2016</A> &#8212; and treated in the community. Type 1 diabetes patients were excluded. There were no exclusion criteria based on comorbidity.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2017-01-18 11:57:00 +0000" MODIFIED_BY="[Empty name]">
<P>We included any treatment approved by international guidelines for Type 2 diabetes given for a minimum of 12 weeks. The following types of interventions were acceptable: diet, exercise, any orally administered or injected antidiabetic drug at any dose (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1610250739037713180787518930694&amp;format=REVMAN#REF-ADA-2016">ADA 2016</A>). Comparator interventions could be treatment as usual, placebo, or an alternative active treatment. We included studies comparing different goals of treatment (intensive or conventional treatment).</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2017-06-06 08:49:58 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Cognitive function measured by validated neuropsychological tests. These may be neuropsychological test batteries, multi-domain or single domain cognitive tests. We sought data on global cognitive function (our most important cognitive outcome) and the specific cognitive subdomains of executive function, processing speed, semantic memory, verbal fluency, working memory and episodic memory.</LI>
<LI>Incidence of mild cognitive impairment (MCI) identified using explicit criteria, including Petersen criteria or revised Petersen criteria (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1610250739037713180787518930694&amp;format=REVMAN#REF-Petersen-1999">Petersen 1999</A>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1610250739037713180787518930694&amp;format=REVMAN#REF-Petersen-2004">Petersen 2004</A>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1610250739037713180787518930694&amp;format=REVMAN#REF-Winblad-2004">Winblad 2004</A>); any of the 16 different definitions of MCI described by <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1610250739037713180787518930694&amp;format=REVMAN#REF-Matthews-2008">Matthews 2008;</A> or a Clinical Dementia Rating of 0.5 (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1610250739037713180787518930694&amp;format=REVMAN#REF-Morris-1993">Morris 1993</A>).</LI>
<LI>Incidence of dementia or any subtype of dementia diagnosed by validated criteria, including National Institute of Neurological Disorders and Stroke and the Alzheimer&#8217;s Disease and Related Disorders Association (NINCDS ADRDA) criteria (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1610250739037713180787518930694&amp;format=REVMAN#REF-McKhann-1984">McKhann 1984</A>), the Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1610250739037713180787518930694&amp;format=REVMAN#REF-DSM_x002d_III_x002d_R-1987">DSM-III-R 1987</A>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1610250739037713180787518930694&amp;format=REVMAN#REF-DSM_x002d_IV-2004">DSM-IV 2004</A>), the International Classification of Diseases (ICD) (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1610250739037713180787518930694&amp;format=REVMAN#REF-ICD_x002d_10">ICD-10</A>), and the National Institute on Aging/Alzheimer Association (NIA-AA) criteria for dementia (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1610250739037713180787518930694&amp;format=REVMAN#REF-McKhann-2011">McKhann 2011</A>).</LI>
<LI>Adverse events: hypoglycaemic episodes.</LI>
<LI>Mortality.</LI>
</UL>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2017-06-06 08:51:39 +0100" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2017-06-06 08:51:39 +0100" MODIFIED_BY="[Empty name]">
<P>We searched ALOIS (<A HREF="http://www.medicine.ox.ac.uk/alois">www.medicine.ox.ac.uk/alois</A>), the Cochrane Dementia and Cognitive Improvement Group&#8217;s Specialized Register, on 15 October 2016. The search terms used were: diabetic OR diabetes OR "type 2" OR "type II".</P>
<P>ALOIS is maintained by the Information Specialists of the Cochrane Dementia and Cognitive Improvement Group and contains studies in the areas of dementia prevention, dementia treatment and cognitive enhancement in healthy people. The studies are identified from:  </P>
<OL>
<LI>monthly searches of a number of major healthcare databases: MEDLINE, Embase, CINAHL, PsycINFO and LILACS;</LI>
<LI>Monthly searches of a number of trial registers: ISRCTN; UMIN (Japan's Trial Register); the WHO portal (which covers ClinicalTrials.gov; ISRCTN; the Chinese Clinical Trials Register; the German Clinical Trials Register; the Iranian Registry of Clinical Trials and the Netherlands National Trials Register, plus others);</LI>
<LI>Quarterly search of the Cochrane Library&#8217;s Central Register of Controlled Trials (CENTRAL);</LI>
<LI>Six-monthly searches of a number of grey literature sources: ISI Web of Knowledge Conference Proceedings; Index to Theses; Australasian Digital Theses.</LI>
</OL>
<P>Details of the search strategies used for the retrieval of reports of trials from the healthcare databases, CENTRAL and conference proceedings can be viewed in the &#8216;Methods used in reviews&#8217; section within the editorial information about the <A HREF="http://mrw.interscience.wiley.com/cochrane/clabout/articles/DEMENTIA/frame.html">Dementia and Cognitive Improvement Group</A>.</P>
<P>Additional searches were performed in many of the sources listed above to cover the timeframe from the last searches performed for ALOIS to ensure that the search for the review was as up to date and as comprehensive as possible. The search strategies used can be seen in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
<P>Searches carried out in the previous versions of the review can be viewed in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>.</P>
<P>To date, this review has had a total of five searches (2008, 2011, 2014, 2015 and 2016).</P>
</ELECTRONIC_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2017-06-03 16:46:49 +0100" MODIFIED_BY="[Empty name]">
<P>We tried to contact the trial investigators whenever data were missing, unclear, or if we believed we had detected a possible error in the published data. If this was unsuccessful, we described the uncertainties. We did not impute any missing data.</P>
<STUDY_SELECTION MODIFIED="2017-05-31 23:38:47 +0100" MODIFIED_BY="[Empty name]">
<P>Two authors (AA, MG) independently assessed the retrieved titles and abstracts to identify potentially eligible studies, for which we obtained the full paper. A third author (GM) resolved disagreements between the two authors. Two authors (AA, MG) independently assessed the full manuscripts against the inclusion criteria. Where necessary, a third author (GM) acted as arbitrator to resolve disagreements that the two review authors were unable to resolve through discussion. If a study did not present all relevant data, we contacted the authors directly to request further information. If the same data set was presented in more than one paper, we included the paper with the largest number of patients or with the most informative data.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2017-05-31 23:44:39 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors (RV, GM), working independently, extracted trial information using a standardised data extraction form (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>). Where possible we extracted, as a minimum, the following information.</P>
<P>
<B>Participant characteristics</B>
</P>
<UL>
<LI>Gender.</LI>
<LI>Age (range, median, mean).</LI>
<LI>Education (level and years of education).</LI>
<LI>Baseline cognitive function.</LI>
<LI>Cognitive diagnostic status.</LI>
<LI>Duration of cognitive symptoms, if any.</LI>
<LI>Ethnicity.</LI>
</UL>
<P>
<B>Intervention characteristics</B>
</P>
<UL>
<LI>Description of the intervention.</LI>
<LI>Description of the control condition.</LI>
<LI>Frequency and dose of treatment.</LI>
<LI>Duration of treatment.</LI>
</UL>
<P>
<B>Methodological characteristics</B>
</P>
<UL>
<LI>Trial design (individual or cluster randomisation; parallel-group, factorial or cross-over design).</LI>
<LI>Number of participants.</LI>
<LI>Outcome measures used.</LI>
<LI>Duration of follow-up as measured from randomisation.</LI>
<LI>Duration of follow-up as measured from end of treatment.</LI>
<LI>Source of financial support.</LI>
<LI>Publication status.</LI>
</UL>
<P>For dichotomous outcomes, we extracted from each trial the number of participants with each outcome at end of treatment. For continuous outcomes, we extracted the number of participants and the mean and standard deviation (SD) of the change from baseline for each outcome at end of treatment. If change from baseline data were not available, we extracted the mean and standard deviation of the final values from each group. The baseline assessment is defined as the latest available assessment prior to randomisation, but no longer than two months before.</P>
<P>We included only one outcome from a study in an analysis for each cognitive subdomain. If a study included more than one scale measuring a single cognitive subdomain, then we favoured the scale which was included in the most studies for that comparison. If this did not identify a preferred scale, then we favoured the scale highest in a hierarchy of scales based on frequency of use in a set of 12 Cochrane Reviews on modifiable risk factors for dementia (see <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>). If study authors had derived composite cognitive outcomes, then we also extracted and described these.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2017-06-03 16:46:49 +0100" MODIFIED_BY="[Empty name]">
<P>Two reviewers of the author team (RV, GM) independently assessed the risk of bias in each of the included trials, using Cochrane's 'Risk of bias' tool (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1610250739037713180787518930694&amp;format=REVMAN#REF-Higgins-2011">Higgins 2011</A>). Disagreements were resolved by discussion until consensus was reached. We assessed the risk of bias potentially introduced by the following features of study design: sequence generation, allocation concealment, blinding of participants and healthcare professionals, blinding of outcome assessors, selective outcome reporting, and incomplete outcome data.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2016-04-12 09:32:20 +0100" MODIFIED_BY="[Empty name]">
<P>We estimated effects of diabetes treatment by using risk ratios (RRs) for dichotomous variables and mean differences (MDs) or standardised mean differences (SMDs) for continuous variables, along with their corresponding 95% confidence intervals (CIs). We calculated SMDs when studies used different instruments to measure the same variable.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2017-01-17 20:48:42 +0000" MODIFIED_BY="[Empty name]">
<P>We used individual study participants in each trial arm as the unit of analysis.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2017-05-31 23:46:28 +0100" MODIFIED_BY="[Empty name]">
<P>We did not numerically impute missing values where participants were lost to follow-up from either group. For continuous outcomes, we analysed the data provided by study authors. Missing data in the individual trials may put the study estimates of effects at a high risk of bias and may lower the overall quality of the evidence according to the GRADE assessment. We included the information about the missing data in our 'Risk of bias' assessments.<BR/>
</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2017-05-28 15:36:09 +0100" MODIFIED_BY="[Empty name]">
<P>We assessed differences between the included studies in the types of participants, interventions or control used before deciding whether to pool data. No subgroup analyses were planned. We assessed heterogeneity between studies using the Chi² test (with a significance level set at P &lt; 0.10) and the I² statistic, which calculates the percentage of variability due to heterogeneity rather than to chance, with I² values over 50% suggesting substantial heterogeneity (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2017-05-31 23:47:38 +0100" MODIFIED_BY="[Empty name]">
<P>We did not find enough trials to be able to explore reporting biases and other biases related to small-study effects.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2017-05-31 23:49:50 +0100" MODIFIED_BY="[Empty name]">
<P>We pooled data from studies only if we considered them to be sufficiently similar in terms of participants, interventions, duration and outcomes and if I² was less than 75%. Additionally, we used a fixed-effect model if we considered all studies in a meta-analysis to be estimating the same underlying effect. If we thought this was not the case due to clinical or statistical heterogeneity, then we used a random-effects model.</P>
<SUBSECTION>
<HEADING LEVEL="4">Summary of findings</HEADING>
<P>We used the principles of the GRADE system to assess the quality of the body of evidence associated with each outcome. We constructed a &#8216;Summary of findings&#8217; table for each comparison using GRADE profiler software (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1610250739037713180787518930694&amp;format=REVMAN#REF-GRADEpro-2008">GRADEpro 2008</A>). The GRADE approach appraises the quality of a body of evidence according to the extent to which one can be confident that an estimate of effect or association reflects the item being assessed. Evaluation of the quality of a body of evidence considers within-study risk of bias, directness of the evidence, heterogeneity in the data, precision of effect estimates and additional considerations (including risk of publication bias) (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1610250739037713180787518930694&amp;format=REVMAN#REF-Guyatt-2008">Guyatt 2008</A>).</P>
<P>Two review authors (GM and RV) independently assessed the quality of the body of evidence on the following outcomes: global cognitive function, incidence of MCI, incidence of dementia, adverse effects (hypoglycaemia) and mortality.</P>
</SUBSECTION>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2016-10-14 16:06:06 +0100" MODIFIED_BY="[Empty name]">
<P>We were not able to include enough trials to conduct subgroup analyses.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2016-10-13 00:02:36 +0100" MODIFIED_BY="[Empty name]">
<P>We did not conduct any sensitivity analyses.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2017-06-06 13:42:16 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2017-06-06 13:42:16 +0100" MODIFIED_BY="[Empty name]">
<P>Details of all included and excluded studies are provided in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> and <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> tables.</P>
<SEARCH_RESULTS MODIFIED="2017-06-06 13:42:16 +0100" MODIFIED_BY="[Empty name]">
<P>Database searches conducted for this review identified a total of 4944 results. After de-duplication and first assessments by the information specialist for the Cochrane Dementia and Cognitive Improvement Group, and a further first assessment by the author team (AA and MG), a total of 34 articles were reviewed in full text. Two reviewers (AA, MG) independently assessed them for inclusion or exclusion. A third reviewer (GM) resolved discrepancies. See <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2017-06-06 08:53:52 +0100" MODIFIED_BY="[Empty name]">
<P>For the current update of this Cochrane Review, we identified seven new included studies (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1610250739037713180787518930694&amp;format=REVMAN#STD-Abbatecola-2006">Abbatecola 2006</A>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1610250739037713180787518930694&amp;format=REVMAN#STD-Ryan-2006">Ryan 2006</A>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1610250739037713180787518930694&amp;format=REVMAN#STD-ADVANCE-2008">ADVANCE 2008</A>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1610250739037713180787518930694&amp;format=REVMAN#STD-Launer-2011">Launer 2011</A>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1610250739037713180787518930694&amp;format=REVMAN#STD-Araki-2012">Araki 2012</A>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1610250739037713180787518930694&amp;format=REVMAN#STD-Guo-2014">Guo 2014</A>; <LINK REF="STD-Zimering-2016" TYPE="STUDY">Zimering 2016</LINK>). Additionally, we excluded the five studies that were included in the 2008 version of this review (see <LINK TAG="EXCLUDED_STUDIES_DESCR" TYPE="SECTION">Excluded studies</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Study designs</HEADING>
<P>All seven included studies were individually randomised, parallel group randomised controlled trials (RCTs). Two studies had a 2 × 2 factorial design (<LINK REF="STD-ADVANCE-2008" TYPE="STUDY">ADVANCE 2008</LINK>; <LINK REF="STD-Launer-2011" TYPE="STUDY">Launer 2011</LINK>). The other studies had single intervention and control groups (<LINK REF="STD-Abbatecola-2006" TYPE="STUDY">Abbatecola 2006</LINK>; <LINK REF="STD-Ryan-2006" TYPE="STUDY">Ryan 2006</LINK>; <LINK REF="STD-Araki-2012" TYPE="STUDY">Araki 2012</LINK>; <LINK REF="STD-Guo-2014" TYPE="STUDY">Guo 2014</LINK>; <LINK REF="STD-Zimering-2016" TYPE="STUDY">Zimering 2016</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Settings</HEADING>
<P>One trial was conducted in a single academic outpatient centre in Italy (<LINK REF="STD-Abbatecola-2006" TYPE="STUDY">Abbatecola 2006</LINK>); one trial was conducted in 215 clinical centres in 20 different countries in Asia, Australasia, Europe, and North America (<LINK REF="STD-ADVANCE-2008" TYPE="STUDY">ADVANCE 2008</LINK>); one trial was conducted in outpatient clinics at 39 hospitals in Japan (<LINK REF="STD-Araki-2012" TYPE="STUDY">Araki 2012</LINK>); one trial was conducted in 52 outpatient clinics in North America (<LINK REF="STD-Launer-2011" TYPE="STUDY">Launer 2011</LINK>); one study was conducted in 20 Veteran Affairs Medical Centers in the USA (<LINK REF="STD-Zimering-2016" TYPE="STUDY">Zimering 2016</LINK>); and two trials provided no information on setting (<LINK REF="STD-Ryan-2006" TYPE="STUDY">Ryan 2006</LINK>; <LINK REF="STD-Guo-2014" TYPE="STUDY">Guo 2014</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Participants</HEADING>
<P>
<LINK REF="STD-Abbatecola-2006" TYPE="STUDY">Abbatecola 2006</LINK> included 156 treatment-naive Type 2 diabetic participants aged between 60 and 78 years. The <LINK REF="STD-ADVANCE-2008" TYPE="STUDY">ADVANCE 2008</LINK> study included 11,140 participants who had their first diagnosis of Type 2 diabetes at age 30 years or older, were age 55 years or older at entry (mean 66 ± 6 years), and were at substantial risk of vascular events. <LINK REF="STD-Araki-2012" TYPE="STUDY">Araki 2012</LINK> included 1173 Type 2 diabetic participants aged over 65 years who also had other cardiovascular risk factors. <LINK REF="STD-Launer-2011" TYPE="STUDY">Launer 2011</LINK> included 1977 participants with Type 2 diabetes, a high HbA1c concentration (&gt; 7.5%, &gt; 58 mmol/mol) and a high risk for cardiovascular disease events. <LINK REF="STD-Guo-2014" TYPE="STUDY">Guo 2014</LINK> included 144 treatment-naive Type 2 diabetic participants aged between 40 and 65 years who also had depression diagnosed according to <LINK REF="REF-DSM_x002d_IV-2004" TYPE="REFERENCE">DSM-IV 2004</LINK> criteria. <LINK REF="STD-Ryan-2006" TYPE="STUDY">Ryan 2006</LINK> included 145 participants with Type 2 diabetes who were treated with metformin. Finally, <LINK REF="STD-Zimering-2016" TYPE="STUDY">Zimering 2016</LINK> included 1791 participants older than 41 years (mean 60 years), who were non-responsive to a maximum dose of at least one oral agent or daily insulin injections, or both.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Interventions</HEADING>
<P>One study compared a variable dose of metformin (initially 0.5 g twice a day) to placebo over 24 weeks (<LINK REF="STD-Guo-2014" TYPE="STUDY">Guo 2014</LINK>).</P>
<P>Two studies compared two different antidiabetic drugs.</P>
<UL>
<LI>
<LINK REF="STD-Abbatecola-2006" TYPE="STUDY">Abbatecola 2006</LINK> compared repaglinide (initially 1 mg twice a day) to glibenclamide (glyburide) (initially 2.5 mg twice a day) over 12 months. (Glibenclamide is known as glyburide in the United States).</LI>
<LI>
<LINK REF="STD-Ryan-2006" TYPE="STUDY">Ryan 2006</LINK> compared rosiglitazone (initially 4.0 mg once a day) plus metformin to glibenclamide (glyburide) (initially 2.5 mg twice a day) plus metformin over 24 weeks (<LINK REF="STD-Ryan-2006" TYPE="STUDY">Ryan 2006</LINK>).</LI>
</UL>
<P>Four studies compared standard and intensive regimes for diabetes control.</P>
<UL>
<LI>
<LINK REF="STD-Launer-2011" TYPE="STUDY">Launer 2011</LINK> randomised the participants to receive 40 months of either intensive glycaemic treatment with an HbA1c target of less than 6.0% or standard glycaemic control with an HbA1c target of 7.0% to 7.9%. All participants received diabetes education, glucose-monitoring equipment, and antidiabetic medications. Participants in the intensive glycaemic group were started on two or more classes of agents. Doses were intensified or a new medication class was added monthly if HbA1c levels were 6% or more, or if more than 50% of premeal or postmeal capillary glucose readings were higher than 5.6 mmol/L (100 mg/dL). Standard glycaemic therapy was intensified whenever HbA1c was 8% or above, or more than 50% of capillary glucose readings were higher than 7.8 mmol/L (140 mg/dL). Antihyperglycaemic drugs that promoted hypoglycaemia (i.e. insulin or insulin secretagogues) were reduced if HbA1c was persistently lowered to less than 7%. All drug combinations from a standard formulary were permitted; specific drugs were reduced only for side effects or contraindications. In addition, the patients were randomly assigned to receive either intensive blood pressure-lowering treatment (systolic blood pressure target &lt; 120 mmHg) or standard treatment (systolic blood pressure target &lt; 140 mmHg); and to receive fenofibrate or placebo.</LI>
<LI>The <LINK REF="STD-ADVANCE-2008" TYPE="STUDY">ADVANCE 2008</LINK> study compared an intensive glucose control regime including gliclazide (modified release, 30 mg to 120 mg daily) plus other treatments at physicians' discretion versus a standard control group, whose treatment could not include gliclazide, for a median follow-up of five years. Eligible participants were also randomised to perindopril-indapamide or placebo. Whenever required, other classes of blood pressure-lowering drugs were prescribed at the discretion of the responsible clinician.</LI>
<LI>
<LINK REF="STD-Araki-2012" TYPE="STUDY">Araki 2012</LINK> randomised participants to either an intensive regime of treatment for diabetes, hypertension and dyslipidaemia or treatment as usual over six years. The diabetes treatment target for the intensive treatment regime was HbA1c lower than 6.9%. (Treatment targets for the other factors are shown in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table.)</LI>
<LI>
<LINK REF="STD-Zimering-2016" TYPE="STUDY">Zimering 2016</LINK> randomised participants to intensive or standard therapy and followed them up for five years. Both intensive and standard therapy groups were divided according to participants' BMI. Those with a BMI of 27 or more were started on two oral agents, rosiglitazone plus metformin; those with a BMI of less than 27 were started on rosiglitazone plus glimepiride. The participants in the intensive therapy treatment started on maximal doses and, before any change in oral medications, insulin was added for patients who did not achieve a glycated haemoglobin level of lower than 6%. In the standard therapy group, the oral treatment was started at half the maximal doses and, before any change in oral medications, insulin was added for participants who did not achieve a glycated haemoglobin level of lower than 9%.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcomes</HEADING>
<P>Four studies measured global cognitive function using the Mini-Mental State Examination (MMSE) (<LINK REF="STD-Abbatecola-2006" TYPE="STUDY">Abbatecola 2006</LINK>; <LINK REF="STD-ADVANCE-2008" TYPE="STUDY">ADVANCE 2008</LINK>; <LINK REF="STD-Launer-2011" TYPE="STUDY">Launer 2011</LINK>; <LINK REF="STD-Araki-2012" TYPE="STUDY">Araki 2012</LINK>). The <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1702021445563396217308308681471&amp;format=REVMAN#STD-ADVANCE-2008">ADVANCE 2008</A> study reported this only as the number of patients who had declined by 3 or more MMSE points from baseline.</P>
<P>Four studies used a variety of cognitive subdomain tests. We extracted outcomes according to the methods specified in <LINK TAG="DATA_EXTRACTION" TYPE="SECTION">Data extraction and management</LINK> (above).</P>
<P>Episodic memory was measured by both <LINK REF="STD-Ryan-2006" TYPE="STUDY">Ryan 2006</LINK> and <LINK REF="STD-Launer-2011" TYPE="STUDY">Launer 2011</LINK> using the Rey Auditory Verbal Learning Test (RAVLT). Executive function was evaluated by <LINK REF="STD-Launer-2011" TYPE="STUDY">Launer 2011</LINK> using the Stroop test. Speed of processing was evaluated by <LINK REF="STD-Ryan-2006" TYPE="STUDY">Ryan 2006</LINK> and <LINK REF="STD-Launer-2011" TYPE="STUDY">Launer 2011</LINK> using the Digit Symbol Substitution Test. Working memory was evaluated by <LINK REF="STD-Ryan-2006" TYPE="STUDY">Ryan 2006</LINK> using the Spatial Working Memory Test. <LINK REF="STD-Guo-2014" TYPE="STUDY">Guo 2014</LINK> measured episodic and working memory using subtests of the Wechsler Memory Scale&#8211;Revised (WMS-R), and <LINK REF="STD-Zimering-2016" TYPE="STUDY">Zimering 2016</LINK> measured executive function using the Trail Making Test-B (TMT-B), speed of processing using Digit Symbol Subtest of the Wechsler Adult Intelligence Scale-Revised (WAIS-R), and working memory using Digit-Span Forwards and Backwards, but they did not present extractable data.</P>
<P>Two studies also reported composite cognitive outcomes. <LINK REF="STD-Abbatecola-2006" TYPE="STUDY">Abbatecola 2006</LINK> reported a cognition composite score of attention and executive functions. <LINK REF="STD-Ryan-2006" TYPE="STUDY">Ryan 2006</LINK> reported composite outcomes in three domains which they called 1) working memory, 2) learning ability and 3) cognitive efficiency. The details of the composite outcomes are given in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table.</P>
<P>No study reported the incidence of MCI.</P>
<P>Only one study reported the incidence of dementia (using DSM-IV criteria) (<LINK REF="STD-ADVANCE-2008" TYPE="STUDY">ADVANCE 2008</LINK>).</P>
<P>Two studies reported adverse events. Both of them reported specifically on hypoglycaemic episodes (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1702021445563396217308308681471&amp;format=REVMAN#STD-ADVANCE-2008">ADVANCE 2008</A>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1702021445563396217308308681471&amp;format=REVMAN#STD-Zimering-2016">Zimering 2016</A>).</P>
<P>Three studies reported mortality (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1702021445563396217308308681471&amp;format=REVMAN#STD-ADVANCE-2008">ADVANCE 2008</A>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1702021445563396217308308681471&amp;format=REVMAN#STD-Launer-2011">Launer 2011</A>; <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1702021445563396217308308681471&amp;format=REVMAN#STD-Zimering-2016">Zimering 2016</A>).</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2017-06-06 08:55:06 +0100" MODIFIED_BY="[Empty name]">
<P>We excluded three studies because they studied the effect of different diabetic treatments on quality of life using questionnaires that included the respondents' subjective impressions of cognitive function (<LINK REF="STD-Testa-1998" TYPE="STUDY">Testa 1998</LINK>; <LINK REF="STD-Tovi-1998" TYPE="STUDY">Tovi 1998</LINK>; <LINK REF="STD-UKPDS-1999" TYPE="STUDY">UKPDS 1999</LINK>), instead of using objective measures. One study was excluded because the participants had pre-diabetes (dysglycaemia) (<LINK REF="STD-Cukierman_x002d_Yaffe-2014" TYPE="STUDY">Cukierman-Yaffe 2014</LINK>). We excluded <LINK REF="STD-Naor-1997" TYPE="STUDY">Naor 1997</LINK>, which compared the effect of intensive inpatient diabetic therapy with unchanged regular diabetic therapy on cognitive function over a short period of time (six weeks). A number of studies were excluded because the interventions were not eligible: these were ginseng (<LINK REF="STD-Sotaniemi--1995" TYPE="STUDY">Sotaniemi 1995</LINK>), vitamin E (<LINK REF="STD-Vijayakumar-2011" TYPE="STUDY">Vijayakumar 2011</LINK>), dietary nitrate supplementation (<LINK REF="STD-Gilchrist-2014" TYPE="STUDY">Gilchrist 2014</LINK>), Sancaijiangtang (<LINK REF="STD-Qiang-2015" TYPE="STUDY">Qiang 2015</LINK>), and telemedicine (<LINK REF="STD-Luchsinger-2011" TYPE="STUDY">Luchsinger 2011</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2017-06-03 17:16:40 +0100" MODIFIED_BY="[Empty name]">
<P>We considered none of the included studies to have an overall low risk of bias (<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>; <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>).
<BR/>

</P>
<ALLOCATION MODIFIED="2017-06-03 17:16:40 +0100" MODIFIED_BY="[Empty name]">
<P>Three studies did not clearly report the method used for random sequence generation and we judged them to have an unclear risk of bias in this domain (<LINK REF="STD-Abbatecola-2006" TYPE="STUDY">Abbatecola 2006</LINK>; <LINK REF="STD-Araki-2012" TYPE="STUDY">Araki 2012</LINK>; <LINK REF="STD-Zimering-2016" TYPE="STUDY">Zimering 2016</LINK>). We judged two studies to have a low risk of bias on the allocation concealment item because the authors described use of a computer-generated unique randomisation sequence (<LINK REF="STD-ADVANCE-2008" TYPE="STUDY">ADVANCE 2008</LINK>), and implemented the randomisation via secure access (<LINK REF="STD-Launer-2011" TYPE="STUDY">Launer 2011</LINK>). The other five studies did not give any description of how allocation was concealed (<LINK REF="STD-Abbatecola-2006" TYPE="STUDY">Abbatecola 2006</LINK>; <LINK REF="STD-Ryan-2006" TYPE="STUDY">Ryan 2006</LINK>; <LINK REF="STD-Araki-2012" TYPE="STUDY">Araki 2012</LINK>; <LINK REF="STD-Guo-2014" TYPE="STUDY">Guo 2014</LINK>; <LINK REF="STD-Zimering-2016" TYPE="STUDY">Zimering 2016</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2017-06-01 20:52:30 +0100" MODIFIED_BY="[Empty name]">
<P>One study was explicitly open label and we judged it to have a high risk of performance and detection bias (<LINK REF="STD-Launer-2011" TYPE="STUDY">Launer 2011</LINK>). None of the other studies clearly described blinding of patients and personnel and we judged them all to be at unclear risk of performance bias. Three studies were also at unclear risk of detection bias due to a lack of information about blinding of outcome assessors (<LINK REF="STD-Araki-2012" TYPE="STUDY">Araki 2012</LINK>; <LINK REF="STD-Guo-2014" TYPE="STUDY">Guo 2014</LINK>; <LINK REF="STD-Zimering-2016" TYPE="STUDY">Zimering 2016</LINK>). Three studies described an adequate method for blinding the outcome assessors and we considered them to be at low risk of detection bias (<LINK REF="STD-Abbatecola-2006" TYPE="STUDY">Abbatecola 2006</LINK>; <LINK REF="STD-Ryan-2006" TYPE="STUDY">Ryan 2006</LINK>; <LINK REF="STD-ADVANCE-2008" TYPE="STUDY">ADVANCE 2008</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2017-06-01 20:52:57 +0100" MODIFIED_BY="[Empty name]">
<P>We considered five studies to have a low risk of attrition bias (<LINK REF="STD-Abbatecola-2006" TYPE="STUDY">Abbatecola 2006</LINK>; <LINK REF="STD-Ryan-2006" TYPE="STUDY">Ryan 2006</LINK>; <LINK REF="STD-ADVANCE-2008" TYPE="STUDY">ADVANCE 2008</LINK>; <LINK REF="STD-Launer-2011" TYPE="STUDY">Launer 2011</LINK>; <LINK REF="STD-Araki-2012" TYPE="STUDY">Araki 2012</LINK>). We considered <LINK REF="STD-Guo-2014" TYPE="STUDY">Guo 2014</LINK> to have a high risk of attrition bias because 19.4% of patients were lost to follow-up; the reasons for these post-randomisation withdrawals were not reported. We considered <LINK REF="STD-Zimering-2016" TYPE="STUDY">Zimering 2016</LINK> to be at unclear risk of attrition bias due to a lack of information about the number of patients lost before final analysis and no description of how losses to follow-up were handled.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2017-06-01 20:53:47 +0100" MODIFIED_BY="[Empty name]">
<P>We considered four studies to have a low risk of reporting bias (<LINK REF="STD-ADVANCE-2008" TYPE="STUDY">ADVANCE 2008</LINK>; <LINK REF="STD-Launer-2011" TYPE="STUDY">Launer 2011</LINK>; <LINK REF="STD-Araki-2012" TYPE="STUDY">Araki 2012</LINK>; <LINK REF="STD-Zimering-2016" TYPE="STUDY">Zimering 2016</LINK>). Two studies did not report the existence of a protocol in which the outcomes were specified, and so we assigned them an unclear risk of bias regarding selective outcome reporting (<LINK REF="STD-Abbatecola-2006" TYPE="STUDY">Abbatecola 2006</LINK>; <LINK REF="STD-Ryan-2006" TYPE="STUDY">Ryan 2006</LINK>). In one study no protocol was identified and only results at 12 weeks were reported although the Methods section described a follow-up time of 24 weeks; we considered this to indicate a high risk of bias (<LINK REF="STD-Guo-2014" TYPE="STUDY">Guo 2014</LINK>).</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2017-01-18 09:06:19 +0000" MODIFIED_BY="[Empty name]">
<P>We identified no other potential sources of bias.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2017-06-06 08:29:37 +0100" MODIFIED_BY="[Empty name]">
<P>See 'Summary of findings' tables for the comparisons of: 1) glibenclamide (glyburide) versus repaglinide; 2) intensive glycaemic control versus standard glycaemic control; and 3) rosiglitazone plus metformin versus glibenclamide (glyburide) plus metformin.</P>
<P>There is no 'Summary of findings' table for the comparison of metformin with placebo because we were unable to extract data from the study concerned (<LINK REF="STD-Guo-2014" TYPE="STUDY">Guo 2014</LINK>).</P>
<P>We were unable to extract any efficacy data from two of the seven included studies. <LINK REF="STD-Araki-2012" TYPE="STUDY">Araki 2012</LINK> did not report the MMSE scores at the end of the follow-up; the authors were contacted twice to request the data for inclusion in this systematic review, but no response was received. It was not possible to extract the data we needed from <LINK REF="STD-Guo-2014" TYPE="STUDY">Guo 2014</LINK> because the results were reported only in an ANOVA format and no data could be extracted from the figures. Similarly, the authors were contacted twice to request the data, but no response was received. <LINK REF="STD-Zimering-2016" TYPE="STUDY">Zimering 2016</LINK> did not report measures of dispersion (e.g. standard deviation) for its cognitive outcomes and so we were not able to include this efficacy data in the meta-analyses. We were able to extract data related to safety from only three studies of the seven studies included (<LINK REF="STD-ADVANCE-2008" TYPE="STUDY">ADVANCE 2008</LINK>; <LINK REF="STD-Launer-2011" TYPE="STUDY">Launer 2011</LINK>; <LINK REF="STD-Zimering-2016" TYPE="STUDY">Zimering 2016</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 1: glibenclamide (glyburide) versus repaglinide</HEADING>
<P>One study with 156 participants made this comparison (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1610250739037713180787518930694&amp;format=REVMAN#STD-Abbatecola-2006">Abbatecola 2006</A>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Outcome: global cognitive function measured with MMSE at 12 months</HEADING>
<P>There was low-quality evidence from one study of a small advantage on global cognitive function measured with the MMSE for glibenclamide (glyburide) over repaglinide after 12 months of treatment (MD &#8722;0.90, 95% CI &#8722;1.68 to &#8722;0.12; 1 study; n = 156; low-quality evidence, downgraded due to risk of bias and imprecision) (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1610250739037713180787518930694&amp;format=REVMAN#CMP-001.01">Analysis 1.1</A>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcome: executive function</HEADING>
<P>No data were reported on executive function.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcome: speed of processing</HEADING>
<P>No data were reported on speed of processing.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcome: semantic memory</HEADING>
<P>No data were reported on semantic memory.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcome: verbal fluency</HEADING>
<P>No data were reported on verbal fluency.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcome: working memory</HEADING>
<P>No data were reported on working memory.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcome: episodic memory</HEADING>
<P>No data were reported on episodic memory.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcome: other cognitive outcomes</HEADING>
<P>
<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1610250739037713180787518930694&amp;format=REVMAN#STD-Abbatecola-2006">Abbatecola 2006</A> also reported a cognition composite score of attention and executive functions. It consisted of the sum of the squared z-scores of TMT-A, TMT-B, DIFF B-A, DSP-Forward, DSP-Backward, and Verbal Fluency. There was no difference between groups on this outcome (MD 0.00, 95% CI &#8722;0.01 to 0.01; 1 study; n = 156; low-quality evidence, downgraded due to risk of bias and imprecision) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcome: incidence of MCI</HEADING>
<P>No data were reported on incidence of MCI.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcome: incidence of dementia or any subtype of dementia</HEADING>
<P>No data were reported on incidence of dementia or any subtype of dementia.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcome: adverse events</HEADING>
<P>No data were reported on adverse events.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcome: mortality</HEADING>
<P>No data were reported on mortality.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 2: intensive glycaemic control versus standard glycaemic control</HEADING>
<P>Four studies with 16,081 participants made this comparison. However, we were not able to include any data from <LINK REF="STD-Araki-2012" TYPE="STUDY">Araki 2012</LINK> (1173 participants).</P>
<SUBSECTION>
<HEADING LEVEL="4">Outcome: global cognitive function</HEADING>
<P>There was no difference between the intensive glycaemic control group and the standard glycaemic control group on global cognitive function measured with the MMSE at 40 months (MD &#8722;0.00, 95% CI &#8722;0.08 to 0.07; 1 study; n = 2794; moderate-quality evidence, downgraded due to risk of bias) (<LINK REF="STD-Launer-2011" TYPE="STUDY">Launer 2011</LINK>) (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcome: global cognitive function (dichotomous)</HEADING>
<P>
<LINK REF="STD-ADVANCE-2008" TYPE="STUDY">ADVANCE 2008</LINK> reported MMSE results only as the number of participants who had declined by 3 or more points from baseline. There was no difference between the intensive glycaemic control group and the standard glycaemic control group on this outcome at five years (RR 0.98, 95% CI 0.88 to 1.08; 1 study; n = 11,140; moderate-quality evidence, downgraded due to risk of bias) (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcome: executive function</HEADING>
<P>There was no clear evidence of a difference between the intensive glycaemic control group and the standard glycaemic control group on executive function measured with the Stroop test at 40 months (MD &#8722;0.61, 95% CI &#8722;1.62 to 0.40; 1 study; n = 2794; moderate-quality evidence, downgraded due to risk of bias) (<LINK REF="STD-Launer-2011" TYPE="STUDY">Launer 2011</LINK>) (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>).</P>
<P>
<LINK REF="STD-Zimering-2016" TYPE="STUDY">Zimering 2016</LINK> reported the mean change after five years on executive function measured with TMT-B, but did not report any measure of dispersion of the data (e.g. standard deviation or standard error) and so we were not able to include this in a meta-analysis. The authors reported no evidence of a difference between the intensive glycaemic control group and the standard glycaemic control group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcome: speed of processing</HEADING>
<P>There was no clear evidence of a difference between the intensive glycaemic control group and the standard glycaemic control group on speed of processing measured by DSST at 40 months (MD 0.32, 95% CI &#8722;0.28 to 0.92; 1 study; n = 2794; moderate-quality evidence, downgraded due to risk of bias) (<LINK REF="STD-Launer-2011" TYPE="STUDY">Launer 2011</LINK>) (<LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>).</P>
<P>
<LINK REF="STD-Zimering-2016" TYPE="STUDY">Zimering 2016</LINK> reported the mean change after five years on speed of processing measured with the DSST, but did not report any measure of dispersion of the data and so we were not able to include this in a meta-analysis. The authors reported no evidence of a difference between the intensive glycaemic control group and the standard glycaemic control group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcome: semantic memory</HEADING>
<P>No data were reported on semantic memory.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcome: verbal fluency</HEADING>
<P>No data were reported on verbal fluency.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcome: working memory</HEADING>
<P>
<LINK REF="STD-Zimering-2016" TYPE="STUDY">Zimering 2016</LINK> reported the mean change after five years on working memory measured by digit span, but did not report any measure of dispersion of the data. The authors reported no evidence of a difference between the intensive glycaemic control group and the standard glycaemic control group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcome: episodic memory</HEADING>
<P>There was no difference between the intensive glycaemic control group and the standard glycaemic control group on episodic memory measured with the RAVLT at 40 months (MD &#8722;0.01, 95% CI &#8722;0.14 to 0.12; 1 study; n = 2794; moderate-quality evidence, downgraded due to risk of bias) (<LINK REF="STD-Launer-2011" TYPE="STUDY">Launer 2011</LINK>) (<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcome: incidence of MCI</HEADING>
<P>No data were reported on incidence of MCI.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcome: incidence of dementia or any subtype of dementia</HEADING>
<P>One study reported the incidence of dementia (<LINK REF="STD-ADVANCE-2008" TYPE="STUDY">ADVANCE 2008</LINK>). The result was imprecise and did not show a statistically significant difference between the intensive glycaemic control group compared with the standard glycaemic control group after five years (RR 1.27, 95% CI 0.87 to 1.85; 1 study; n = 11,140; low-quality evidence, downgraded due to risk of bias and imprecision) (<LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcome: adverse events; hypoglycaemia</HEADING>
<P>
<LINK REF="STD-ADVANCE-2008" TYPE="STUDY">ADVANCE 2008</LINK> defined a severe hypoglycaemic episode as a participant with transient dysfunction of the central nervous system, unable to treat themselves and requiring help from another person. <LINK REF="STD-Zimering-2016" TYPE="STUDY">Zimering 2016</LINK> also reported severe hypoglycaemic episodes defined as death, hospitalisation, disability or incapacity, or other important event requiring medical intervention/treatment due to a hypoglycaemic episode. There was moderate-quality evidence from two studies of a greater risk of at least one severe hypoglycaemic episode for the intensive glycaemic control group over the standard glycaemic control group after five years of treatment (RR 2.18, 95% CI 1.52 to 3.14; 2 studies; n = 12,827; moderate-quality evidence, downgraded due to risk of bias) (<LINK REF="CMP-002.07" TYPE="ANALYSIS">Analysis 2.7</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcome: mortality</HEADING>
<P>There was no difference in all-cause mortality between the intensive glycaemic control group and the standard glycaemic control group, but the result was imprecise and compatible with a small increase in mortality in either group (RR 0.99, 95% CI 0.87 to 1.13, 3 studies, n = 15,888; low-quality evidence, downgraded due to risk of bias and imprecision) (<LINK REF="CMP-002.08" TYPE="ANALYSIS">Analysis 2.8</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 3: rosiglitazone plus metformin versus glibenclamide (glyburide) plus metformin</HEADING>
<P>One study with 145 participants made this comparison (<LINK REF="STD-Ryan-2006" TYPE="STUDY">Ryan 2006</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Outcome: global cognitive function</HEADING>
<P>No data were reported on global cognitive function.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcome: executive function</HEADING>
<P>No data were reported on executive function.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcome: speed of processing</HEADING>
<P>There was no clear evidence of a difference between rosiglitazone plus metformin and glibenclamide (glyburide) plus metformin in cognitive speed measured with the DSST after 24 weeks of treatment (MD &#8722;0.20, 95% CI &#8722;0.50 to 0.10; 1 study; n = 136; low-quality evidence, downgraded due to risk of bias and imprecision) (<LINK REF="STD-Ryan-2006" TYPE="STUDY">Ryan 2006</LINK>) (<LINK REF="CMP-003.09" TYPE="ANALYSIS">Analysis 3.9</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcome: semantic memory</HEADING>
<P>No data were reported on semantic memory.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcome: verbal fluency</HEADING>
<P>No data were reported on verbal fluency.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcome: working memory</HEADING>
<P>There was no difference between rosiglitazone plus metformin and glibenclamide (glyburide) plus metformin in working memory measured with the Spatial Working Memory Test after 24 weeks of treatment (MD 0.40, 95% CI &#8722;0.24 to 1.04; 1 study; n = 136; low-quality evidence, downgraded due to risk of bias and imprecision) (<LINK REF="STD-Ryan-2006" TYPE="STUDY">Ryan 2006</LINK>) (<LINK REF="CMP-003.06" TYPE="ANALYSIS">Analysis 3.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcome: episodic memory</HEADING>
<P>There was low-quality evidence from <LINK REF="STD-Ryan-2006" TYPE="STUDY">Ryan 2006</LINK> of a small advantage for rosiglitazone plus metformin over glibenclamide (glyburide) plus metformin on episodic memory measured with the RAVLT (immediate) after 24 weeks of treatment (MD &#8722;1.40, 95% CI &#8722;1.70 to &#8722;1.10; 1 study; n = 136; low-quality evidence, downgraded due to risk of bias and imprecision) (<LINK REF="CMP-003.10" TYPE="ANALYSIS">Analysis 3.10</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcome: other cognitive outcomes</HEADING>
<P>There was no difference between rosiglitazone plus metformin and glibenclamide (glyburide) plus metformin on the study authors' composite outcomes of working memory, learning ability and cognitive efficiency (defined in <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table) (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>; <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>; <LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>). After 24 weeks, there were small numerical advantages for rosiglitazone plus metformin over glibenclamide (glyburide) plus metformin on the CANTAB items of Paired Associates Learning, Pattern Recognition Memory and Rapid Visual Information Processing and a small numerical advantage for glibenclamide (glyburide) plus metformin over rosiglitazone plus metformin on the CANTAB item Reaction Time (<LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>; <LINK REF="CMP-003.05" TYPE="ANALYSIS">Analysis 3.5</LINK>; <LINK REF="CMP-003.07" TYPE="ANALYSIS">Analysis 3.7</LINK>; <LINK REF="CMP-003.08" TYPE="ANALYSIS">Analysis 3.8</LINK> respectively). We considered all these results to be low-quality evidence, downgraded due to risk of bias and imprecision.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcome: incidence of MCI</HEADING>
<P>No data were reported on the incidence of MCI.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcome: incidence of dementia or any subtype of dementia</HEADING>
<P>No data were reported on the incidence of dementia.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcome: adverse events</HEADING>
<P>No data were reported on hypoglycaemic events.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcome: mortality</HEADING>
<P>No data were reported on mortality.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 4: Metformin versus placebo</HEADING>
<P>One study with 72 participants made this comparison in Type 2 diabetes participants with depression; however, we were unable to extract the data because the results were reported only in an ANOVA format and no data could be extracted from the figures (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1610250739037713180787518930694&amp;format=REVMAN#STD-Guo-2014">Guo 2014</A>)</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2017-06-06 13:30:16 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2017-06-06 13:30:16 +0100" MODIFIED_BY="[Empty name]">
<P>We included seven studies of treatments recommended by international clinical practice guidelines (CPGs) for the management of Type 2 diabetes. Objective tests of cognitive function were used in all seven studies, but two studies did not report useable data. Consequently, data were available for three comparisons: 1) repaglinide versus glibenclamide (glyburide) (one study); 2) standard versus intensive glycaemic control (three studies); and 3) rosiglitazone plus metformin versus glibenclamide (glyburide) plus metformin (one study).</P>
<P>1. Repaglinide versus glibenclamide (glyburide): we identified one study with 156 older people (age range 60 to 78 years) with Type 2 diabetes. Using this study in our analysis, we found low-quality evidence of a small advantage on global cognitive function measured with the MMSE for glibenclamide (glyburide) over repaglinide after 12 months of treatment. However, we identified no difference in a composite score of attention and executive functions. The difference in MMSE score was 0.9 points. No Minimal Clinically Important Difference (MCID) for prevention studies has been established, but in participants without cognitive impairment at baseline the MMSE has a 'ceiling effect' (<LINK REF="REF-Spencer-2013" TYPE="REFERENCE">Spencer 2013</LINK>), and the FDA considers any statistically significant difference in cognitive outcomes in a prevention trial to be of interest (<LINK REF="REF-FDA-2013" TYPE="REFERENCE">FDA 2013</LINK>). Hence a difference of 0.9 MMSE points, although smaller than is often considered clinically important in dementia treatment trials, may be important in this context.</P>
<P>2. Intensive versus standard glycaemic control: we found four studies with 16,081 participants, but only two studies with 13,934 participants had extractable efficacy data and three studies with 14,908 participants had extractable data on adverse effects. We found moderate-quality evidence to suggest that there is probably little or no difference between intensive and standard treatment regimes on global cognitive function measured with the MMSE. We also found moderate-quality evidence of no effect on several cognitive subdomains. We found low-quality evidence from one study suggesting that there may be no difference in the incidence of dementia; moderate-quality evidence from two studies that patients receiving an intensive treatment strategy are more likely to experience at least one severe hypoglycaemic episode; and low-quality evidence from three studies that the treatment strategies may not be associated with any difference in all-cause mortality.</P>
<P>3. Rosiglitazone plus metformin versus glibenclamide (glyburide) plus metformin: we found only one study with 145 participants. We found low-quality evidence to suggest that there may be little or no difference in cognitive speed or working memory, but that there may be a small advantage for rosiglitazone plus metformin over glibenclamide (glyburide) plus metformin on episodic memory.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2017-06-03 21:29:37 +0100" MODIFIED_BY="[Empty name]">
<P>The studies identified for inclusion in this review were insufficient to address all of its objectives.</P>
<P>We found data on only two comparisons of different drug regimes. Both were small and relatively short studies and both used glibenclamide (glyburide) in one study arm. This is a long-acting sulphonylurea associated with a high risk of hypoglycaemia and is contraindicated in those over 65 years old (<LINK REF="REF-AGS-2012" TYPE="REFERENCE">AGS 2012</LINK>; <LINK REF="REF-ADA-2017d" TYPE="REFERENCE">ADA 2017d</LINK>). Therefore, we believe that these studies are not helpful to clinicians who are treating older people, in whom Type 2 diabetes is most common.</P>
<P>More data were available to compare intensive with standard glycaemic control. For this comparison we could include data from three much larger studies. One study focused on people older than 55 years with a high risk for cardiovascular disease events (<LINK REF="STD-Launer-2011" TYPE="STUDY">Launer 2011</LINK>). The intensive glycaemic control group in this study had a target HbA1c of less than 6.0% and the standard control group had a target HbA1c between 7.0% and 7.9%. Since this study was conducted, the target HbA1c in current clinical practice guidelines (CPGs) has been reduced to less than 6.5% (<LINK REF="REF-NICE-2016" TYPE="REFERENCE">NICE 2016</LINK>; <LINK REF="REF-AACE_x002f_ACE-2017" TYPE="REFERENCE">AACE/ACE 2017</LINK>) or less than 7% (<LINK REF="REF-ADA-2017e" TYPE="REFERENCE">ADA 2017e</LINK>). The standard control group in the trial has the HbA1c now expected for people who are frail, disabled, or have multiple comorbidities, although trial participants did not have these characteristics (<LINK REF="REF-ADA-2017d" TYPE="REFERENCE">ADA 2017d</LINK>). Therefore the findings in this trial might not be very applicable to current practice. The second study, <LINK REF="STD-ADVANCE-2008" TYPE="STUDY">ADVANCE 2008</LINK>, focused on patients aged over 55 years at the start of the study (mean 66 years) and with a history of major macrovascular or microvascular disease or at least one other risk factor for vascular disease. The intensive glycaemic group was treated with gliclazide plus other treatments to achieve a HbA1c of 6.5% or less, while the standard group was treated on the basis of local guidelines. This intensive glycaemic control is similar to the goal of current CPGs (<LINK REF="REF-ADA-2017c" TYPE="REFERENCE">ADA 2017c</LINK>; <LINK REF="REF-NICE-2016" TYPE="REFERENCE">NICE 2016</LINK>); hence the results of this study might be more useful to answer our clinical question, especially considering the long follow-up of five years. However, although the study evaluated global cognition and mortality, the incidence of dementia or MCI was not an outcome. The third study in this comparison, <LINK REF="STD-Zimering-2016" TYPE="STUDY">Zimering 2016</LINK>, focused on participants from the Veteran Affairs Medical Centers in US who were older than 41 years and who were non-responsive to a maximum dose of at least one oral agent or daily insulin injections, or both. A limitation of this study in the context of our clinical question is the average age of only 60 years at the start of the study, so that the study population was at low risk of cognitive decline over the five-year follow-up period.</P>
<P>An important point to note is that our analyses are not adjusted for the level of glycaemic control such as HbA1c, fasting plasma glucose (FPG), or postprandial plasma glucose. <LINK REF="STD-Abbatecola-2006" TYPE="STUDY">Abbatecola 2006</LINK> did adjust some analyses for haemoglobin A1c and coefficient of variation of FPG and found that the statistically significant differences in the composite score and MMSE were maintained. <LINK REF="STD-Ryan-2006" TYPE="STUDY">Ryan 2006</LINK> found some correlation between FPG and reduction in Paired Associates Learning (PAL) errors for both treatments (<LINK REF="STD-Ryan-2006" TYPE="STUDY">Ryan 2006</LINK>).</P>
<P>The included studies had a wide range of durations. Three of the seven studies had a follow-up for five years or more but only one of these had extractable data on cognition. Two studies had only six months of follow-up. A prolonged follow-up is necessary to detect those people who will progress to MCI or dementia over time, probably the most important cognitive outcomes in studies of this nature. The MMSE is not sensitive enough to detect small changes in cognition over short time periods and this is a limitation of those studies with short follow-up.</P>
<P>Overall, the review is limited by the small number of included studies and limited range of comparisons. Few studies of the efficacy of treatments for Type 2 diabetes have included measures of cognition. Where cognition has been studied, the tools used have not been standardised, and each study has used scales which evaluate different cognitive domains. This makes it very difficult to compare the findings of these studies.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2017-06-01 22:36:29 +0100" MODIFIED_BY="[Empty name]">
<P>We evaluated the quality of evidence according to the GRADE approach (<LINK REF="REF-Guyatt-2008" TYPE="REFERENCE">Guyatt 2008</LINK>). This considers study limitations, directness of the evidence, heterogeneity in the data, precision of effect estimates, and other reasons to downgrade the quality (including indications of publication bias). In this review, we evaluated the overall quality of evidence for all results to be low or moderate, meaning that our confidence in the results is limited. Reasons for rating down the quality of evidence were risk of bias in the included studies and imprecision of the results or small sample sizes.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2017-06-01 22:37:18 +0100" MODIFIED_BY="[Empty name]">
<P>It is likely that we identified all relevant studies due to the strengths of the search strategy. We were, however, unable to obtain the data we needed from study authors when it had not been included in the published papers.</P>
<P>We have excluded some studies which report cognitive effects of treatments of Type 2 diabetes by deciding to exclude interventions that are not recommended by international CPGs (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1610250739037713180787518930694&amp;format=REVMAN#STD-Sotaniemi--1995">Sotaniemi 1995</A>; <LINK REF="STD-Qiang-2015" TYPE="STUDY">Qiang 2015</LINK>). However, we consider this exclusion to be important in order to represent usual clinical practice.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2017-06-03 17:41:58 +0100" MODIFIED_BY="[Empty name]">
<P>The question whether Type 2 diabetes treatments could have some positive effect over cognition or decrease the incidence of dementia in randomised clinical trials has, to our knowledge, been evaluated only by one other meta-analysis (<LINK REF="REF-Tuligenga-2015" TYPE="REFERENCE">Tuligenga 2015</LINK>). Tuligenga's review focused on intensive glycaemic control versus standard glycaemic control and the search was up to date until October 2014 in MEDLINE and ALOIS. It included five studies, of which we included only two. The reason why we did not include the <LINK REF="STD-Cukierman_x002d_Yaffe-2014" TYPE="STUDY">Cukierman-Yaffe 2014</LINK> study is because this study was not only focused on Type 2 diabetes but included participants with impaired glucose tolerance and impaired fasting glucose. Data for Type 2 diabetes patients were not reported separately. We also excluded <LINK REF="REF-Weinstock-2011" TYPE="REFERENCE">Weinstock 2011</LINK> because the intervention &#8212; telemedicine &#8212; is not an approved intervention by international CPGs for Type 2 diabetes; and <LINK REF="REF-Koekkoek-2012" TYPE="REFERENCE">Koekkoek 2012</LINK>, which did not assess cognition at baseline. <LINK REF="REF-Tuligenga-2015" TYPE="REFERENCE">Tuligenga 2015</LINK> also found no differences in cognitive function between the intensive glycaemic control group and the standard glycaemic control group, in agreement with our results for this comparison.<BR/>
</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2017-04-25 21:52:00 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2017-04-25 21:52:00 +0100" MODIFIED_BY="[Empty name]">
<P>From the evidence available, there is no reason to favour any particular type of diabetic treatment in order to prevent cognitive impairment in people with Type 2 diabetes.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2017-04-17 16:54:03 +0100" MODIFIED_BY="[Empty name]">
<P>This review shows that the question of the effect of the treatment of Type 2 diabetes mellitus on the development of cognitive impairment and dementia studied in these trials should not be regarded as answered. Further research regarding the different treatments for Type 2 diabetes should include reliable and validated measures of cognitive function. A battery of tests covering a range of domains of cognitive function is desirable, to detect differential changes and to assist in avoiding confounding from factors such as education and premorbid abilities. Studies should be designed to permit analysis of changes in cognitive function in relation to the mechanisms and metabolic effects of treatment, in particular insulin and glucose levels, and indices of glucose homoeostasis. Relationships of cognitive function with mood and other aspects of functional status and quality of life also need further elucidation.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2017-02-09 09:21:21 +0000" MODIFIED_BY="[Empty name]">
<P>The authors would like to thank Anna Noel-Storr, Trials Search Co-ordinator of the Cochrane Dementia and Cognitive Improvement Group, for her assistance with the design of the search strategy.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2017-06-03 17:45:46 +0100" MODIFIED_BY="[Empty name]">
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2017-06-03 17:45:41 +0100" MODIFIED_BY="[Empty name]">
<P>AAS: conceived the review, conducted trial selection, participated in completion of the report and writing the final draft.</P>
<P>MCH: conducted trial selection.</P>
<P>RV: coordinated the review process, data extraction, risk of bias assessment, analyses, GRADE assessment, 'Summary of findings' table construction, interpretation of results, participated in completion of the report and writing the final draft.</P>
<P>GM: coordinated the review process, data extraction, risk of bias assessment, analyses, GRADE assessment, 'Summary of findings' table construction, interpretation of results, participated in completion of the report and writing the final draft.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2017-06-03 17:46:01 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>We have updated the methods in the review since the original review in accordance with current Cochrane and Cochrane Dementia and Cognitive Improvement Group guidelines.</LI>
<LI>We included 'Summary of findings' tables and a methodological assessment of the quality of evidence with the GRADE methodology.</LI>
<LI>We separated blinding of participants and personnel from blinding of outcome assessment.</LI>
<LI>We added two new inclusion criteria: we included only trials that assessed a treatment for Type 2 diabetes that was approved by international guidelines; and we required a minimum intervention duration of 12 weeks.</LI>
<LI>We specified a method for selecting among multiple scales used in a study to measure the same cognitive domain.</LI>
<LI>The authors of the review have changed.</LI>
</UL>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2017-06-15 11:20:32 +0100" MODIFIED_BY="Sue Marcus">
<STUDIES MODIFIED="2017-06-03 20:33:05 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2017-06-03 19:25:04 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Abbatecola-2006" MODIFIED="2017-01-21 22:40:45 +0000" MODIFIED_BY="[Empty name]" NAME="Abbatecola 2006" YEAR="2006">
<REFERENCE MODIFIED="2017-01-21 22:40:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abbatecola AM, Rizzo MR, Barbieri M, Grella R, Arciello A, Laieta MT, et al</AU>
<TI>Postprandial plasma glucose excursions and cognitive functioning in aged type 2 diabetics</TI>
<SO>Neurology</SO>
<YR>2006</YR>
<VL>67</VL>
<NO>2</NO>
<PG>235-40</PG>
<IDENTIFIERS MODIFIED="2017-01-21 22:40:45 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5764892"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2017-01-21 22:40:35 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5764891"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ADVANCE-2008" MODIFIED="2017-06-01 23:38:02 +0100" MODIFIED_BY="[Empty name]" NAME="ADVANCE 2008" YEAR="2001">
<REFERENCE MODIFIED="2017-06-01 23:38:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Advance Collaborative Group 2001</AU>
<TI>Rationale and design of the ADVANCE study: a randomised trial of blood pressure lowering and intensive glucose control in high-risk individuals with type 2 diabetes mellitus Action in Diabetes and Vascular Disease: PreterAx and DiamicroN Modified-Release Controlled Evaluation</TI>
<SO>Journal of Hypertension. Supplement</SO>
<YR>2001</YR>
<VL>19 Suppl</VL>
<NO>4</NO>
<PG>S21-8</PG>
<IDENTIFIERS MODIFIED="2017-01-21 22:42:20 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5764893"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2017-01-21 22:42:49 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2850593"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Araki-2012" MODIFIED="2017-06-03 19:24:05 +0100" MODIFIED_BY="[Empty name]" NAME="Araki 2012" YEAR="2012">
<REFERENCE MODIFIED="2017-06-03 19:24:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Araki A, limuro S, Sakurai T, Umegaki H, Iijima K, Nakano H, et al</AU>
<TI>Long-term multiple risk factor interventions in Japanese elderly diabetic patients: the Japanese Elderly Diabetes Intervention Trial--study design, baseline characteristics and effects of intervention</TI>
<SO>Geriatrics &amp; Gerontology International</SO>
<YR>2012</YR>
<VL>Suppl 1</VL>
<PG>7-17</PG>
<IDENTIFIERS MODIFIED="2017-01-21 22:44:33 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5764894"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2017-01-21 22:43:12 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2850595"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guo-2014" MODIFIED="2017-06-03 19:25:04 +0100" MODIFIED_BY="[Empty name]" NAME="Guo 2014" YEAR="2014">
<REFERENCE MODIFIED="2017-06-03 19:25:04 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guo M, Mi J, Jiang QM, Xu JM, Tang YY, Tian G, et al</AU>
<TI>Metformin may produce antidepressant effects through improvement of cognitive function among depressed patients with diabetes mellitus</TI>
<SO>Clinical and Experimental Pharmacology &amp; Physiology</SO>
<YR>2014</YR>
<VL>41</VL>
<NO>9</NO>
<PG>650-6</PG>
<IDENTIFIERS MODIFIED="2017-01-21 22:45:01 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5764895"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2017-01-21 22:44:47 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2850597"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Launer-2011" MODIFIED="2017-06-01 00:07:54 +0100" MODIFIED_BY="[Empty name]" NAME="Launer 2011" YEAR="2011">
<REFERENCE MODIFIED="2017-06-01 00:07:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Launer LJ, Miller ME, Williamson JD, Lazar RM, Gerstein HC, Murray AM, et al</AU>
<TI>Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy</TI>
<SO>Lancet Neurology</SO>
<YR>2011</YR>
<VL>10</VL>
<NO>11</NO>
<PG>969&#8211;77</PG>
<IDENTIFIERS MODIFIED="2017-01-21 22:46:42 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5764896"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2017-01-21 22:45:11 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2850599"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ryan-2006" MODIFIED="2017-01-21 22:47:16 +0000" MODIFIED_BY="[Empty name]" NAME="Ryan 2006" YEAR="2006">
<REFERENCE MODIFIED="2017-01-21 22:47:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ryan CM, Freed MI, Rood JA, Cobitz AR, Waterhouse BR, Strachan MW</AU>
<TI>Improving metabolic control leads to better working memory in adults with type 2 diabetes</TI>
<SO>Diabetes Care</SO>
<YR>2006</YR>
<VL>29</VL>
<NO>2</NO>
<PG>345-51</PG>
<IDENTIFIERS MODIFIED="2017-01-21 22:47:16 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5764897"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2017-01-21 22:46:52 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2850603"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zimering-2016" MODIFIED="2017-06-01 00:09:16 +0100" MODIFIED_BY="[Empty name]" NAME="Zimering 2016" YEAR="2016">
<REFERENCE MODIFIED="2017-06-01 00:09:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zimering MB, Knight J, Ge L, Bahn G, and the VADT Investigators</AU>
<TI>Predictors of Cognitive Decline in Older Adult Type 2 Diabetes from the Veterans Affairs Diabetes Trial</TI>
<SO>Frontiers in Endocrinology [electronic resource]</SO>
<YR>2016</YR>
<VL>7</VL>
<PG>1-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5764899"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5764898"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2017-06-03 19:41:36 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Baker-2010" MODIFIED="2017-06-01 23:47:26 +0100" MODIFIED_BY="[Empty name]" NAME="Baker 2010" YEAR="2010">
<REFERENCE MODIFIED="2017-06-01 23:47:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baker LD, Frank LL, Foster-Schubert K, Green PS, Wilkinson CW, McTiernan A, et al</AU>
<TI>Aerobic exercise improves cognition for older adults with glucose intolerance, a risk factor for Alzheimer's disease</TI>
<SO>Journal of Alzheimer's Disease</SO>
<YR>2010</YR>
<VL>22</VL>
<NO>2</NO>
<PG>569-79</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5764901"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5764900"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cukierman_x002d_Yaffe-2014" MODIFIED="2017-06-03 19:27:13 +0100" MODIFIED_BY="[Empty name]" NAME="Cukierman-Yaffe 2014" YEAR="2014">
<REFERENCE MODIFIED="2017-06-03 19:27:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cukierman-Yaffe T, Bosch J, Diaz R, Dyal L, Hancu N, Hildebrandt P, et al; ORIGIN Investigators</AU>
<TI>Effects of basal insulin glargine and omega-3 fatty acid on cognitive decline and probable cognitive impairment in people with dysglycaemia: a substudy of the ORIGIN trial</TI>
<SO>Lancet: Diabetes and Endocrinology</SO>
<YR>2014</YR>
<VL>2</VL>
<NO>7</NO>
<PG>562-72</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5764903"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5764902"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Daly-2014" MODIFIED="2017-06-03 19:28:12 +0100" MODIFIED_BY="[Empty name]" NAME="Daly 2014" YEAR="2014">
<REFERENCE MODIFIED="2017-06-03 19:28:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Daly RM, Miller EG, Dunstan DW, Kerr DA, Solah V, Menzies D, et al</AU>
<TI>The effects of progressive resistance training combined with a whey-protein drink and vitamin D supplementation on glycaemic control, body composition and cardiometabolic risk factors in older adults with type 2 diabetes: study protocol for a randomized controlled trial</TI>
<SO>Trials</SO>
<YR>2014</YR>
<VL>15</VL>
<PG>431</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5764905"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5764904"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Davies-2015" MODIFIED="2017-02-02 13:26:51 +0000" MODIFIED_BY="[Empty name]" NAME="Davies 2015" YEAR="2015">
<REFERENCE MODIFIED="2017-02-02 13:26:51 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davies AK, McGale N, Humphries SE, Hirani SP, Beaney KE, Bappa DAS, et al</AU>
<TI>Effectiveness of a self-management intervention with personalised genetic and lifestyle-related risk information on coronary heart disease and diabetes-related risk in type 2 diabetes (CoRDia): study protocol for a randomised controlled trial</TI>
<SO>Trials</SO>
<YR>2015</YR>
<VL>16</VL>
<NO>547</NO>
<PG>1-10</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5764907"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5764906"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Espeland-2016" MODIFIED="2017-06-03 19:29:44 +0100" MODIFIED_BY="[Empty name]" NAME="Espeland 2016" YEAR="2016">
<REFERENCE MODIFIED="2017-06-03 19:29:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Espeland MA, Erickson K, Neiberg RH, Jakicic JM, Wadden TA, Wing RR, et al</AU>
<TI>Brain and white matter hyperintensity volumes after 10 years of random assignment to lifestyle intervention</TI>
<SO>Diabetes Care</SO>
<YR>2016</YR>
<VL>39</VL>
<NO>5</NO>
<PG>764-71</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5764909"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5764908"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gatskikh-2015" MODIFIED="2017-06-03 19:31:11 +0100" MODIFIED_BY="[Empty name]" NAME="Gatskikh 2015" YEAR="2015">
<REFERENCE MODIFIED="2017-06-03 19:31:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gatskikh IV, Veselova OF, Brikman IN, Shalda TP, Varygina EL, Kuznetsov MN, et al</AU>
<TI>[Effectiveness of cytoflavin for the correction of cognitive impairments in patients with type 2 diabetes mellitus][article in Russian]</TI>
<SO>Eksperimental'naia i klinicheskaia farmakologiia</SO>
<YR>2015</YR>
<VL>78</VL>
<NO>11</NO>
<PG>21-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5764911"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5764910"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gilchrist-2014" MODIFIED="2017-06-01 23:52:42 +0100" MODIFIED_BY="[Empty name]" NAME="Gilchrist 2014" YEAR="2014">
<REFERENCE MODIFIED="2017-06-01 23:52:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gilchrist M, Winyard PG, Fulford J, Anning C, Shore AC, Benjamin N</AU>
<TI>Dietary nitrate supplementation improves reaction time in type 2 diabetes: Development and application of a novel nitrate-depleted beetroot juice placebo</TI>
<SO>Nitric Oxide : Biology and Chemistry</SO>
<YR>2014</YR>
<VL>40</VL>
<PG>67-74</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5764913"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5764912"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gradman-1993" MODIFIED="2017-06-03 19:36:30 +0100" MODIFIED_BY="[Empty name]" NAME="Gradman 1993" YEAR="1993">
<REFERENCE MODIFIED="2017-06-03 19:36:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gradman TJ, Laws A, Thompson LW, Reaven GM</AU>
<TI>Verbal learning and/or memory improves with glycemic control in older subjects with non-insulin dependent diabetes mellitus</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>1993</YR>
<VL>41</VL>
<NO>12</NO>
<PG>1305-12</PG>
<IDENTIFIERS MODIFIED="2017-01-21 22:37:09 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5764914"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2017-01-21 22:37:47 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2850605"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Inouye-2015" MODIFIED="2017-06-01 23:54:54 +0100" MODIFIED_BY="[Empty name]" NAME="Inouye 2015" YEAR="2015">
<REFERENCE MODIFIED="2017-06-01 23:54:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Inouye J, Li D, Davis J, Arakaki R</AU>
<TI>Psychosocial and Clinical Outcomes of a Cognitive Behavioral Therapy for Asians and Pacific Islanders with Type 2 Diabetes: A Randomized Clinical Trial</TI>
<SO>Hawai'i Journal of Medicine &amp; Public Health : a journal of Asia Pacific Medicine &amp; Public Health</SO>
<YR>2015</YR>
<VL>74</VL>
<NO>11</NO>
<PG>360-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5764916"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5764915"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Luchsinger-2011" MODIFIED="2017-06-03 19:38:18 +0100" MODIFIED_BY="[Empty name]" NAME="Luchsinger 2011" YEAR="2011">
<REFERENCE MODIFIED="2017-06-03 19:38:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Luchsinger JA, Palmas W, Teresi JA, Silver S, Kong J, Eimicke JP, et al</AU>
<TI>Improved diabetes control in the elderly delays global cognitive decline</TI>
<SO>Journal of Nutrition, Health &amp; Aging</SO>
<YR>2011</YR>
<VL>15</VL>
<NO>6</NO>
<PG>445-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2850602"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2017-01-21 22:38:23 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2850601"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meneilly-1993" MODIFIED="2017-06-01 23:57:41 +0100" MODIFIED_BY="[Empty name]" NAME="Meneilly 1993" YEAR="1993">
<REFERENCE MODIFIED="2017-06-01 23:57:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meneilly GS, Cheung E, Tessier D, Yakura C, Tuokko H</AU>
<TI>The effect of improved glycemic control on cognitive functions in the elderly with diabetes</TI>
<SO>Journal of Gerontology</SO>
<YR>1993</YR>
<VL>48</VL>
<NO>4</NO>
<PG>M117-21</PG>
<IDENTIFIERS MODIFIED="2017-01-21 22:38:34 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5764917"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2017-01-21 22:38:06 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2850607"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Naor-1997" MODIFIED="2017-06-01 23:58:29 +0100" MODIFIED_BY="[Empty name]" NAME="Naor 1997" YEAR="1997">
<REFERENCE MODIFIED="2017-06-01 23:58:29 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Naor M, Steingrüber HJ, Westhoff K, Schottenfeld-Naor Y, Gries AF.</AU>
<TI>Cognitive function in elderly non-insulin-dependent diabetic patients before and after inpatient treatment for metabolic control</TI>
<SO>Journal of Diabetes and Its Complications</SO>
<YR>1997</YR>
<VL>11</VL>
<NO>1</NO>
<PG>40-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5764919"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5764918"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT02415556" MODIFIED="2017-06-01 23:58:45 +0100" MODIFIED_BY="[Empty name]" NAME="NCT02415556" YEAR="2015">
<REFERENCE MODIFIED="2017-06-01 23:58:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<TI>Memory Aid by Intranasal Insulin in Diabetes (MemAID) (MemAID)</TI>
<SO>clinicaltrials.gov/ct2/show/NCT02415556</SO>
<YR>(First received: March 23, 2015)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5764921"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5764920"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT02486341" MODIFIED="2017-06-01 23:59:09 +0100" MODIFIED_BY="[Empty name]" NAME="NCT02486341" YEAR="2015">
<REFERENCE MODIFIED="2017-06-01 23:59:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<TI>Daily Glycaemic Variability in Frail or Disabled Older Patients With Diabetes Over 75 Treated With Basal Insulin (VARQUOGLY)</TI>
<SO>clinicaltrials.gov/ct2/show/NCT02486341</SO>
<YR>(First received: 9 June 2015)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5764923"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5764922"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT02879409" MODIFIED="2017-06-03 19:39:09 +0100" MODIFIED_BY="[Empty name]" NAME="NCT02879409" YEAR="2016">
<REFERENCE MODIFIED="2017-06-03 19:39:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<TI>HbA1c Variability in Type II Diabetes</TI>
<SO>clinicaltrials.gov/ct2/show/NCT02879409</SO>
<YR>(First received: 13 July 2016)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5764925"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5764924"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Padwal-2016" MODIFIED="2017-06-03 19:39:42 +0100" MODIFIED_BY="[Empty name]" NAME="Padwal 2016" YEAR="2016">
<REFERENCE MODIFIED="2017-06-03 19:39:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Padwal R, McAlister FA, Wood PW, Boulanger P, Fradette M, Klarenbach S, et al</AU>
<TI>Telemonitoring and Protocolized Case Management for Hypertensive Community-Dwelling Seniors With Diabetes: Protocol of the TECHNOMED Randomized Controlled Trial</TI>
<SO>Journal of Medical Internet Research</SO>
<YR>2016</YR>
<VL>5</VL>
<NO>2</NO>
<PG>e107</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5764927"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5764926"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Qiang-2015" MODIFIED="2017-06-02 00:06:59 +0100" MODIFIED_BY="[Empty name]" NAME="Qiang 2015" YEAR="2015">
<REFERENCE MODIFIED="2017-06-02 00:06:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Qiang G, Wenzhai C, Huan Z, Yuxia Z, Dongdong Y, Sen Z, et al</AU>
<TI>Effect of Sancaijiangtang on plasma nitric oxide and endothelin-1 levels in patients with type 2 diabetes mellitus and vascular dementia: a single-blind randomized controlled trial</TI>
<SO>Journal of Traditional Chinese Medicine / Chung i Tsa Chih Ying Wen Pan - sponsored by All-China Association of Traditional Chinese Medicine, Academy of Traditional Chinese Medicine</SO>
<YR>2015</YR>
<VL>35</VL>
<NO>4</NO>
<PG>375-80</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5764929"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5764928"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sotaniemi--1995" MODIFIED="2016-08-03 21:54:19 +0100" MODIFIED_BY="[Empty name]" NAME="Sotaniemi  1995" YEAR="1995">
<REFERENCE MODIFIED="2016-08-03 21:54:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sotaniemi EA, Haapakosi E, Rautio A</AU>
<TI>Ginseng therapy in non-insulin-dependent diabetic patients</TI>
<SO>Diabetes Care</SO>
<YR>1995</YR>
<VL>18</VL>
<NO>10</NO>
<PG>1373-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5764931"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5764930"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Testa-1998" MODIFIED="2017-06-02 00:07:33 +0100" MODIFIED_BY="[Empty name]" NAME="Testa 1998" YEAR="1998">
<REFERENCE MODIFIED="2017-06-02 00:07:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Testa MA, Simonson DC</AU>
<TI>Health economics benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled, double-blind trial</TI>
<SO>Journal of the American Medical Association</SO>
<YR>1998</YR>
<VL>280</VL>
<NO>17</NO>
<PG>1490-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5764933"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5764932"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tovi-1998" MODIFIED="2017-06-02 00:07:44 +0100" MODIFIED_BY="[Empty name]" NAME="Tovi 1998" YEAR="1998">
<REFERENCE MODIFIED="2017-06-02 00:07:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tovi J, Engfeldt P</AU>
<TI>Well-being and symptoms in the elderly type 2 diabetes patients with poor metabolic control: effect of insulin treatment.</TI>
<SO>Practical Diabetes International</SO>
<YR>1998</YR>
<VL>15</VL>
<NO>3</NO>
<PG>73-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5764935"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5764934"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-UKPDS-1999" MODIFIED="2017-06-02 00:09:34 +0100" MODIFIED_BY="[Empty name]" NAME="UKPDS 1999" YEAR="1999">
<REFERENCE MODIFIED="2017-06-02 00:09:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>UK Prospective Study Diabetes Group.</AU>
<TI>Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control</TI>
<SO>Diabetes Care</SO>
<YR>1999</YR>
<VL>22</VL>
<NO>7</NO>
<PG>1125-36</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5764937"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5764936"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vijayakumar-2011" MODIFIED="2017-06-02 00:10:23 +0100" MODIFIED_BY="[Empty name]" NAME="Vijayakumar 2011" YEAR="2011">
<REFERENCE MODIFIED="2017-06-02 00:10:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anand Vijayakumar PR, Kumar BJ, Varghese Jenny M, Das Sushanta K.</AU>
<TI>Supplementation of vitamin e improves cognitive status and oxidative stress in type 2 diabetes mellitus</TI>
<SO>International Research Journal of Pharmacy</SO>
<YR>2011</YR>
<VL>2</VL>
<NO>11</NO>
<PG>169-72</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5764939"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5764938"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wong-2016" MODIFIED="2017-06-03 19:41:36 +0100" MODIFIED_BY="[Empty name]" NAME="Wong 2016" YEAR="2016">
<REFERENCE MODIFIED="2017-06-03 19:41:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wong RH, Raederstorff D, Howe PR</AU>
<TI>Acute Resveratrol Consumption Improves Neurovascular Coupling Capacity in Adults with Type 2 Diabetes Mellitus</TI>
<SO>Nutrients</SO>
<YR>Acute Resveratrol Consumption Improves Neurovascular Coupling Capacity in Adults with Type 2 Diabetes Mellitus.</YR>
<VL>8</VL>
<NO>7</NO>
<PG>E425</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5764941"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5764940"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2016-08-03 18:11:45 +0100" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES MODIFIED="2017-06-03 20:33:05 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="UNPUB" ID="STD-ACTRN12614000222640" MODIFIED="2017-06-03 19:41:52 +0100" MODIFIED_BY="[Empty name]" NAME="ACTRN12614000222640" YEAR="2640">
<REFERENCE MODIFIED="2017-06-03 19:41:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<TI>Cognition and Type 2 Diabetes &#8211; A pilot randomised controlled trial (RCT) of exercise</TI>
<SO>apps.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12614000222640</SO>
<YR>2014</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5764943"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5764942"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT02348801" MODIFIED="2017-06-03 20:33:05 +0100" MODIFIED_BY="[Empty name]" NAME="NCT02348801" YEAR="2015">
<REFERENCE MODIFIED="2017-06-03 20:33:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<TI>Lifestyle Intervention for Senior Diabetics (LISD)</TI>
<SO>clinicaltrials.gov/ct2/show/NCT02348801</SO>
<YR>2015</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5764945"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5764944"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT02409238" MODIFIED="2017-06-03 19:42:09 +0100" MODIFIED_BY="[Empty name]" NAME="NCT02409238" YEAR="2015">
<REFERENCE MODIFIED="2017-06-03 19:42:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<TI>Insulin Resistance and Mild Cognitive Impairment (MCI) in Older Chinese Adults With Pre-Diabetes and Diabetes: Cognitive Effects of Lifestyle Intervention and Metformin Treatment in a Randomized Controlled Trial</TI>
<SO>clinicaltrials.gov/show/NCT02409238</SO>
<YR>2015</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5764947"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5764946"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Watson-2015" MODIFIED="2017-06-03 19:42:39 +0100" MODIFIED_BY="[Empty name]" NAME="Watson 2015" YEAR="2015">
<REFERENCE MODIFIED="2017-06-03 19:42:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Watson NA, Dyer KA, Buckley JD, Brinkworth GD, Coates AM, Parfitt G, et al</AU>
<TI>A randomised trial comparing low-fat diets differing in carbohydrate and protein ratio, combined with regular moderate intensity exercise, on glycaemic control, cardiometabolic risk factors, food cravings, cognitive function and psychological wellbeing in adults with type 2 diabetes: Study protocol</TI>
<SO>Contemporary Clinical Trials</SO>
<YR>2015</YR>
<VL>45</VL>
<PG>217-25</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5764949"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5764948"/></IDENTIFIERS>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2017-06-08 09:48:06 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2017-06-08 09:48:06 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-AACE_x002f_ACE-2017" MODIFIED="2017-06-03 19:44:18 +0100" MODIFIED_BY="[Empty name]" NAME="AACE/ACE 2017" TYPE="OTHER">
<AU>Garber AJ, Abrahamson MJ, Joshua I. Barzilay JI, Blonde L, Bloomgarden ZT, et al</AU>
<TI>Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm &#8211; 2017 Executive Summary</TI>
<SO>Endocrine Practice journals.aace.com/doi/pdf/10.4158/EP161682.CS</SO>
<YR>2017</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Abraira-2003" MODIFIED="2017-06-03 19:44:54 +0100" MODIFIED_BY="[Empty name]" NAME="Abraira 2003" TYPE="JOURNAL_ARTICLE">
<AU>Abraira C, Duckworth W, McCarren M, Emanuele N, Arca D, Reda D, et al</AU>
<TI>Design of the cooperative study on glycemic controland complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial</TI>
<SO>Journal of Diabetes and Its Complications</SO>
<YR>2003</YR>
<VL>17</VL>
<NO>6</NO>
<PG>314-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ADA-2017a" MODIFIED="2017-02-01 13:40:58 +0000" MODIFIED_BY="[Empty name]" NAME="ADA 2017a" TYPE="JOURNAL_ARTICLE">
<AU>American Diabetes Association</AU>
<TI>Classification and Diagnosis of Diabetes</TI>
<SO>Diabetes Care</SO>
<YR>2017</YR>
<VL>40 Suppl 1</VL>
<PG>S11-S24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ADA-2017b" MODIFIED="2017-02-01 13:38:43 +0000" MODIFIED_BY="[Empty name]" NAME="ADA 2017b" TYPE="JOURNAL_ARTICLE">
<AU>American Diabetes Association</AU>
<TI>Pharmacologic Approaches to Glycemic Treatment</TI>
<SO>Diabetes Care</SO>
<YR>2017</YR>
<VL>40 Suppl 1</VL>
<PG>S64-S74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ADA-2017c" MODIFIED="2017-02-01 13:38:36 +0000" MODIFIED_BY="[Empty name]" NAME="ADA 2017c" TYPE="JOURNAL_ARTICLE">
<AU>American Diabetes Association</AU>
<TI>Lifestyle Management</TI>
<SO>Diabetes Care</SO>
<YR>2017</YR>
<VL>40 Suppl 1</VL>
<PG>S33-S43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ADA-2017d" MODIFIED="2017-02-01 13:38:31 +0000" MODIFIED_BY="[Empty name]" NAME="ADA 2017d" TYPE="JOURNAL_ARTICLE">
<AU>American Diabetes Association</AU>
<TI>Older Adults</TI>
<SO>Diabetes Care</SO>
<YR>2017</YR>
<VL>40 Suppl 1</VL>
<PG>S99-S104</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ADA-2017e" MODIFIED="2017-02-01 13:38:24 +0000" MODIFIED_BY="[Empty name]" NAME="ADA 2017e" TYPE="JOURNAL_ARTICLE">
<AU>American Diabetes Association</AU>
<TI>Glycemic Targets</TI>
<SO>Diabetes Care</SO>
<YR>2017</YR>
<VL>40 Suppl 1</VL>
<PG>S48-S56</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-AGS-2012" MODIFIED="2017-01-27 14:42:35 +0000" MODIFIED_BY="[Empty name]" NAME="AGS 2012" TYPE="JOURNAL_ARTICLE">
<AU>American Geriatrics Society</AU>
<TI>American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>2012</YR>
<VL>60</VL>
<NO>4</NO>
<PG>616-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Atkinson-1994" MODIFIED="2017-06-02 00:12:40 +0100" MODIFIED_BY="[Empty name]" NAME="Atkinson 1994" TYPE="JOURNAL_ARTICLE">
<AU>Atkinson MA, Maclaren NK</AU>
<TI>The pathogenesis of insulin-dependent diabetes mellitus</TI>
<SO>New England Journal of Medicine</SO>
<YR>1994</YR>
<VL>331</VL>
<NO>21</NO>
<PG>1428-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barzilay-2013" MODIFIED="2017-06-02 00:13:56 +0100" MODIFIED_BY="[Empty name]" NAME="Barzilay 2013" TYPE="JOURNAL_ARTICLE">
<AU>Barzilay JI, Lovato JF, Murray AM, Williamson J, Ismail-Beigi F, Karl D, et al</AU>
<TI>Albuminuria and cognitive decline in people with diabetes and normal renal function</TI>
<SO>Clinical Journal of the American Society of Nephrology</SO>
<YR>2013</YR>
<VL>8</VL>
<NO>11</NO>
<PG>1907-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bruce-2008" MODIFIED="2017-06-03 19:48:23 +0100" MODIFIED_BY="[Empty name]" NAME="Bruce 2008" TYPE="JOURNAL_ARTICLE">
<AU>Bruce DG, Davis WA, Casey GP, Starkstein SE, Clarnette RM, Almeida OP, et al</AU>
<TI>Predictors of cognitive decline in older individuals with diabetes</TI>
<SO>Diabetes Care</SO>
<YR>2008</YR>
<VL>31</VL>
<NO>11</NO>
<PG>2103-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bunn-2014" MODIFIED="2017-06-02 00:19:36 +0100" MODIFIED_BY="[Empty name]" NAME="Bunn 2014" TYPE="JOURNAL_ARTICLE">
<AU>Bunn F, Burn A-M, Goodman C, Rait G, Norton S, Robinson L, et al</AU>
<TI>Comorbidity and dementia: a scoping review of the literature</TI>
<SO>BMC Medicine</SO>
<YR>2014</YR>
<VL>12</VL>
<NO>192</NO>
<PG>1-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cheng-2012" MODIFIED="2017-06-03 19:45:56 +0100" MODIFIED_BY="[Empty name]" NAME="Cheng 2012" TYPE="JOURNAL_ARTICLE">
<AU>Cheng G, Huang C, Deng H, Wang H</AU>
<TI>Diabetes as a risk factor for dementia and mild cognitive impairment: a meta-analysis of longitudinal studies</TI>
<SO>Internal Medicine Journal</SO>
<YR>2012</YR>
<VL>42</VL>
<NO>5</NO>
<PG>484-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Crane-2013" MODIFIED="2017-06-03 19:45:39 +0100" MODIFIED_BY="[Empty name]" NAME="Crane 2013" TYPE="JOURNAL_ARTICLE">
<AU>Crane PK, Walker R, Hubbard RA, Li G, Nathan DM, Zheng H, et al</AU>
<TI>Glucose levels and risk of dementia</TI>
<SO>New England Journal of Medicine</SO>
<YR>2013</YR>
<VL>369</VL>
<NO>6</NO>
<PG>540-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cukierman-2005" MODIFIED="2015-08-09 19:15:40 +0100" MODIFIED_BY="[Empty name]" NAME="Cukierman 2005" TYPE="JOURNAL_ARTICLE">
<AU>Cukierman T, Gerstein HC, Williamson JD</AU>
<TI>Cognitive decline and dementia in diabetes&#8212;systematic overview of prospective observational studies</TI>
<SO>Diabetologia</SO>
<YR>2005</YR>
<VL>48</VL>
<NO>12</NO>
<PG>2460-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DCCT_x002f_EDIC-2007" MODIFIED="2017-06-02 00:20:37 +0100" MODIFIED_BY="[Empty name]" NAME="DCCT/EDIC 2007" TYPE="JOURNAL_ARTICLE">
<AU>The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group</AU>
<TI>Long-Term Effect of Diabetes and Its Treatment on Cognitive Function</TI>
<SO>New England Journal of Medicine</SO>
<YR>2007</YR>
<VL>356</VL>
<NO>18</NO>
<PG>1842-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-de-la-Monte-2008" MODIFIED="2017-06-02 00:21:17 +0100" MODIFIED_BY="[Empty name]" NAME="de la Monte 2008" TYPE="JOURNAL_ARTICLE">
<AU>de la Monte SM, Wands JR</AU>
<TI>Alzheimer's disease is type 3 diabetes-evidence reviewed</TI>
<SO>Journal of Diabetes Science and Technology</SO>
<YR>2008</YR>
<VL>2</VL>
<NO>6</NO>
<PG>1101-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-De-la-Torre-2000" NAME="De la Torre 2000" TYPE="OTHER">
<AU>De la Torre DJ</AU>
<TI>Critically attained threshold of cerebral hypoperfusion: can it cause Alzheimer&#8217;s disease?</TI>
<SO>Annals of the New York Academy of Sciences</SO>
<YR>2000</YR>
<PG>136-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DSM_x002d_5-2013" MODIFIED="2017-05-31 22:07:41 +0100" MODIFIED_BY="[Empty name]" NAME="DSM-5 2013" TYPE="BOOK">
<AU>American Psychiatric Association</AU>
<SO>Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)</SO>
<YR>2013</YR>
<PB>Arlington</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DSM_x002d_IV-2004" MODIFIED="2016-04-04 11:36:09 +0100" MODIFIED_BY="[Empty name]" NAME="DSM-IV 2004" TYPE="BOOK">
<AU>American Psychiatric Association</AU>
<SO>Diagnostic and Statistical Manual of Mental Disorders</SO>
<YR>1994</YR>
<EN>4th</EN>
<PB>American Psychiatric Association</PB>
<CY>Washington, DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Duckworth-2009" MODIFIED="2017-06-01 00:10:17 +0100" MODIFIED_BY="[Empty name]" NAME="Duckworth 2009" TYPE="JOURNAL_ARTICLE">
<AU>Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al</AU>
<TI>Glucose control and vascular complications in veterans with type 2 diabetes</TI>
<SO>New England Journal of Medicine</SO>
<YR>2009</YR>
<VL>360</VL>
<NO>2</NO>
<PG>129-39</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Exalto-2014" MODIFIED="2017-06-02 00:22:16 +0100" MODIFIED_BY="[Empty name]" NAME="Exalto 2014" TYPE="JOURNAL_ARTICLE">
<AU>Exalto LG, Biessels GJ, Karter AJ, Huang ES, Quesenberry CP Jr, Whitmer RA</AU>
<TI>Severe diabetic retinal disease and dementia risk in type 2 diabetes</TI>
<SO>Journal of Alzheimer's Disease</SO>
<YR>2014</YR>
<VL>42</VL>
<NO>Suppl 3</NO>
<PG>S109-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-FDA-2013" MODIFIED="2017-06-02 00:22:36 +0100" MODIFIED_BY="[Empty name]" NAME="FDA 2013" TYPE="OTHER">
<AU>U.S. Department of Health and Human Services Food and Drug AdministrationCenter for Drug Evaluation and Research (CDER)</AU>
<TI>Guidance for Industry Alzheimer&#8217;s Disease: Developing Drugs for the Treatment of Early Stage Disease</TI>
<SO>www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm338287.pdf</SO>
<YR>2013</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gregg-2000" NAME="Gregg 2000" TYPE="OTHER">
<AU>Gregg EW, Yaffe K, Cauley JA, Rolka DB, Blackwell TL, Narayan V, Cummings SR</AU>
<TI>Is diabetes associated with cognitive impairment and cognitive decline among older women</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2000</YR>
<VL>160</VL>
<PG>174-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2008" MODIFIED="2017-06-03 19:51:02 +0100" MODIFIED_BY="[Empty name]" NAME="Guyatt 2008" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al; GRADE Working Group</AU>
<TI>GRADE: an emerging consensus on rating quality of evidence and strength of recommendations</TI>
<SO>BMJ</SO>
<YR>2008</YR>
<VL>336</VL>
<NO>7650</NO>
<PG>924-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2017-06-01 00:14:37 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JP, Green S, (editors)</AU>
<TI>
<I>Cochrane Handbook for Systematic Reviews of Interventions</I> Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from handbook.cochrane.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hugo-2014" MODIFIED="2017-06-02 00:30:30 +0100" MODIFIED_BY="[Empty name]" NAME="Hugo 2014" TYPE="JOURNAL_ARTICLE">
<AU>Hugo J, Ganguli M</AU>
<TI>Dementia and Cognitive impairment</TI>
<SO>Clinics in Geriatric Medicine</SO>
<YR>2014</YR>
<VL>30</VL>
<NO>3</NO>
<PG>421-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kahn-2014" MODIFIED="2017-01-20 18:50:16 +0000" MODIFIED_BY="[Empty name]" NAME="Kahn 2014" TYPE="JOURNAL_ARTICLE">
<AU>Kahn SE, Cooper ME, Del Prato S</AU>
<TI>Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future</TI>
<SO>Lancet</SO>
<YR>2014</YR>
<VL>383</VL>
<NO>9922</NO>
<PG>1068-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kalaria-2000" MODIFIED="2017-06-03 19:52:28 +0100" MODIFIED_BY="[Empty name]" NAME="Kalaria 2000" TYPE="OTHER">
<AU>Kalaria R</AU>
<TI>The role of cerebral ischemia in Alzheimer&#8217;s disease</TI>
<SO>Neurobiology of Aging</SO>
<YR>2000</YR>
<VL>21</VL>
<NO>2</NO>
<PG>321-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kilander-1998" MODIFIED="2017-06-03 19:52:58 +0100" MODIFIED_BY="[Empty name]" NAME="Kilander 1998" TYPE="OTHER">
<AU>Kilander L, Nyman H, Boberg M, Hansson L, Lithell H</AU>
<TI>Hypertension is related to cognitive impairment a 20 year follow up of 999 men</TI>
<SO>Hypertension</SO>
<YR>1998</YR>
<VL>31</VL>
<NO>3</NO>
<PG>780-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kodl-2008" MODIFIED="2017-06-02 00:33:01 +0100" MODIFIED_BY="[Empty name]" NAME="Kodl 2008" TYPE="JOURNAL_ARTICLE">
<AU>Kodl CT, Seaquist ER</AU>
<TI>Cognitive Dysfunction and Diabetes Mellitus</TI>
<SO>Endocrine Reviews</SO>
<YR>2008</YR>
<VL>29</VL>
<NO>4</NO>
<PG>494-511</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Koekkoek-2012" MODIFIED="2017-06-02 00:33:58 +0100" MODIFIED_BY="[Empty name]" NAME="Koekkoek 2012" TYPE="JOURNAL_ARTICLE">
<AU>Koekkoek PS, Ruis C, van den Donk M, Biessels GJ, Gorter KJ, Kappelle LJ, et al</AU>
<TI>Intensive multifactorial treatment and cognitive functioning in screen-detected type 2 diabetes &#8211; the ADDITION-Netherlands study: a cluster-randomized trial</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>2012</YR>
<VL>314</VL>
<NO>1-2</NO>
<PG>71-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Morris-2003" MODIFIED="2017-06-02 00:34:42 +0100" MODIFIED_BY="[Empty name]" NAME="Morris 2003" TYPE="JOURNAL_ARTICLE">
<AU>Morris JC</AU>
<TI>Dementia update 2003</TI>
<SO>Alzheimer Disease and Associated Disorders</SO>
<YR>2003</YR>
<VL>17</VL>
<NO>4</NO>
<PG>245-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NICE-2016" MODIFIED="2017-06-02 00:34:56 +0100" MODIFIED_BY="[Empty name]" NAME="NICE 2016" TYPE="OTHER">
<AU>National Institute for Health and Care Excellence</AU>
<TI>Type 2 diabetes in adults: management</TI>
<SO>www.nice.org.uk/guidance/ng28</SO>
<YR>2016</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ott-1999" MODIFIED="2017-06-03 19:54:08 +0100" MODIFIED_BY="[Empty name]" NAME="Ott 1999" TYPE="OTHER">
<AU>Ott A, Stolk RP, Van Harskamp F, Pols HAP, Holfman A, Breteler MMB</AU>
<TI>Diabetes mellitus and the risk of dementia: The Rotterdam study</TI>
<SO>Neurology</SO>
<YR>1999</YR>
<VL>53</VL>
<NO>9</NO>
<PG>1937-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Prince-1996" MODIFIED="2017-06-03 19:55:05 +0100" MODIFIED_BY="[Empty name]" NAME="Prince 1996" TYPE="OTHER">
<AU>Prince MJ, Bird AS, Blizard RA, Mann AH</AU>
<TI>Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council&#8217;s treatment trial of hypertension in older adults</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>312</VL>
<NO>7034</NO>
<PG>801-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rockwood-2002" MODIFIED="2017-06-03 19:56:04 +0100" MODIFIED_BY="[Empty name]" NAME="Rockwood 2002" TYPE="OTHER">
<AU>Rockwood K, Krikland S, Hogan D, MacKnight C, Merry H, Verreault R, et al</AU>
<TI>Use of lipid lowering agents indications bias and the risk of dementia in community dwelling elderly people</TI>
<SO>Archives of Neurology</SO>
<YR>2002</YR>
<VL>59</VL>
<NO>2</NO>
<PG>223-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shi-2000" MODIFIED="2017-06-03 19:56:47 +0100" MODIFIED_BY="[Empty name]" NAME="Shi 2000" TYPE="JOURNAL_ARTICLE">
<AU>Shi J, Perry G, Smith MA, Friedland RP</AU>
<TI>Vascular abnormalities: the insidious pathogenesis of Alzheimer&#8217;s disease</TI>
<SO>Neurobiology of Aging</SO>
<YR>2000</YR>
<VL>21</VL>
<NO>2</NO>
<PG>357-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Spencer-2013" MODIFIED="2017-06-03 19:57:06 +0100" MODIFIED_BY="[Empty name]" NAME="Spencer 2013" TYPE="JOURNAL_ARTICLE">
<AU>Spencer RJ, Wendell CR, Giggey PP, Katzel LI, Lefkowitz DM, Siegel EL, et al</AU>
<TI>Psychometric limitations of the mini-mental state examination among nondemented older adults: an evaluation of neurocognitive and magnetic resonance imaging correlates</TI>
<SO>Experimental Aging Research</SO>
<YR>2013</YR>
<VL>39</VL>
<NO>4</NO>
<PG>382-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tab_x00e1_k-2014" MODIFIED="2017-06-02 00:36:14 +0100" MODIFIED_BY="[Empty name]" NAME="Tabák 2014" TYPE="JOURNAL_ARTICLE">
<AU>Tabák AG, Akbaraly TN, Batty GD, Kivimäki M</AU>
<TI>Depression and type 2 diabetes: a causal association?</TI>
<SO>Lancet Diabetes Endocrinology</SO>
<YR>2014</YR>
<VL>2</VL>
<NO>3</NO>
<PG>236-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tuligenga-2015" MODIFIED="2017-06-02 00:37:12 +0100" MODIFIED_BY="[Empty name]" NAME="Tuligenga 2015" TYPE="JOURNAL_ARTICLE">
<AU>Tuligenga RH</AU>
<TI>Intensive glycaemic control and cognitive decline in patients with type 2 diabetes: a meta-analysis</TI>
<SO>Endocrine Connections</SO>
<YR>2015</YR>
<VL>4</VL>
<NO>2</NO>
<PG>R16-R24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Weinstock-2011" MODIFIED="2017-01-27 16:00:38 +0000" MODIFIED_BY="[Empty name]" NAME="Weinstock 2011" TYPE="JOURNAL_ARTICLE">
<AU>Weinstock RS, Teresi JA, Goland R, Izquierdo R, Palmas W, Eimicke JP, et al</AU>
<TI>Glycemic Control and Health Disparities in Older Ethnically Diverse Underserved Adults With Diabetes Five-year results from the Informatics for Diabetes Education and Telemedicine (IDEATel) study</TI>
<SO>Diabetes Care</SO>
<YR>2011</YR>
<VL>34</VL>
<NO>2</NO>
<PG>274-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Whitmer-2009" MODIFIED="2015-08-09 20:08:09 +0100" MODIFIED_BY="[Empty name]" NAME="Whitmer 2009" TYPE="JOURNAL_ARTICLE">
<AU>Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP Jr, Selby JV</AU>
<TI>Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus</TI>
<SO>JAMA</SO>
<YR>2009</YR>
<VL>301</VL>
<NO>15</NO>
<PG>1565-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2016b" MODIFIED="2017-06-03 19:57:50 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 2016b" TYPE="OTHER">
<TI>World Health Day 2016: WHO calls for global action to halt rise in and improve care for people with diabetes</TI>
<SO>www.who.int/mediacentre/news/releases/2016/world-health-day/en/</SO>
<IDENTIFIERS MODIFIED="2017-06-03 19:57:50 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2017" MODIFIED="2017-06-06 08:44:58 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 2017" TYPE="OTHER">
<TI>Dementia World Health Organization</TI>
<SO>www.who.int/mediacentre/factsheets/fs362/en/</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wickelgren-1998" NAME="Wickelgren 1998" TYPE="OTHER">
<AU>Wickelgren I</AU>
<TI>Tracking insulin to the mind</TI>
<SO>Science</SO>
<YR>1998</YR>
<VL>280</VL>
<PG>517</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wright-2016" MODIFIED="2016-06-20 15:19:49 +0100" MODIFIED_BY="[Empty name]" NAME="Wright 2016" TYPE="JOURNAL_ARTICLE">
<AU>Wright JJ, Tylee TS</AU>
<TI>Pharmacologic Therapy of Type 2 Diabetes</TI>
<SO>Medical Clinics of North America</SO>
<YR>2016</YR>
<VL>100</VL>
<NO>4</NO>
<PG>647-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Xu-2010" MODIFIED="2015-08-09 19:27:35 +0100" MODIFIED_BY="[Empty name]" NAME="Xu 2010" TYPE="JOURNAL_ARTICLE">
<AU>Xu W, Caracciolo B, Wang HX, Winblad B, Bäckman L, Qiu C, Fratiglioni L</AU>
<TI>Accelerated progression from mild cognitive impairment to dementia in people with diabetes</TI>
<SO>Diabetes</SO>
<YR>2010</YR>
<VL>59</VL>
<NO>11</NO>
<PG>2928-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yaffe-2006" MODIFIED="2017-06-03 19:58:31 +0100" MODIFIED_BY="[Empty name]" NAME="Yaffe 2006" TYPE="JOURNAL_ARTICLE">
<AU>Yaffe K, Blackwell T, Whitmer RA, Krueger K, Barrett Connor E</AU>
<TI>Glycosylated hemoglobin level and development of mild cognitive impairment or dementia in older women</TI>
<SO>Journal of Nutrition, Health &amp; Aging</SO>
<YR>2006</YR>
<VL>10</VL>
<NO>4</NO>
<PG>293-5</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2017-02-02 14:43:23 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Cochrane-2002" MODIFIED="2017-02-02 14:43:23 +0000" MODIFIED_BY="[Empty name]" NAME="Cochrane 2002" TYPE="COCHRANE_REVIEW">
<AU>Areosa SA, Grimley EV</AU>
<TI>Effect of the treatment of Type II diabetes mellitus on the development of cognitive impairment and dementia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2017-02-02 14:43:23 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2017-02-02 14:43:23 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003804"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2017-06-06 09:00:49 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2017-06-03 21:32:18 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2017-06-03 17:48:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Abbatecola-2006">
<CHAR_METHODS MODIFIED="2017-06-01 22:47:59 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Study design</B>: randomised controlled trial.</P>
<P>
<B>Unit of allocation</B>: by individuals.</P>
<P>
<B>Start date</B>: September 2001 (initial recruitment).</P>
<P>
<B>End date</B>: September 2004 (final recruitment).</P>
<P>
<B>Duration of participation</B>: 12 months.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-06-03 17:47:38 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Participants</B>: 156 older people with Type 2 diabetes (age range 60 to 78 years) volunteered for the study. Participants were selected from a group of approximately 250 individuals with diagnosed Type 2 diabetes from university outpatient offices. Physicians were asked to refer older persons with Type 2 diabetes who had not previously undergone any antidiabetic drug treatment to their offices where further selection was performed.</P>
<P>
<B>Population description</B>: not reported.</P>
<P>
<B>Setting</B>: academic centre.</P>
<P>
<B>Method of recruitment of participants</B>: recruited from outpatient university clinics and referred to the study office.</P>
<P>
<B>Total number randomised</B>: 156.</P>
<P>
<B>Baseline imbalances</B>: no significant differences were found between study groups.</P>
<P>
<B>Age</B>: glibenclamide (glyburide) group = 74.3 (SD 2.3) years; repaglinide group = 74.5 (SD 2.5) years.</P>
<P>
<B>Sex</B>: glibenclamide (glyburide) group = 41 female/38 male; repaglinide group = 39 female/38 male.</P>
<P>
<B>Race (white)</B>: not reported.</P>
<P>
<B>BMI</B>: glibenclamide (glyburide) group = 26.7 (SD 0.4); repaglinide group = 27.1 (SD 0.2).</P>
<P>
<B>Glycated haemoglobin, standardised level-%</B>
</P>
<P>Glibenclamide (glyburide) group = 7.2 (SD 0.7).</P>
<P>Repaglinide group = 7.3 (SD 0.8).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-06-01 22:54:07 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Types of intervention</B>: glibenclamide (glyburide) initially started with 2.5 mg twice a day, given up to 30 minutes before daily meals.</P>
<P>
<B>Types of comparison</B>: repaglinide initially started with 1 mg twice a day, given up to 30 minutes before daily meals.</P>
<P>To achieve target glycaemic control, titration adjustments were made according to World Health Organization recommendations over an initial 3-week period prior to the beginning of study protocol, but no data regarding the increasing doses were found in the reference given by the author in the study about this point.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-06-03 15:07:25 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Global cognitive function</B>: MMSE.</P>
<P>
<B>Composite outcome</B>:<B> 'Cognition Composite Score' (attention and executive function)</B>
</P>
<P>TMT-A, TMT-B, TMT-B minus TMT-A (DIFF B-A), Wechsler Adult Intelligence Scale&#8211;Revised Digit Span: Backward Digit Span (DSP&#8211;Backward), Wechsler Adult Intelligence Scale&#8211;Revised Digit Span: Forward Digit Span (DSP&#8211;Forward), Verbal Fluency Test.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-06-03 17:48:41 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Sample size calculation</B>: sample size calculation, performed with an alfa = 0.05 and a beta = 0.80, was found to be at least 110 subjects in order to prove a significant decline of 3% to 4% in the MMSE at the 12th month.</P>
<P>
<B>Funding</B>: funded by the Second University of Naples (fiscal year 2004).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-06-03 18:29:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ADVANCE-2008">
<CHAR_METHODS MODIFIED="2017-06-03 14:28:48 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Study design</B>: factorial randomised controlled trial</P>
<P>
<B>Unit of allocation</B>: by individuals.</P>
<P>
<B>Start date</B>: June 2001 (initial recruitment)</P>
<P>
<B>End date</B>: March 2003 (final recruitment)</P>
<P>
<B>Duration of participation</B>: median follow-up = 5 years.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-06-03 17:14:26 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Participants</B>: diagnosis of Type 2 diabetes mellitus at 30 years of age or older, an age of at least 55 years at the time of study entry, and a history of major macrovascular or microvascular disease or at least one other risk factor for vascular disease.</P>
<P>
<B>Population description</B>: not reported.</P>
<P>
<B>Setting</B>: 215 collaborating centres in 20 countries from Asia, Australasia, Europe, and North America.</P>
<P>
<B>Method of recruitment of participants</B>: not reported.</P>
<P>
<B>Total number randomised</B>: 11,140.</P>
<P>
<B>Baseline imbalances</B>: not reported.</P>
<P>
<B>Age</B>: intervention group = 66 (SD 6); standard group = 66 (SD 6).</P>
<P>
<B>Sex (female)</B>: intervention group = 42.6%; standard group = 42.3%.</P>
<P>
<B>Race (white)</B>: not reported.</P>
<P>
<B>BMI</B>: intervention group = 28.0 (SD 5); standard group = 28.0 (SD 5).</P>
<P>
<B>Glycated haemoglobin, standardised level-%</B>
</P>
<P>Mean Intervention group: 7.48 (SD 1.65).</P>
<P>Standard group: 7.48 (SD 1.63).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-06-03 18:29:23 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Types of intervention</B>: intensive glucose control were given gliclazide (modified release, 30 mg to 120 mg daily) and were required to discontinue any other sulfonylurea, plus other treatments decided by their physicians, to achieve a glycated haemoglobin value of 6.5% or less.</P>
<P>
<B>Types of comparison</B>: participants in the standard-control group who were using gliclazide (modified release) when they entered the study were required to substitute this drug with another sulfonylurea, if continued therapy was required with target glycated haemoglobin levels defined on the basis of local guidelines.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-06-01 23:01:22 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Types of outcome measures</B>: cognitive decline (reduction in the Mini&#8211;Mental State Examination score by at least 3 points, as compared with the baseline score) and dementia (DSM-IV) (dichotomous).</P>
<P>All cause of mortality and hypoglycaemic events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-06-01 23:01:36 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Sample size calculation</B>: not reported for the cognitive outcome.</P>
<P>
<B>Funding</B>: supported by grants from Servier (the major financial sponsor) and the National Health and Medical Research Council of Australia (211086 and 358395). Servier manufactures gliclazide (modified release) and the fixed combination of perindopril and indapamide</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-06-03 18:30:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Araki-2012">
<CHAR_METHODS MODIFIED="2017-06-01 23:12:28 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Study design</B>: randomised controlled trial.</P>
<P>
<B>Unit of allocation</B>: by individuals.</P>
<P>
<B>Start date</B>: March 2001 (initial recruitment).</P>
<P>
<B>End date</B>: February 2002 (final recruitment).</P>
<P>
<B>Duration of participation</B>: 6 years.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-06-03 18:30:01 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Participants</B>: inclusion criteria included age 65 to 85 years, HbA1c &#8805; 7.9% or HbA1c &#8805; 7.4% with at least one of following criteria: BMI &#8805; 25 kg/m2, blood pressure &#8805; 130/85 mmHg, serum total cholesterol &#8805; 200 mg/dL (or low-density lipoprotein cholesterol (LDL-C) &#8805; 120 mg/dL in participants without coronary heart disease (CHD)) or &#8805; 180 mg/dL (or LDL-C &#8805; 100 mg/dL in participants with CHD), triglycerides &#8805; 150 mg/dL and HDL-C &lt; 40 mg/dL.</P>
<P>
<B>Population description</B>: diabetic outpatients.</P>
<P>
<B>Setting</B>: outpatients at 39 Japanese hospitals.</P>
<P>
<B>Method of recruitment of participants</B>: recruited from hospitals.</P>
<P>
<B>Total number randomised</B>: 585 participants to the intervention group and 588 in the control group.</P>
<P>
<B>Baseline imbalances</B>: significant baseline imbalances found in &#945;-Blockers, EPA, and HbA1c.</P>
<P>
<B>Age</B>: intervention group = 71.9 (SD 4.6); control group = 71.7 (SD 7.7).</P>
<P>
<B>Sex (female)</B>: intervention group = 53.7%; control group = 53.7%.</P>
<P>
<B>Race</B>: not reported.</P>
<P>
<B>BMI</B>: intervention group = 24.0 (SD 3.9); repaglinide group = 24.3 (SD 7.3).</P>
<P>
<B>Glycated haemoglobin, standardised level-%</B>: intervention group = 8.5 (SD 0.9); control group = 8.4 (0.8).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-06-03 18:30:29 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Types of intervention</B>: the treatment goal in the intensive treatment group was HbA1c &lt; 6.9%, BMI &lt; 25 kg/m2, systolic blood pressure (SBP) &lt; 130 mmHg, diastolic blood pressure (DBP) &lt; 85 mmHg, HDL-C &gt; 40 mg/dL, serum triglycerides &lt; 150 mg/dL and serum total cholesterol &lt; 180 mg/dL (or LDL-C &lt; 100 mg/dL if participants had CHD) or &lt; 200 mg/dL (or LDL-C &lt; 120 mg/dL if participants did not have CHD; Table 1). If HbA1c levels did not reduce to &lt; 6.9%, oral hypoglycaemic drugs (sulphonylurea, biguanides, &#945;-glucosidase inhibitors and pioglitazone) or insulin therapy was introduced by the physician. If total cholesterol or LDL-C levels did not reach the treatment goal, the physicians were advised to use atorvastatin. Participants with a history of cerebral infarction also had antiplatelet therapy where possible.</P>
<P>
<B>Types of comparison</B>: the conventional treatment group continued their baseline treatment for diabetes, hypertension or dyslipidaemia without a specific treatment goal. Each participant had a standardised medical history and physical examination at baseline, and then annually.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-06-01 23:15:28 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Primary cognitive outcome</B>: cognitive function measured by MMSE.</P>
<P>
<B>Secondary outcome</B>: no secondary outcomes.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-06-01 23:15:23 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Sample size calculation</B>: not reported.</P>
<P>
<B>Funding</B>: not reported.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-06-03 17:57:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Guo-2014">
<CHAR_METHODS MODIFIED="2017-06-01 23:17:41 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Study design</B>: randomised controlled trial.</P>
<P>
<B>Unit of allocation</B>: by individuals.</P>
<P>
<B>Start date</B>: April 2013 (initial recruitment).</P>
<P>
<B>End date</B>: May 2013 (final recruitment).</P>
<P>
<B>Duration of participation</B>: 24 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-06-03 17:15:24 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Participants</B>: participants with depression diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders&#8211;Fourth Edition (DSM-IV) and a Type 2 diabetes newly diagnosed by laboratory.</P>
<P>
<B>Population description</B>: not reported.</P>
<P>
<B>Setting</B>: not reported.</P>
<P>
<B>Method of recruitment of participants</B>: not reported.</P>
<P>
<B>Total number randomised</B>: 72 for both groups.</P>
<P>
<B>Baseline imbalances</B>: not reported.</P>
<P>
<B>Age</B>: intervention group = 54.7 (SD 7.3); control group = 53.3 (SD 7.3).</P>
<P>
<B>Sex (male/female)</B>: intervention group = 17/12; control group = 19/10.</P>
<P>
<B>Race (white)</B>: not reported.</P>
<P>
<B>BMI</B>: not reported.</P>
<P>
<B>Glycated haemoglobin, standardised level-%</B>: intervention group = 7.82 (SD 0.82); control group = 8.01 (SD 0.59).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-06-01 23:19:30 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Types of intervention</B>: metformin: the recommended starting dose for metformin is 0.5 g per tablet, two tablets per day with meals. If the blood glucose level is not well controlled after taking metformin for 7 days, the dose should be increased gradually to 1.5 g/day over a period of 2 weeks and the maximum dose should not exceed 2.0 g/day before each meal (three times per day) or before sleep.</P>
<P>
<B>Types of comparison</B>: placebo was vitamin C with the same appearance as the metformin tablet.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-06-03 17:57:54 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Primary cognitive outcome</B>: no primary outcome reported. However, all outcomes are cognitive function measured by WMS-R subtest, verbal memory index, visual memory index, general memory index, attention and concentration, and delayed memory index.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-06-01 23:19:52 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Sample size calculation</B>: not reported.</P>
<P>
<B>Funding</B>: this study was supported, in part, by a grant for diabetes research from Peking University, Program for Scientific Research Innovation Team in Colleges and Universities of Shandong Province and Taishan Scholars Construction Engineering.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-06-03 21:30:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Launer-2011">
<CHAR_METHODS MODIFIED="2017-06-01 23:22:27 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Study design</B>: double 2 × 2 factorial parallel group randomised trial.</P>
<P>
<B>Unit of allocation</B>: by individuals.</P>
<P>
<B>Start date</B>: August 2003 (initial recruitment).</P>
<P>
<B>End date</B>: December 2005 (final recruitment).</P>
<P>
<B>Duration of participation</B>: 40 months.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-06-03 18:30:41 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Participants</B>: participants targeted by ACCORD MIND, which was done in 77 clinics in North America, were aged 45 to 79 years and had Type 2 diabetes, high HbA1c concentrations (&gt; 7.5%, &gt; 58 mmol/mol), and a high risk for cardiovascular disease events suggested by significant atherosclerosis, albuminuria, left ventricular hypertrophy, or at least two additional risk factors for cardiovascular disease.</P>
<P>
<B>Population description</B>: not reported.</P>
<P>
<B>Setting</B>: the MIND participants were therefore drawn from 52 North American clinics in six of the seven clinical centre networks and participants younger than 55 years old were excluded.</P>
<P>
<B>Method of recruitment of participants</B>: recruited from outpatient clinics.</P>
<P>
<B>Total number randomised</B>: 1469 participants to the intervention group and 1508 in the control group (2794 analysed).</P>
<P>
<B>Baseline imbalances</B>: not reported.</P>
<P>
<B>Age</B>: intervention group = 62.3 (SD 5.7); control group = 62.7 (SD 5.9).</P>
<P>
<B>Sex (female)</B>: intervention group = 48%; control group = 49%.</P>
<P>
<B>Race (white)</B>: intervention group = 69.4%; control group = 69.9%.</P>
<P>
<B>BMI</B>: intervention group = 33.0 (SD 5.4); control group = 32.9 (SD 5.3).</P>
<P>
<B>Glycated haemoglobin, standardised level-%</B>
</P>
<P>Intervention group: 8.3 (1.0).</P>
<P>Control group: 8.3 (1.1).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-06-03 18:04:47 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Types of intervention</B>: intensive glycaemic control;</P>
<P>(glycaemic treatment targeting HbA1c less than 6.0%, diabetes education, glucose-monitoring equipment, and antidiabetic medications to achieve this goal).</P>
<P>Therapy was intensified whenever HbA1c was &#8805; 6%, or &gt; 50% of capillary glucose readings were &gt; 5.6 mmol/L (100 mg/dL). All drug combinations from a standard formulary were permitted; specific drugs were reduced only for side effects or contraindications).</P>
<P>
<B>Types of comparison</B>: standard glycaemic control;</P>
<P>(glycaemic treatment targeting HbA1c to 7.0% to 7.9%, diabetes education, glucose-monitoring equipment, and antidiabetic medications to achieved this goal).</P>
<P>Therapy was intensified whenever HbA1c was &#8805; 8%, or &gt; 50% of capillary glucose readings were &gt; 7.8 mmol/L (140 mg/dL). Antihyperglycemic drugs that promoted hypoglycaemia (i.e. insulin or insulin secretagogues) were reduced if HbA1c was persistently lowered to &lt; 7%. All drug combinations from a standard formulary were permitted; specific drugs were reduced only for side effects or contraindications).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-06-03 21:30:53 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Types of outcome measures</B>
</P>
<P>
<B>Primary cognitive outcome</B>:</P>
<UL>
<LI>Digit Symbol Substitution Test.</LI>
</UL>
<P>
<B>Secondary outcome</B>:</P>
<UL>
<LI>Total brain volume (MRI).</LI>
<LI>Memory (Rey Auditory Verbal Learning Test (RAVLT)).</LI>
<LI>Executive function (Stroop test).</LI>
<LI>General cognitive function (MMSE).</LI>
<LI>All-cause mortality.</LI>
<LI>Hypoglycaemic events.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-06-01 23:25:21 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Sample size calculation</B>: for the planned comparison of cognitive function between the intensive glycaemic control and standard glycaemic control groups, using a 2-sided significance level of 0.05, a sample of 1400 per group provides approximately 90% power to detect a difference of 1.0 between 40-month mean DSST scores. For the comparison of cognitive function between the intensive blood pressure control and standard blood pressure control groups (or fibrate versus placebo in the lipid trial), using a 2-sided significance level of 0.05, this sample size will provide approximately 80% power to detect a difference of 1.2 on the 40-month mean DSST scores. To account for a 15% loss to follow-up, the recruitment of 350 participants was planned within each cell.</P>
<P>
<B>Funding</B>: funded by US National Institute on Aging and US National Heart, Lung, and Blood Institute.</P>
<P>
<B>Arm cancelled</B>: the intensive intervention was stopped on 6 February 2008, when an increased risk (hazard ratio 1.22, 95% CI 1.01 to 1.46) for mortality was reported; participants in that group were moved to standard glycaemic treatment. MIND assessments continued in accordance with the original protocol.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-06-03 21:32:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ryan-2006">
<CHAR_METHODS MODIFIED="2017-06-01 23:27:06 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Study design</B>: randomised controlled trial</P>
<P>
<B>Unit of allocation</B>: by individuals.</P>
<P>
<B>Start date</B>: not reported.</P>
<P>
<B>End date</B>: not reported.</P>
<P>
<B>Duration of participation</B>: 24 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-06-03 21:32:18 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Participants</B>: 145 adults with Type 2 diabetes were recruited from 18 centres in the US. Adults were eligible if they were receiving oral metformin combination therapy and had HbA1c (A1C) &#8804; 8%, BMI &#8804; 27 kg/m2, no evidence of dementia (score &#8805; 27 on the Mini-Mental State Examination), and no evidence of current depression as determined by the Mini International Neuropsychiatric Interview (MINI).</P>
<P>
<B>Population description</B>: not reported.</P>
<P>
<B>Setting</B>: not reported.</P>
<P>
<B>Method of recruitment of participants</B>: not reported.</P>
<P>
<B>Total number randomised</B>: 145.</P>
<P>
<B>Baseline imbalances</B>: imbalances found on fasting insulin (pmol/l) and C-peptide (nmol/l).</P>
<P>
<B>Age</B>: rosiglitazone plus metformin group = 60.7 (SD 1.0 years); glibenclamide (glyburide) plus metformin group = 59.6 (SD 0.8 years).</P>
<P>
<B>Sex (female)</B>: rosiglitazone plus metformin group = 43%; glibenclamide (glyburide) plus metformin group = 36% female.</P>
<P>
<B>Race (Caucasian)</B>: rosiglitazone plus metformin group = 80%; glibenclamide (glyburide) plus metformin group = 79%.</P>
<P>
<B>BMI</B>: rosiglitazone plus metformin group = 33.8 (SD 0.7); glibenclamide plus metformin group = 32.5 (SD 0.06).</P>
<P>
<B>Glycated haemoglobin, standardised level-%</B>
</P>
<P>Rosiglitazone plus metformin group: 7.6 (SD 0.1).</P>
<P>Glibenclamide (glyburide) plus metformin group: 7.6 (SD 0.1).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-06-03 18:31:20 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Types of intervention</B>: rosiglitazone plus metformin group.</P>
<P>During the first 8 weeks of treatment, study medication was given as 4.0 mg rosiglitazone once daily. To titrate participants to equal glycaemic control, FPG was assessed at weeks 8 and 16, and the dose was adjusted if FPG &#8805; 7.8 mmol/l. Rosiglitazone could be increased to 8 mg once daily or 4 mg twice daily.</P>
<P>No changes were made to the background dose of metformin during blinded treatment.</P>
<P>
<B>Types of comparison</B>: glibenclamide (glyburide) plus metformin group</P>
<P>During the first 8 weeks of treatment, study medication was given as 2.5 mg twice daily, with glibenclamide (glyburide) increased to 2.5 mg twice daily after 4 weeks of treatment. To titrate participants to equal glycaemic control, FPG was assessed at 8 and 16 weeks, and the dose was adjusted if FPG &gt; 7.8 mmol/l. Glibenclamide (glyburide) could be increased to 5 mg twice daily or up to a maximal dose of 7.5 mg twice daily.</P>
<P>No changes were made to the background dose of metformin during blinded treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-06-03 18:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Types of outcome</B>:</P>
<UL>
<LI>Digit Symbol Substitution Test</LI>
</UL>
<UL>
<LI>Rey Auditory Verbal Learning Test (immediate)</LI>
</UL>
<UL>
<LI>Cambridge Neuropsychological Test Automated Battery (CANTAB)</LI>
</UL>
<UL>
<UL>
<LI>Paired Associates Learning (PAL)</LI>
</UL>
</UL>
<UL>
<UL>
<LI>Pattern Recognition Memory</LI>
</UL>
</UL>
<UL>
<UL>
<LI>Spatial Working Memory Test</LI>
</UL>
</UL>
<UL>
<UL>
<LI>Rapid Visual Information Processing</LI>
</UL>
</UL>
<UL>
<UL>
<LI>Reaction Time</LI>
</UL>
</UL>
<P>
<B>As composite outcome (cognitive domains)</B>:</P>
<UL>
<LI>Working memory (sum of z-scores of CANTAB PAL, CANTAB Rapid Visual Information Processing, CANTAB Spatial Working Memory Test and Digit Symbol Substitution Test)</LI>
</UL>
<UL>
<LI>Learning Ability (sum of z-scores of Rey Total Learning Score, Pattern Recognition Memory)</LI>
</UL>
<UL>
<LI>Cognitive Efficiency (sum of z-scores of Rey Forgetting Score and Reaction time)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-06-01 23:31:30 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Sample size calculation</B>: not reported for the cognitive outcome.</P>
<P>
<B>Funding</B>: not reported.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-06-03 18:34:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zimering-2016">
<CHAR_METHODS MODIFIED="2017-06-01 23:32:28 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Study design</B>: randomised controlled trial.</P>
<P>
<B>Unit of allocation</B>: by individuals.</P>
<P>
<B>Start date</B>: December 2000 (initial recruitment).</P>
<P>
<B>End date</B>: May 2003 (final recruitment).</P>
<P>
<B>Duration of participation</B>: 5 years.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-06-03 18:33:16 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Participants</B>: 
</P>
<P>The participants were recruited from 20 participating Veteran Affairs Medical Centers in the USA.</P>
<P>Inclusion criteria included &gt; 41 years old, who are non-responsive to a maximum dose of at least one oral agent and/or daily insulin injections. Non-responsiveness is defined as having centrally measured HbA1c level &gt; 4 standard deviations above the normal mean, that is, &gt; 7.5%, or else local HbA1c &gt; 8.3%.</P>
<P>
<B>Population description</B>: not reported</P>
<P>
<B>Setting</B>: people from 20 participating Veteran Affairs Medical Centers in the USA, no additional data regarding the setting was described.</P>
<P>
<B>Method of recruitment of participants</B>: not reported</P>
<P>
<B>Total number randomised</B>: 892 participants to the intensive group and 899 in the standard group.</P>
<P>
<B>Baseline imbalances</B>: no significant baseline imbalances were found.</P>
<P>
<B>Age</B>: intensive group = 60.5 (SD 9.0); standard group = 60.3 (SD 9.0).</P>
<P>
<B>Sex (female)</B>: intensive group = 53.7%; standard group = 53.7%.</P>
<P>
<B>Race</B>: in the intensive group there were 539 non-Hispanic white, 155 Hispanic white, 152 black and 46 participants with other race. In the standard group there were 572 non-Hispanic white, 136 Hispanic with, 147 black and 44 participants with other race.</P>
<P>
<B>BMI</B>: intensive group = 31.3 (SD 3.0); standard group = 31.2 (SD 4.0).</P>
<P>
<B>Glycated haemoglobin, standardised level-%</B>: intensive group = 9.4 (SD 2.0); standard group = 9.4 (SD 2.0).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-06-03 17:06:54 +0100" MODIFIED_BY="[Empty name]">
<P>In both study groups, participants with a BMI of 27 or more were started on two oral agents, rosiglitazone plus metformin; those with a BMI of less than 27 were started on rosiglitazone plus glimepiride.</P>
<P>
<B>Types of intervention</B>: participants in the intensive-therapy group were started on maximal doses. Before any change in oral medications, insulin was added for those who did not achieve a glycated haemoglobin level of less than 6%. Subsequent changes in medication were determined according to protocol guidelines and local assessment. The guidelines allowed for the use of any approved drug at the discretion of the investigator. The goal for glycated haemoglobin levels was an absolute reduction of 1.5 percentage points.</P>
<P>
<B>Types of comparison</B>: participants in the standard-therapy group were started on half the maximal doses. Before any change in oral medications, insulin was added for those who did not achieve a glycated haemoglobin level of less than 9%. Subsequent changes in medication were determined according to protocol guidelines and local assessment. The guidelines allowed for the use of any approved drug at the discretion of the investigator.</P>
<P>Other modifiable cardiovascular risk factors were treated identically in the two study groups. Treatment guidelines (based on recommendations of the American Diabetes Association, which were updated as necessary) for blood pressure and lipid control, as well as for dietary, exercise, and diabetes education, were provided to all participants.</P>
<P>All participants were prescribed aspirin and a hydroxymethylglutaryl coenzyme A reductase inhibitor (statin) unless contraindicated.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-06-03 17:07:17 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Types of outcome measures</B>: 
</P>
<P>TMT-B.</P>
<P>Digit Span.</P>
<P>Digit symbol substitution task (DSym).</P>
<P>All cause of mortality.</P>
<P>Hypoglycaemic events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-06-03 18:34:14 +0100" MODIFIED_BY="[Empty name]">
<P>There is a difference of 3 participants in standard group between the original study (<LINK REF="REF-Duckworth-2009" TYPE="REFERENCE">Duckworth 2009</LINK>) and <LINK REF="STD-Zimering-2016" TYPE="STUDY">Zimering 2016</LINK>.</P>
<P>Data from mortality and hypoglycaemia were reported in <LINK REF="REF-Duckworth-2009" TYPE="REFERENCE">Duckworth 2009</LINK>.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2017-06-03 21:33:11 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2017-06-03 18:35:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Baker-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-03 18:35:21 +0100" MODIFIED_BY="[Empty name]">
<P>Wrong participants: prediabetes participants.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-03 18:35:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cukierman_x002d_Yaffe-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-03 18:35:23 +0100" MODIFIED_BY="[Empty name]">
<P>Wrong participants: dysglycemia participants.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-03 18:35:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Daly-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-03 18:35:27 +0100" MODIFIED_BY="[Empty name]">
<P>Wrong intervention: it compared ingestion of a whey-protein drink combined with vitamin D supplementation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-03 18:35:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Davies-2015">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-03 18:35:35 +0100" MODIFIED_BY="[Empty name]">
<P>Wrong intervention: group self-management plus personalised genetic- and lifestyle-associated risk information.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-03 18:35:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Espeland-2016">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-03 18:35:37 +0100" MODIFIED_BY="[Empty name]">
<P>Wrong design: no cognitive evaluation at baseline.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-03 18:35:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gatskikh-2015">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-03 18:35:43 +0100" MODIFIED_BY="[Empty name]">
<P>Wrong intervention: intervention group received a complex metabolic drug cytoflavin daily intravenously.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-03 18:36:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gilchrist-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-03 18:36:01 +0100" MODIFIED_BY="[Empty name]">
<P>Wrong intervention: nitrate-depleted beetroot juice is not an accepted treatment for Type 2 diabetes.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-03 18:36:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gradman-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-03 18:36:08 +0100" MODIFIED_BY="[Empty name]">
<P>Wrong design: non-randomised and inappropriately controlled trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-03 21:33:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Inouye-2015">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-03 21:33:11 +0100" MODIFIED_BY="[Empty name]">
<P>Wrong intervention: it compared cognitive behavioural therapy to diabetes education and support.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-03 18:36:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Luchsinger-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-03 18:36:15 +0100" MODIFIED_BY="[Empty name]">
<P>Wrong intervention: telemedicine is not an accepted treatment for Type 2 diabetes.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-03 18:36:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Meneilly-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-03 18:36:21 +0100" MODIFIED_BY="[Empty name]">
<P>Wrong design: no control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-03 18:36:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Naor-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-03 18:36:28 +0100" MODIFIED_BY="[Empty name]">
<P>Wrong setting: inpatient treatment.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-03 18:36:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT02415556">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-03 18:36:31 +0100" MODIFIED_BY="[Empty name]">
<P>Wrong intervention: 40 IU of intranasal insulin (INI) compared to placebo (sterile saline).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-03 18:36:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT02486341">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-03 18:36:38 +0100" MODIFIED_BY="[Empty name]">
<P>Wrong outcome: intra-day glycaemic variability according basal insulin at 5 days.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-03 18:36:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT02879409">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-03 18:36:42 +0100" MODIFIED_BY="[Empty name]">
<P>Wrong outcome: determination of the variability of HbA1c.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-03 18:36:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Padwal-2016">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-03 18:36:50 +0100" MODIFIED_BY="[Empty name]">
<P>Wrong intervention: home BP telemonitoring, used with or without protocolised case management, compared with &#8220;enhanced usual care&#8221;.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-03 18:37:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Qiang-2015">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-03 18:37:12 +0100" MODIFIED_BY="[Empty name]">
<P>Wrong intervention: interventional proposed treatment is the Sancaijiangtang powders (with pioglitazone hydrochloride) used in traditional medicine, which is not an accepted treatment for Type 2 diabetes in international guidelines.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-03 18:37:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sotaniemi--1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-03 18:37:17 +0100" MODIFIED_BY="[Empty name]">
<P>Wrong intervention: this study was focused on the effect of ginseng which is not an accepted treatment for Type 2 diabetes.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-03 18:37:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Testa-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-03 18:37:20 +0100" MODIFIED_BY="[Empty name]">
<P>Wrong outcome: subjective impressions of cognitive function.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-03 18:37:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tovi-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-03 18:37:23 +0100" MODIFIED_BY="[Empty name]">
<P>Wrong outcome: subjective impressions of cognitive function.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-03 18:37:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-UKPDS-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-03 18:37:24 +0100" MODIFIED_BY="[Empty name]">
<P>Wrong outcome: subjective impressions of cognitive function.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-03 18:37:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vijayakumar-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-03 18:37:29 +0100" MODIFIED_BY="[Empty name]">
<P>Wrong intervention: Vitamin E is not approved by international guidelines for Type 2 diabetes.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-03 18:37:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wong-2016">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-03 18:37:33 +0100" MODIFIED_BY="[Empty name]">
<P>Wrong intervention: resveratrol consumption is not approved by international guidelines for Type 2 diabetes.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2016-08-03 18:11:45 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2017-06-06 09:00:49 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2017-06-06 09:00:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ACTRN12614000222640">
<CHAR_STUDY_NAME MODIFIED="2016-09-15 10:20:52 +0100" MODIFIED_BY="[Empty name]">
<P>Cognition and Type 2 Diabetes &#8211; A pilot randomised controlled trial (RCT) of exercise</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2016-09-15 10:20:51 +0100" MODIFIED_BY="[Empty name]">
<P>Interventional study. Randomized controlled trial. </P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-06-03 18:39:37 +0100" MODIFIED_BY="[Empty name]">
<P>50 participants between 50 and 75 years old will be recruited. Inclusion criteria: 1) Type 2 diabetes as diagnosed by fasting blood glucose greater or equal to 7 mmol/L or HbA1C greater than 6.4% or 2-hr post-prandial glucose greater than 11 mmol/L according to current American Diabetes Association Guidelines; 2) age 50 to 75 years; 3) be willing and able to participate in a structured exercise program for 6 months. Exclusion criteria: 1) any severe medical condition that precludes safe participation in exercise; 2) moderate or severe dementia; 3) known central nervous system disorders that may have confounding effects on cognitive function (e.g. tumour, multiple sclerosis, Parkinson's disease); 4) contra-indication to MRI; 5) exercising greater than the equivalent of 30 minutes once a week in the last 3 months.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-06-06 09:00:49 +0100" MODIFIED_BY="[Empty name]">
<P>The intervention group will receive a 6-month structured exercise program by fully trained exercise physiologists. Two one-hour supervised sessions per week will occur at the Menzies Research Institute gymnasium on non-consecutive days, plus a further one-hour per week unsupervised session at the participant&#8217;s home with prescribed exercises (e.g. walking). Each supervised session will consist of a warm-up and cool-down, moderate- to high-intensity progressive resistance training exercises using body weight, simple machine or free weights of 8 to 15 repetitions (e.g. free weights: bicep curls, shoulder press, chest press; body weight: step ups or sit to stand ± weight vest; machine weights: quadriceps press, shoulder press, chest press, knee extension), and an aerobic component involving stationary cycling, cross-trainer or treadmill walking at 40% to 84% of VO2R. The program will be tailored to participant&#8217;s abilities and progressive intensity applied with increasing fitness. Adherence will be assessed by attendance at the supervised exercise sessions and completion of personal exercise diaries.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-11-28 12:36:01 +0000" MODIFIED_BY="[Empty name]">
<P>Assessments of selective attention, executive function, processing speed and memory will be made using standard neurological tests:</P>
<P>Hopkins Verbal Learning Test &#8211; R, Form 1; Wechsler Adult Intelligence Scale &#8211; Third Edition (WAIS-III) Subsets of Digit Span, Digit Symbol Coding and Symbol Search; Controlled Oral Word Association Test (COWAT); Category Fluency Test; Rey Complex Figure copying and delayed recall task; Stroop Test (Victoria Form);Trails A &amp; B.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2017-06-03 18:49:00 +0100" MODIFIED_BY="[Empty name]">
<P>28 March 2014</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2017-06-03 21:34:18 +0100" MODIFIED_BY="[Empty name]">
<P>Name: Dr Michele Callisaya. Stroke and Ageing Research Group Southern Clinical School Level 5 E Block, Monash Medical Centre Monash University 246 Clayton Road, Clayton, Victoria 3168, Australia Telephone: +61 3 62264785 Email: michele.callisaya@monash.edu</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2017-06-03 18:49:27 +0100" MODIFIED_BY="[Empty name]">
<P>Study status: recruiting participants.</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2017-06-03 21:35:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT02348801">
<CHAR_STUDY_NAME MODIFIED="2016-11-28 12:07:22 +0000" MODIFIED_BY="[Empty name]">
<P>Lifestyle Intervention for Senior Diabetics (LISD)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2016-11-28 12:08:31 +0000" MODIFIED_BY="[Empty name]">
<P>Interventional study. Randomized, parallel assignment, open label treatment study<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-06-03 18:59:01 +0100" MODIFIED_BY="[Empty name]">
<P>Subjects will be older (age 65 to 85 years) adults with Type 2 diabetes. Diabetes will be determined by self-report with verification (medical records, current treatment, confirmation from health care provider, fasting glucose &#8805;126 mg/dL, symptoms of hyperglycaemia with plasma glucose &#8805; 200 mg/dL or 2-hour plasma glucose &#8805; 200 mg/dL after a 75 g glucose load on at least two occasions, or HbA1C of &#8805; 6.5%). All subjects will have a BMI of &#8805; 27 kg/m2 and have stable weight (±2 kg) and on stable medications during the last 6 months.</P>
<P>Volunteers will be excluded if they fail to provide informed consent, have any major comorbid disease that is uncontrolled, or any condition that is likely to limit life span and/or affect the safety of the interventions, or interfere with the conduct of the trial.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-06-03 19:00:43 +0100" MODIFIED_BY="[Empty name]">
<P>Intervention group: the participants will receive therapy sessions designed to acquire positive weight-control skills and attitudes, and practice weight-maintenance skills. A balanced diet will be prescribed to provide a deficit of 500 to 750 kcal/day from daily energy requirement and exercise sessions of ~ 90 min duration (15 min warm-up of flexibility exercise, followed by ~ 30 min of aerobic exercise; after a brief rest period, ~ 30 min of resistance training; and finally ~ 15 min balance exercise) conducted three times weekly supervised at [an] exercise facility for first six months, and regular exercises continued at community-fitness centres and at home for the following six months.</P>
<P>Control group: diabetes support and education.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-06-03 21:35:02 +0100" MODIFIED_BY="[Empty name]">
<P>Change in the modified mini-mental state exam at 12 months.<BR/>Change in Stroop colour naming test at 12 months.<BR/>Change in word list fluency test at 12 months.<BR/>Change in Ray auditory verbal learning test (RAVLT) at 12 months.<BR/>Change in Trail A/B at 12 months.</P>
<P>Change in composite cognitive z-score at 12 months.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2016-11-28 12:25:44 +0000" MODIFIED_BY="[Empty name]">
<P>January 2015</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2016-11-28 12:26:41 +0000" MODIFIED_BY="[Empty name]">
<P>Dennis T Villareal 713-794-7156 email: dennis.villareal@bcm.edu</P>
<P>Alessandra Celli 713-578-4300 email: Alessandra.celli@va.gov</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2017-06-01 23:35:50 +0100" MODIFIED_BY="[Empty name]">
<P>Study status: recruiting participants.</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2017-06-03 21:36:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT02409238">
<CHAR_STUDY_NAME MODIFIED="2016-09-15 10:20:54 +0100" MODIFIED_BY="[Empty name]">
<P>Insulin Resistance and Mild Cognitive Impairment (MCI) in Older Chinese Adults With Pre-Diabetes and Diabetes: Cognitive Effects of Lifestyle Intervention and Metformin Treatment in a Randomized Controlled Trial</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2016-09-15 10:20:55 +0100" MODIFIED_BY="[Empty name]">
<P>Interventional study. Randomized controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-06-03 21:36:10 +0100" MODIFIED_BY="[Empty name]">
<P>360 participants, 55 years old and older.</P>
<P>Inclusion criteria:</P>
<P>1) Chinese Singapore Citizen or permanent resident.</P>
<P>2) BMI of 23 or higher; and/or waist circumference &#8805; 90 cm and &#8805; 80 cm for Chinese men and women respectively.</P>
<P>3) Prediabetes (if not diabetic).</P>
<P>4) Type 2 diabetes (if not prediabetic) yet to be treated with anti-diabetic drug treatment ('on diet control only'), with HbA1c &lt; 8.0% OR diabetics who have been taken off medication for &#8805; 1 year with HbA1c &lt; 8.0% will be considered for recruitment.</P>
<P>5) Mild cognitive impairment.</P>
<P>Exclusion criteria:</P>
<P>1) Contraindications to metformin treatment: creatinine of &gt; 150 umol/L, history of decompensated liver disease, liver cirrhosis, or unexplained elevated hepatic transaminases (ALT or AST &gt; 3× upper limit of normal (upper limits as accepted by SingHealth Polyclinics as 66 U/L for ALT and 42 U/L). This contraindication would not affect subjects with a history of high baseline ALT and/or AST which have been evaluated by a hepatologist to be due to non-alcoholic fatty liver disease without cirrhosis.</P>
<P>2) Severe neuro-musculoskeletal and sensory disabilities.</P>
<P>3) Severe psychiatric disorders (e.g. alcohol abuse, severe depression, schizophrenia, bipolar disorder).</P>
<P>4) illnesses that seriously reduce life expectancy or ability to participate in the trial.</P>
<P>5) Congestive heart failure (New York Heart Association cardiac status classes 2, 3 or 4), myocardial infarction or coronary artery bypass surgery or percutaneous coronary intervention within the past 6 months, cardiac arrhythmias, severe hypertension.</P>
<P>6) Concurrent use or recent use (within 1 week or 5 half-lives of the drug whichever is longer) of drugs with anticholinesterase, sedating or central nervous system (CNS) side effects: antispasmodics, antiemetics, antidiarrhoeal, antihistamines, hypnotics, antidepressants, antipsychotics, bronchodilators.</P>
<P>7) Concurrent use of drugs (for &gt; 4 consecutive weeks) or use of drugs within 12 weeks of screening) that are known to adversely affect glucose tolerance and its interpretation.</P>
<P>8) History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes.</P>
<P>9) Use of an investigative drug within 30 days or 5 half-lives of the drug whichever is longer.</P>
<P>10) Potentially unreliable and/or judged by the investigator to be unsuitable for the study.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-06-03 19:11:01 +0100" MODIFIED_BY="[Empty name]">
<P>This 3-year open-label study aims to recruit 360 subjects with 50% (180 subjects) randomised to receiving intensive lifestyle intervention with metformin (if diabetic) vs the other 50% who would receive only the usual standard level of care in the primary care setting.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-06-03 19:12:41 +0100" MODIFIED_BY="[Empty name]">
<P>Change in composite z-score of memory and multi-domain non-amnestic cognitive test performance using a neuropsychological assessment performed at baseline and at 2 years.</P>
<P>Change in subjective memory and cognitive complaint (SMCC) as measured at baseline and at 2 years.</P>
<P>Change in Cognitive Instrumental Activities of Daily Living Scale (Cog-IADL) as measured at baseline and at 2 years.</P>
<P>Change in Global Clinical Dementia Rating Sum of Boxes (version with Informant and version without need for Informant &#8211; CDR-SB) as measured at baseline and at 2 years.</P>
<P>Change in Mini-Mental State Examination (MMSE) as measured at baseline and at 2 years.</P>
<P>Change in Montreal Cognitive Assessment scale (MoCA) as measured at baseline and at 2 years.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2016-09-14 23:02:39 +0100" MODIFIED_BY="[Empty name]">
<P>April 2015</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2017-06-03 19:13:50 +0100" MODIFIED_BY="[Empty name]">
<P>Name: Wee Kien Han, Andrew; MCI Address: SingHealth Polyclinics - Marine Parade Polyclinic Singapore, Singapore, 440080; Telephone: 65-96615423; email: andrew.wee@singhealth.com.sg</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2017-06-03 19:14:28 +0100" MODIFIED_BY="[Empty name]">
<P>Study status: recruiting participants.</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2017-06-03 19:18:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Watson-2015">
<CHAR_STUDY_NAME MODIFIED="2017-06-03 19:14:25 +0100" MODIFIED_BY="[Empty name]">
<P>A randomised trial comparing low-fat diets differing in carbohydrate and protein ratio, combined with regular moderate intensity exercise, on glycaemic control, cardiometabolic risk factors, food cravings, cognitive function and psychological well being in adults with type 2 diabetes</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2016-09-15 10:21:15 +0100" MODIFIED_BY="[Empty name]">
<P>Interventional study. Randomized controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-06-03 19:16:18 +0100" MODIFIED_BY="[Empty name]">
<P>61 participants, 18 to 70 years old</P>
<P>Inclusion criteria: diagnosed with Type 2 diabetes, aged 18 to 70 years, HbA1c between 6.5% and 10.5% at screening, BMI greater than 25 kg/m2, weight &#8804; 135 kg (maximum capacity for dual X-ray absorptiometry (DEXA), non-smoker for more than 6 months, proficient in written and spoken English (to perform the cognitive tests), age-appropriate cognitive abilities (determined using the DemTect questionnaire).</P>
<P>Exclusion criteria: liver, kidney, gastrointestinal or cardiovascular disease, respiratory disease (apart from stable asthma), retinopathy, malignancy (within last 6 months), proteinuria, uncontrolled hypertension (N170/100), taking medication for a neurological or psychiatric condition (except stable antidepressants N3 months), neurological or psychiatric condition, history of head or brain injury, musculoskeletal injury or peripheral vascular disease sufficient to impede exercise, undertaking a weight loss programme or taking appetite suppressants, pregnant or lactating, unable to participate in the trial for 6 months if participated in another study within last 30 days.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-06-03 19:17:30 +0100" MODIFIED_BY="[Empty name]">
<P>Overweight/obese adults with Type 2 diabetes were randomised to consume either a HP diet (n = 32, ~ 32% protein, 33% carbohydrate, 30% fat) or a higher-carbohydrate diet (HC, n = 29, ~ 22% protein, 51% carbohydrate, 22% fat) for 24 weeks with 30 min of moderate intensity exercise five days/week for the study duration. There were 2 phases: a 12-week weight loss phase; followed by a 12-week weight maintenance phase.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-06-03 19:17:51 +0100" MODIFIED_BY="[Empty name]">
<P>Memory.</P>
<P>Psychomotor and executive function.</P>
<P>Outcomes will be measured at baseline and the end of each 12-week intervention phase.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2017-06-03 19:17:56 +0100" MODIFIED_BY="[Empty name]">
<P>Not available.</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2017-06-03 19:18:49 +0100" MODIFIED_BY="[Empty name]">
<P>Name: Watson NA. Address: Alliance for Research in Exercise, Nutrition and Activity, Sansom Institute for Health Research, University of South Australia, GPO Box 2471, Adelaide, SA 5001, Australia; email: nerylee.watson@mymail.unisa.edu.au</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2017-06-03 18:35:15 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2017-06-03 17:58:24 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-06-03 14:34:00 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ADVANCE-2008">
<DESCRIPTION>
<P>
<B>Quote</B>: "Central, computer-based randomisation was stratified according to several factors".</P>
<P>
<B>Comments</B>: randomisation performed by central and computer-based software is considered adequate.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-06-01 22:56:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Abbatecola-2006">
<DESCRIPTION>
<P>Comments: no methods for generating a random sequence have been described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-06-01 23:16:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Araki-2012">
<DESCRIPTION>
<P>
<B>Quote</B>: "A total of 1173 diabetic outpatients were enrolled and randomly allocated to either the intensive or conventional treatment group. The randomised factors were age, sex, diabetes treatment, HbA1c, total cholesterol, triglycerides, HDL-C, blood pressure, diabetic microangiopathy, atherosclerotic disease, hypertension, hyperlipidaemia and institutions."</P>
<P>
<B>Comments</B>: no methodology for generating the random sequence has been reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-06-03 17:58:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Guo-2014">
<DESCRIPTION>
<P>
<B>Quote</B>: "The present study was a randomised double-blind placebo-controlled study. The participants were randomly divided into either the metformin- or placebo-treated groups using random numbers."</P>
<P>
<B>Comments</B>: the participants were randomly divided into either the metformin- or placebo-treated groups using random numbers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-06-01 23:25:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Launer-2011">
<DESCRIPTION>
<P>
<B>Quote</B>: "The CCC computer generated unique randomisation sequences for every clinical site and electronically verified exclusion and inclusion criteria for every individual before assigning a treatment group. Clinic staff implemented the randomisation via secure access to the ACCORD trial website".</P>
<P>
<B>Comments</B>: computer generated unique randomisation sequences were considered adequate.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-29 12:04:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ryan-2006">
<DESCRIPTION>
<P>
<B>Quote</B>: "For random assignment to treatment, we used a computer-generated allocation sequence."</P>
<P>
<B>Comments</B>: computer-generated allocation sequence is considered adequate.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-06-01 23:34:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zimering-2016">
<DESCRIPTION>
<P>
<B>Quote</B>: "Eligible patients without significant renal insufficiency or congestive heart failure were randomly assigned to STD vs. INT glycaemic treatment".</P>
<P>
<B>Comments</B>: no methodology for generating a random sequence has been reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2017-06-03 18:13:25 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-06-03 14:34:03 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ADVANCE-2008">
<DESCRIPTION>
<P>
<B>Quote</B>: "Central, computer-based randomisation was stratified according to several factors".</P>
<P>
<B>Comments</B>: the central, computer-based randomisation provided adequate allocation concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-06-01 22:56:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Abbatecola-2006">
<DESCRIPTION>
<P>Comments: no methods for allocation concealment have been described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-06-01 23:16:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Araki-2012">
<DESCRIPTION>
<P>
<B>Comments</B>: no methodology for allocation concealment has been reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-06-01 23:20:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Guo-2014">
<DESCRIPTION>
<P>
<B>Comments</B>: no methods for allocation concealment have been described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-06-03 18:13:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Launer-2011">
<DESCRIPTION>
<P>
<B>Quote</B>: "The CCC computer generated unique randomisation sequences for every clinical site and electronically verified exclusion and inclusion criteria for every individual before assigning a treatment group. Clinic staff implemented the randomisation via secure access to the ACCORD trial website."</P>
<P>
<B>Comments</B>: allocation concealment was considered adequate.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-06-01 23:31:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ryan-2006">
<DESCRIPTION>
<P>
<B>Comments</B>: no methods for allocation concealment have been identified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-25 09:26:35 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zimering-2016">
<DESCRIPTION>
<P>
<B>Comments</B>: no methodology for allocation concealment has been reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2017-06-03 18:34:28 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2017-06-01 23:10:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-ADVANCE-2008">
<DESCRIPTION>
<P>
<B>Comments</B>: no methods for blinding of participants and personnel have been identified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2017-06-01 22:56:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Abbatecola-2006">
<DESCRIPTION>
<P>Comments: no methods for blinding the participants have been described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2017-06-01 23:16:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Araki-2012">
<DESCRIPTION>
<P>
<B>Comments</B>: no methods regarding blinding of participants have been provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2017-06-01 23:20:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Guo-2014">
<DESCRIPTION>
<P>
<B>Comments</B>: no methods for blinding participants have been described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2017-06-03 15:10:48 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Launer-2011">
<DESCRIPTION>
<P>
<B>Quote</B>: "Glycaemia trial treatment assignment was open label, and both clinic staff and patients were aware of the assigned glycaemic goal."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2017-06-01 23:31:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ryan-2006">
<DESCRIPTION>
<P>
<B>Comments</B>: no methods for blinding of participants and personnel have been identified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2017-06-03 18:34:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zimering-2016">
<DESCRIPTION>
<P>
<B>Comments</B>: no methodology for blinding participants, personnel, or outcome assessors has been reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2017-06-03 18:34:34 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-06-01 23:10:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-ADVANCE-2008">
<DESCRIPTION>
<P>
<B>Comments</B>: no methods for blinding of participants and personnel have been identified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-06-01 22:56:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Abbatecola-2006">
<DESCRIPTION>
<P>Comments: no methods for blinding the participants and personnel have been described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-06-03 14:36:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Araki-2012">
<DESCRIPTION>
<P>
<B>Comments</B>: no methods regarding blinding of personnel have been provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-06-01 23:20:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Guo-2014">
<DESCRIPTION>
<P>
<B>Comments</B>: no methods for blinding personnel have been described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-06-03 15:10:52 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Launer-2011">
<DESCRIPTION>
<P>
<B>Quote</B>: "Glycaemia trial treatment assignment was open label, and both clinic staff and patients were aware of the assigned glycaemic goal."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-06-01 23:31:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ryan-2006">
<DESCRIPTION>
<P>
<B>Comments</B>: no methods for blinding of participants and personnel have been identified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-06-03 18:34:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zimering-2016">
<DESCRIPTION>
<P>
<B>Comments</B>: no methodology for blinding participants, personnel, or outcome assessors has been reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2017-06-03 18:34:39 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-06-01 23:11:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ADVANCE-2008">
<DESCRIPTION>
<P>
<B>Quote</B>: "An independent End Point Adjudication Committee, unaware of the group assignments, reviewed source documentation for all suspected primary end points and deaths."</P>
<P>
<B>Comments</B>: an independent committee for analysing the interim analysis and the outcomes is considered adequate.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-12-16 17:21:37 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Abbatecola-2006">
<DESCRIPTION>
<P>Quote: 1. "All MRI evaluations were made by physicians not involved in the study and blind toward the study design." 2. "All cognitive evaluations were made by physicians who were unaware of both study design and patient treatment allocation".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-06-01 23:16:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Araki-2012">
<DESCRIPTION>
<P>
<B>Quote</B>: "Possible clinical end-points were noted in the annual data sheets, with the diagnostic criteria for each endpoint being predetermined. When an end point was notified on a data sheet, the administrator requested full information from the data management and statistical analysis centre, followed by a review by two clinical assessors of the event assignment committee."</P>
<P>
<B>Comments</B>: despite the aforementioned information, they were not explicit about the existence of a blinding methodology of the assessors.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-06-01 23:20:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Guo-2014">
<DESCRIPTION>
<P>
<B>Comments</B>: no methods for blinding outcome assessors have been described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-06-03 18:28:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Launer-2011">
<DESCRIPTION>
<P>
<B>Comments</B>: it is unclear whether the outcome assessors were blinded in the interim and final analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-06-03 18:24:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ryan-2006">
<DESCRIPTION>
<P>
<B>Quote</B>: "Cognitive tests were administered at week 0 and again at week 24 by staff blinded to subjects&#8217; treatment assignment."</P>
<P>
<B>Comments</B>: outcome assessors seemed to be blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-06-03 18:34:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zimering-2016">
<DESCRIPTION>
<P>
<B>Comments</B>: no methodology for blinding participants, personnel, or outcome assessors has been reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2017-06-03 18:35:03 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-06-03 18:29:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ADVANCE-2008">
<DESCRIPTION>
<P>
<B>Quote</B>: "In the intervention group 4828/5571 and in control group 4741/5569 patients were assessed at final visit." "All analyses were conducted according to the intention-to-treat principle".</P>
<P>
<B>Comments</B>: over 85% of the participants were assessed at final visit and the analysis performed was with the ITT principle and is considered adequate.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-05-31 23:53:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Abbatecola-2006">
<DESCRIPTION>
<P>Quote: "In the Repaglinide group 65/77 patients and in Glibenclamide (glyburide) group 63/79 patients completed the study, the analyses were performed according to the intention-to-treat (ITT) principle."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-03-29 12:23:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Araki-2012">
<DESCRIPTION>
<P>
<B>Quote</B>: "All major analyses were according to assigned allocations (intention to treat), without exclusion of protocol deviants."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-06-03 17:59:22 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Guo-2014">
<DESCRIPTION>
<P>
<B>Comments</B>: the initial number of participants were 72 and before the first five weeks 14 (19.4%) dropped out; the analyses were not performed according to the intention-to-treat (ITT) principle.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-06-03 18:30:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Launer-2011">
<DESCRIPTION>
<P>
<B>Comments</B>: approximately 10% of the participants were lost to follow-up and no reasons have been given. No information has been given about the statistical analyses used to correct for missing values.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-02-07 16:04:23 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ryan-2006">
<DESCRIPTION>
<P>
<B>Quote</B>: "The intent-to-treat population consisted of all randomised subjects with at least one valid observation for an efficacy variable while receiving treatment." In table 2, the in cognitive scores were in rosiglitazone plus metformin group 66/69 and in glibenclamide (glyburide) plus metformin group was 70/72</P>
<P>
<B>Comment</B>: ITT analysis is considered adequate.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-06-03 18:35:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zimering-2016">
<DESCRIPTION>
<P>
<B>Comments</B>: statistical analyses to account for participants that were lost to follow-up are not specified and it is not clear how many participants were lost before final analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2017-06-03 18:35:15 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-06-01 23:11:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ADVANCE-2008">
<DESCRIPTION>
<P>
<B>Comments</B>: protocol identified (NCT00145925), no differences found in the outcomes reported in the protocol and the articles.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-06-01 22:56:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Abbatecola-2006">
<DESCRIPTION>
<P>Comments: no protocol identified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-14 13:47:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Araki-2012">
<DESCRIPTION>
<P>
<B>Comments</B>: UMIN000000890 protocol was identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-06-03 18:00:23 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Guo-2014">
<DESCRIPTION>
<P>
<B>Comments</B>: no protocol was identified; in the methods the follow up was until 24 weeks and the results showed in the study are only reported at 12 weeks.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-06-01 23:26:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Launer-2011">
<DESCRIPTION>
<P>
<B>Comments</B>: protocol identified (NCT00182910), no differences found in the outcomes reported in the protocol and the articles.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-06-01 23:31:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ryan-2006">
<DESCRIPTION>
<P>
<B>Comments</B>: no protocol identified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-06-03 18:35:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zimering-2016">
<DESCRIPTION>
<P>
<B>Comments</B>: protocol identified (<LINK REF="REF-Abraira-2003" TYPE="REFERENCE">Abraira 2003</LINK>); no differences found in the outcomes reported in the protocol and the articles.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2017-06-03 15:23:17 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-06-01 23:12:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-ADVANCE-2008">
<DESCRIPTION>
<P>
<B>Comments</B>: none identified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-06-01 22:56:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Abbatecola-2006">
<DESCRIPTION>
<P>Comments: none identified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-29 12:23:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Araki-2012">
<DESCRIPTION>
<P>
<B>Comments</B>: none identified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-06-03 15:23:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Guo-2014">
<DESCRIPTION>
<P>
<B>Comments</B>: none identified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-06-01 23:26:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Launer-2011">
<DESCRIPTION>
<P>
<B>Comments</B>: none identified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-06-01 23:31:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ryan-2006">
<DESCRIPTION>
<P>
<B>Comments</B>: none identified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-25 09:27:28 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zimering-2016">
<DESCRIPTION>
<P>
<B>Comments</B>: none identified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2017-06-06 08:33:24 +0100" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2017-06-03 19:21:02 +0100" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2016-11-07 08:24:02 +0000" MODIFIED_BY="[Empty name]">Glibenclamide (glyburide) compared to Repaglinide for Type 2 diabetes</TITLE>
<TABLE COLS="7" ROWS="12">
<TR>
<TD COLSPAN="7">
<P>
<B>Glibenclamide (glyburide) compared to Repaglinide for Type 2 diabetes</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population</B>: patients with Type 2 diabetes<BR/>
<B>Settings</B>: general population<BR/>
<B>Intervention</B>: Glibenclamide (glyburide)<BR/>
<B>Comparison</B>: Repaglinide</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No. of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Repaglinide</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Glibenclamide (glyburide)</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Global cognitive function </B>measured by MMSE at 12 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean MMSE at 12 months in the intervention groups was<BR/>
<B>0.90 lower</B>
<BR/>(<B>0.12 to 1.68 lower)</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>156<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Evidence of a small effect on the MMSE favouring glibenclamide (glyburide) at 12 months.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Incidence of MCI</B>
</P>
</TD>
<TD COLSPAN="6">
<P>No evidence identified.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Incidence of dementia</B>
</P>
</TD>
<TD COLSPAN="6">
<P>No evidence identified.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Adverse events</B> (Hypoglycaemia)</P>
</TD>
<TD COLSPAN="6">
<P>No evidence identified.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Mortality</B>
</P>
</TD>
<TD COLSPAN="6">
<P>No evidence identified.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% CI) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI</B>: Confidence interval;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality</B>: further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality</B>: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality</B>: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality</B>: we are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Abbatecola et al (2006) has an unclear risk of bias due to no description on the random sequence generation, allocation concealment, blinding of participants and personnel, and selective reporting.<BR/>
<SUP>2</SUP> Single study with a small sample size: 156 patients.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2017-06-06 08:33:24 +0100" MODIFIED_BY="[Empty name]" NO="2" READONLY="YES">
<TITLE MODIFIED="2017-02-13 19:12:29 +0000" MODIFIED_BY="[Empty name]">Intensive glycaemic control compared to standard glycaemic control for Type 2 diabetes</TITLE>
<TABLE COLS="7" ROWS="13">
<TR>
<TD COLSPAN="7">
<P>
<B>Intense glycaemic control compared to standard glycaemic control for Type 2 diabetes</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population</B>: patients with Type 2 diabetes<BR/>
<B>Settings</B>: general population<BR/>
<B>Intervention</B>: intense glycaemic control<BR/>
<B>Comparison</B>: standard glycaemic control</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Standard glycaemic control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Intense glycaemic control</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Global cognitive function </B>(defined as reduction of at least 3 points in MMSE)</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>164 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>160 per 1000</B>
<BR/>(144 to 177)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>RR 0.98 </B>
<BR/>(0.88 to 1.08)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>11,140<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
<BR/>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Evidence of no significant difference between intensive and standard glycaemic control.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Global cognitive function </B>measured by MMSE at 40 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean general cognitive function measured by MMSE at 40 months in the intervention groups was<BR/>
<B>0.01 lower</B>
<BR/>(0.18 lower to 0.16 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>2794<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2</SUP>
<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Evidence of no significant difference between intensive and standard glycaemic control.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Incidence of MCI</B>
</P>
</TD>
<TD COLSPAN="6">
<P>No evidence identified.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Incidence of dementia </B>(defined as dementia according to DSM-IV)</P>
</TD>
<TD>
<P>
<B>9 per 1000</B>
</P>
</TD>
<TD>
<P>
<B>11 per 1000</B>
<BR/>(7 to 16)</P>
</TD>
<TD>
<P>
<B>RR 1.27 </B>
<BR/>(0.87 to 1.85)</P>
</TD>
<TD>
<P>11,140<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,3</SUP>
</P>
</TD>
<TD>
<P>Evidence of no significant difference between intensive and standard glycaemic control.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Adverse events </B>(Hypoglycaemia)</P>
</TD>
<TD>
<P>
<B>17 per 1000</B>
</P>
</TD>
<TD>
<P>
<B>36 per 1000</B>
</P>
<P>(25 to 52)</P>
</TD>
<TD>
<P>
<B>RR 2.18</B>
</P>
<P>(1.52 to 3.14)</P>
</TD>
<TD>
<P>12,931</P>
<P>(2 studies)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,4</SUP>
</P>
</TD>
<TD>
<P>Evidence of a significantly higher incidence of hypoglycaemic events for intensive glycaemic control compared with standard glycaemic control.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Mortality</B>
</P>
</TD>
<TD>
<P>
<B>81 per 1000</B>
</P>
</TD>
<TD>
<P>
<B>81 per 1000</B>
<BR/>(64 to 102)</P>
</TD>
<TD>
<P>
<B>RR 1.0 </B>
<BR/>(0.79 to 1.26)</P>
<P/>
</TD>
<TD>
<P>15,888<BR/>(3 studies)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
<BR/>
</P>
</TD>
<TD>
<P>Evidence of no significant difference between intensive and standard glycaemic control.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% CI) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI</B>: Confidence interval; <B>RR</B>: Risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality</B>: further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality</B>: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality</B>: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality</B>: we are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> The ADVANCE study has an unclear risk of bias due to no description in the random sequence generation, allocation concealment, and blinding of participants and personnel.</P>
<P>
<SUP>2 </SUP>Launer et al has a high risk of bias in the blinding of participants and personnel and an unclear risk of bias due to no description in the blinding of outcome assessors and incomplete outcome data.<BR/>
<BR/>
<SUP>3</SUP> Event rate low (61 in the intervention group and 48 in the control group).</P>
<P>
<SUP>4</SUP> Wide 95% confidence interval around the pooled estimate of effect.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-03" MODIFIED="2017-06-03 19:23:17 +0100" MODIFIED_BY="[Empty name]" NO="3" READONLY="YES">
<TITLE MODIFIED="2017-02-07 15:56:51 +0000" MODIFIED_BY="[Empty name]">Rosiglitazone plus metformin compared to glibenclamide (glyburide) plus metformin for Type 2 diabetes</TITLE>
<TABLE COLS="7" ROWS="12">
<TR>
<TD COLSPAN="7">
<P>
<B>Rosiglitazone plus metformin compared to glibenclamide (glyburide) plus metformin for Type 2 diabetes</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population</B>: patients with Type 2 diabetes<BR/>
<B>Settings</B>: general population<BR/>
<B>Intervention</B>: rosiglitazone plus metformin<BR/>
<B>Comparison</B>: glibenclamide (glyburide) plus metformin</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Glibenclamide (glyburide) plus metformin</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Rosiglitazone plus metformin</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Global cognitive function</B>
</P>
</TD>
<TD COLSPAN="6" ROWSPAN="1" VALIGN="TOP">
<P>No evidence identified.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Incidence of MCI</B>
</P>
</TD>
<TD COLSPAN="6">
<P>No evidence identified.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Incidence of dementia</B>
</P>
</TD>
<TD COLSPAN="6">
<P>No evidence identified.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Adverse events</B>
</P>
<P>(Hypoglycaemia)</P>
</TD>
<TD COLSPAN="6" ROWSPAN="1" VALIGN="TOP">
<P>No evidence identified.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Mortality</B>
</P>
</TD>
<TD COLSPAN="6" ROWSPAN="1" VALIGN="TOP">
<P>No evidence identified.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% CI) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI</B>: Confidence interval</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality</B>: further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality</B>: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality</B>: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality</B>: we are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2017-06-03 20:31:16 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2017-02-02 14:09:34 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Glibenclamide (glyburide) versus repaglinide</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.11532197441054204" CI_START="-1.6846780255894551" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.8999999999999986" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.01" MODIFIED="2017-02-02 14:09:25 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.024575264787087908" Q="0.0" RANDOM="YES" SCALE="2.84" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="79" TOTAL_2="77" UNITS="" WEIGHT="100.0" Z="2.248014508576227">
<NAME>MMSE at 12 months</NAME>
<GROUP_LABEL_1>Glibenclamide</GROUP_LABEL_1>
<GROUP_LABEL_2>Repaglinide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Glibenclamide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Repaglinide</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.11532197441054204" CI_START="-1.6846780255894551" EFFECT_SIZE="-0.8999999999999986" ESTIMABLE="YES" MEAN_1="24.1" MEAN_2="25.0" MODIFIED="2016-06-15 16:16:10 +0100" MODIFIED_BY="[Empty name]" ORDER="21" SD_1="2.5" SD_2="2.5" SE="0.40035328800880865" STUDY_ID="STD-Abbatecola-2006" TOTAL_1="79" TOTAL_2="77" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.010221497332130033" CI_START="-0.01302149733213003" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.0013999999999999985" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2017-02-02 14:09:34 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.8133474586055345" Q="0.0" RANDOM="YES" SCALE="0.04" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="79" TOTAL_2="77" UNITS="" WEIGHT="100.0" Z="0.2361098144186513">
<NAME>Cognition composite score at 12 months</NAME>
<GROUP_LABEL_1>Glibenclamide</GROUP_LABEL_1>
<GROUP_LABEL_2>Repaglinide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Glibenclamide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Repaglinide</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.010221497332130033" CI_START="-0.01302149733213003" EFFECT_SIZE="-0.0013999999999999985" ESTIMABLE="YES" MEAN_1="0.039" MEAN_2="0.0404" MODIFIED="2016-06-15 16:17:50 +0100" MODIFIED_BY="[Empty name]" ORDER="23" SD_1="0.036" SD_2="0.038" SE="0.005929444328466706" STUDY_ID="STD-Abbatecola-2006" TOTAL_1="79" TOTAL_2="77" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2017-06-03 20:31:16 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Intense glycaemic control versus standard glycaemic control</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.06987835035322451" CI_START="-0.07845388848386378" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.0042877690653196285" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.01" MODIFIED="2017-02-10 14:06:36 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.9097836141740819" Q="0.0" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1378" TOTAL_2="1416" UNITS="" WEIGHT="100.0" Z="0.11331148249277524">
<NAME>Global cognitive function measured by MMSE 40 months</NAME>
<GROUP_LABEL_1>Intense control</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Intense control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Standard control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.06987835035322451" CI_START="-0.07845388848386378" EFFECT_SIZE="-0.0042877690653196285" ESTIMABLE="YES" MEAN_1="27.05" MEAN_2="27.06" MODIFIED="2016-04-05 10:12:32 +0100" MODIFIED_BY="[Empty name]" ORDER="13" SD_1="2.27" SD_2="2.39" SE="0.037840552175222114" STUDY_ID="STD-Launer-2011" TOTAL_1="1378" TOTAL_2="1416" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.082417013605561" CI_START="0.8848398432542979" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9786550468140088" ESTIMABLE="YES" EVENTS_1="895" EVENTS_2="911" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.03439460995407328" LOG_CI_START="-0.053135329850526984" LOG_EFFECT_SIZE="-0.009370359948226869" METHOD="MH" MODIFIED="2017-02-10 14:07:17 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.6747478619630427" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="5571" TOTAL_2="5569" WEIGHT="100.0" Z="0.4196408237387142">
<NAME>Global cognitive function (defined as reduction of at least 3 points in the MMSE)</NAME>
<GROUP_LABEL_1>Intense control</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Intense control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Standard control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.082417013605561" CI_START="0.8848398432542979" EFFECT_SIZE="0.9786550468140088" ESTIMABLE="YES" EVENTS_1="895" EVENTS_2="911" LOG_CI_END="0.03439460995407328" LOG_CI_START="-0.053135329850526984" LOG_EFFECT_SIZE="-0.009370359948226869" MODIFIED="2016-04-04 14:14:38 +0100" MODIFIED_BY="[Empty name]" ORDER="9" O_E="0.0" SE="0.05141551992141209" STUDY_ID="STD-ADVANCE-2008" TOTAL_1="5571" TOTAL_2="5569" VAR="0.002643555688789124" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.40492227150814264" CI_START="-1.6249222715081486" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.610000000000003" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.03" MODIFIED="2017-02-10 14:07:38 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.2387967862108129" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1378" TOTAL_2="1416" UNITS="" WEIGHT="100.0" Z="1.1779996006914342">
<NAME>Executive function measured by Stroop test at 40 months</NAME>
<GROUP_LABEL_1>Intense control</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Intense control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Standard control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.40492227150814264" CI_START="-1.6249222715081486" EFFECT_SIZE="-0.610000000000003" ESTIMABLE="YES" MEAN_1="31.45" MEAN_2="32.06" MODIFIED="2016-04-05 10:04:11 +0100" MODIFIED_BY="[Empty name]" ORDER="12" SD_1="13.64" SD_2="13.73" SE="0.5178270006559932" STUDY_ID="STD-Launer-2011" TOTAL_1="1378" TOTAL_2="1416" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.1244521731699576" CI_START="-0.14445217316995718" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.009999999999999787" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.04" MODIFIED="2017-02-02 14:08:53 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.8840997502556797" Q="0.0" RANDOM="YES" SCALE="1.66" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1378" TOTAL_2="1416" UNITS="" WEIGHT="100.0" Z="0.14577406510659183">
<NAME>Episodic memory measured by RAVLT at 40 months</NAME>
<GROUP_LABEL_1>Intense control</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Intense control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Standard control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.1244521731699576" CI_START="-0.14445217316995718" EFFECT_SIZE="-0.009999999999999787" ESTIMABLE="YES" MEAN_1="7.98" MEAN_2="7.99" MODIFIED="2016-04-05 10:00:47 +0100" MODIFIED_BY="[Empty name]" ORDER="11" SD_1="1.89" SD_2="1.73" SE="0.06859930806407616" STUDY_ID="STD-Launer-2011" TOTAL_1="1378" TOTAL_2="1416" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.9174024761876136" CI_START="-0.27740247618761305" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.3200000000000003" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.05" MODIFIED="2017-06-03 20:31:16 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.29378287585344975" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1378" TOTAL_2="1416" UNITS="" WEIGHT="100.0" Z="1.0498591821300893">
<NAME>Speed measured by DDST at 40 months</NAME>
<GROUP_LABEL_1>Intense control</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Intense control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Standard control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.9174024761876136" CI_START="-0.27740247618761305" EFFECT_SIZE="0.3200000000000003" ESTIMABLE="YES" MEAN_1="50.93" MEAN_2="50.61" MODIFIED="2016-04-05 09:55:59 +0100" MODIFIED_BY="[Empty name]" ORDER="10" SD_1="8.05" SD_2="8.06" SE="0.30480278255103044" STUDY_ID="STD-Launer-2011" TOTAL_1="1378" TOTAL_2="1416" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.8508515029026908" CI_START="0.8719543290666067" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2703771016573924" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="48" I2="0.0" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="0.26737157593442584" LOG_CI_START="-0.059506261803433845" LOG_EFFECT_SIZE="0.10393265706549601" METHOD="MH" MODIFIED="2017-06-03 20:31:16 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.2126310850571157" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="5571" TOTAL_2="5569" WEIGHT="100.0" Z="1.24636326571204">
<NAME>Incidence of dementia (defined as dementia according to DSM-IV)</NAME>
<GROUP_LABEL_1>Intense control</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Intense control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Standard control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8508515029026908" CI_START="0.8719543290666067" EFFECT_SIZE="1.2703771016573924" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="48" LOG_CI_END="0.26737157593442584" LOG_CI_START="-0.059506261803433845" LOG_EFFECT_SIZE="0.10393265706549601" MODIFIED="2015-12-13 18:10:10 +0000" MODIFIED_BY="[Empty name]" ORDER="9" O_E="0.0" SE="0.1920096599586115" STUDY_ID="STD-ADVANCE-2008" TOTAL_1="5571" TOTAL_2="5569" VAR="0.03686770951742161" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.1852869689800167" CI_END="3.139403349974013" CI_START="1.5173812504986184" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="2.182583739745882" ESTIMABLE="YES" EVENTS_1="226" EVENTS_2="108" I2="54.23941961879952" I2_Q="0.0" ID="CMP-002.07" LOG_CI_END="0.4968471173612184" LOG_CI_START="0.1810947134071729" LOG_EFFECT_SIZE="0.33897091538419566" METHOD="MH" MODIFIED="2017-06-03 20:31:16 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.13933517080661006" P_Q="1.0" P_Z="2.5744074310549602E-5" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.03878635729284316" TOTALS="YES" TOTAL_1="6463" TOTAL_2="6468" WEIGHT="100.0" Z="4.208175631538755">
<NAME>Hypoglycaemia</NAME>
<GROUP_LABEL_1>Intense control</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Intense control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Standard control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.4523349963047854" CI_START="1.432553556411568" EFFECT_SIZE="1.874326871297792" ESTIMABLE="YES" EVENTS_1="150" EVENTS_2="80" LOG_CI_END="0.38957979582565583" LOG_CI_START="0.15611086716245182" LOG_EFFECT_SIZE="0.2728453314940539" MODIFIED="2016-11-07 13:47:09 +0000" MODIFIED_BY="[Empty name]" ORDER="22" O_E="0.0" SE="0.13714080438660162" STUDY_ID="STD-ADVANCE-2008" TOTAL_1="5571" TOTAL_2="5569" VAR="0.018807600227804127" WEIGHT="59.72987607621874"/>
<DICH_DATA CI_END="4.17711039947951" CI_START="1.7915331264830492" EFFECT_SIZE="2.7355861627162077" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="28" LOG_CI_END="0.6208759536589814" LOG_CI_START="0.2532248429323742" LOG_EFFECT_SIZE="0.4370503982956779" MODIFIED="2016-11-28 12:56:48 +0000" MODIFIED_BY="[Empty name]" ORDER="24" O_E="0.0" SE="0.21596008234315814" STUDY_ID="STD-Zimering-2016" TOTAL_1="892" TOTAL_2="899" VAR="0.046638757165663645" WEIGHT="40.27012392378127"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.351999032658294" CI_END="1.1250831695034522" CI_START="0.8678830201937701" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9881500792480035" ESTIMABLE="YES" EVENTS_1="647" EVENTS_2="667" I2="14.965951421351354" I2_Q="0.0" ID="CMP-002.08" LOG_CI_END="0.05118462797745052" LOG_CI_START="-0.061538808358113456" LOG_EFFECT_SIZE="-0.005177090190331448" METHOD="MH" MODIFIED="2017-06-03 20:31:16 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.3085105152174358" P_Q="1.0" P_Z="0.857127481542267" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.002747896860477158" TOTALS="YES" TOTAL_1="7923" TOTAL_2="7965" WEIGHT="100.0" Z="0.1800319551572075">
<NAME>All cause mortality</NAME>
<GROUP_LABEL_1>Intense control</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Intense control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Standard control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.049263283640392" CI_START="0.8313959608511686" EFFECT_SIZE="0.9339985309881681" ESTIMABLE="YES" EVENTS_1="498" EVENTS_2="533" LOG_CI_END="0.020884476072904737" LOG_CI_START="-0.0801920897459818" LOG_EFFECT_SIZE="-0.029653806836538506" MODIFIED="2016-10-17 12:33:48 +0100" MODIFIED_BY="[Empty name]" ORDER="24" O_E="0.0" SE="0.0593728750990841" STUDY_ID="STD-ADVANCE-2008" TOTAL_1="5571" TOTAL_2="5569" VAR="0.0035251382975314406" WEIGHT="69.89175110812411"/>
<DICH_DATA CI_END="1.8775811265671005" CI_START="0.8132155600895441" EFFECT_SIZE="1.2356691253951528" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="39" LOG_CI_END="0.273598711087256" LOG_CI_START="-0.08979432015158893" LOG_EFFECT_SIZE="0.09190219546783353" MODIFIED="2016-10-17 12:34:45 +0100" MODIFIED_BY="[Empty name]" ORDER="25" O_E="0.0" SE="0.2134588653742132" STUDY_ID="STD-Launer-2011" TOTAL_1="1460" TOTAL_2="1497" VAR="0.045564687206846484" WEIGHT="9.0749319337813"/>
<DICH_DATA CI_END="1.4085711217338384" CI_START="0.8313119573992784" EFFECT_SIZE="1.0821099834788765" ESTIMABLE="YES" EVENTS_1="102" EVENTS_2="95" LOG_CI_END="0.14877878032196376" LOG_CI_START="-0.08023597266161278" LOG_EFFECT_SIZE="0.03427140383017549" MODIFIED="2016-11-17 11:28:57 +0000" MODIFIED_BY="[Empty name]" ORDER="67" O_E="0.0" SE="0.13452439954386328" STUDY_ID="STD-Zimering-2016" TOTAL_1="892" TOTAL_2="899" VAR="0.018096814072636965" WEIGHT="21.03331695809459"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2017-02-10 14:20:34 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Rosiglitazone plus metformin versus glibenclamide (glyburide) plus metformin</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.4891617420430683" CI_START="-0.6891617420430682" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.09999999999999998" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.01" MODIFIED="2017-02-10 14:10:50 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.7393834470323937" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="66" TOTAL_2="70" UNITS="" WEIGHT="100.0" Z="0.3326699350408226">
<NAME>Composite outcome: working memory</NAME>
<GROUP_LABEL_1>Rosiglitazone</GROUP_LABEL_1>
<GROUP_LABEL_2>Glibenclamide (glyburide)</GROUP_LABEL_2>
<GRAPH_LABEL_1>Rosiglitazone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Glibenclamide (glyburide)</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.4891617420430683" CI_START="-0.6891617420430682" EFFECT_SIZE="-0.09999999999999998" ESTIMABLE="YES" MEAN_1="-0.7" MEAN_2="-0.6" MODIFIED="2017-02-07 14:36:31 +0000" MODIFIED_BY="[Empty name]" ORDER="24" SD_1="1.6" SD_2="1.9" SE="0.30059824909554506" STUDY_ID="STD-Ryan-2006" TOTAL_1="66" TOTAL_2="70" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.5381042601060402" CI_START="-0.5381042601060402" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.02" MODIFIED="2017-02-10 14:13:55 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="66" TOTAL_2="70" UNITS="" WEIGHT="100.0" Z="0.0">
<NAME>Composite outcome: learning ability</NAME>
<GROUP_LABEL_1>Rosiglitazone</GROUP_LABEL_1>
<GROUP_LABEL_2>Glibenclamide (glyburide)</GROUP_LABEL_2>
<GRAPH_LABEL_1>Rosiglitazone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Glibenclamide (glyburide)</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.5381042601060402" CI_START="-0.5381042601060402" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.1" MEAN_2="0.1" MODIFIED="2016-06-09 13:36:42 +0100" MODIFIED_BY="[Empty name]" ORDER="11" SD_1="1.5" SD_2="1.7" SE="0.2745480347345859" STUDY_ID="STD-Ryan-2006" TOTAL_1="66" TOTAL_2="70" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.44007850846235497" CI_START="-0.6400785084623549" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.1" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.03" MODIFIED="2017-02-10 14:14:12 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.7166769486976573" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="66" TOTAL_2="70" UNITS="" WEIGHT="100.0" Z="0.36290353232536926">
<NAME>Composite outcome: cognitive efficiency</NAME>
<GROUP_LABEL_1>Rosiglitazone</GROUP_LABEL_1>
<GROUP_LABEL_2>Glibenclamide (glyburide)</GROUP_LABEL_2>
<GRAPH_LABEL_1>Rosiglitazone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Glibenclamide (glyburide)</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.44007850846235497" CI_START="-0.6400785084623549" EFFECT_SIZE="-0.1" ESTIMABLE="YES" MEAN_1="-0.1" MEAN_2="0.0" MODIFIED="2016-06-09 13:46:12 +0100" MODIFIED_BY="[Empty name]" ORDER="11" SD_1="1.7" SD_2="1.5" SE="0.27555532281328904" STUDY_ID="STD-Ryan-2006" TOTAL_1="66" TOTAL_2="70" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-2.4947022458672494" CI_START="-3.70529775413275" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.0999999999999996" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.04" MODIFIED="2017-02-10 14:13:21 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="1.0391384016797172E-23" Q="0.0" RANDOM="YES" SCALE="5.78" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="66" TOTAL_2="70" UNITS="" WEIGHT="100.0" Z="10.037850480346634">
<NAME>CANTAB Paired AssociatesLearning (PAL) test</NAME>
<GROUP_LABEL_1>Rosiglitazone</GROUP_LABEL_1>
<GROUP_LABEL_2>Glibenclamide (glyburide)</GROUP_LABEL_2>
<GRAPH_LABEL_1>Rosiglitazone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Glibenclamide (glyburide)</GRAPH_LABEL_2>
<CONT_DATA CI_END="-2.4947022458672494" CI_START="-3.70529775413275" EFFECT_SIZE="-3.0999999999999996" ESTIMABLE="YES" MEAN_1="-10.2" MEAN_2="-7.1" MODIFIED="2016-06-16 19:21:07 +0100" MODIFIED_BY="[Empty name]" ORDER="16" SD_1="1.8" SD_2="1.8" SE="0.3088310596047998" STUDY_ID="STD-Ryan-2006" TOTAL_1="66" TOTAL_2="70" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.09911704097787497" CI_START="-0.30088295902212503" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.2" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.05" MODIFIED="2017-02-10 14:14:54 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="1.0206925189381049E-4" Q="0.0" RANDOM="YES" SCALE="1.02" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="66" TOTAL_2="70" UNITS="" WEIGHT="100.0" Z="3.8856195407793437">
<NAME>CANTAB Pattern recognition memory (delayed) test</NAME>
<GROUP_LABEL_1>Rosiglitazone</GROUP_LABEL_1>
<GROUP_LABEL_2>Glibenclamide (glyburide)</GROUP_LABEL_2>
<GRAPH_LABEL_1>Rosiglitazone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Glibenclamide (glyburide)</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.09911704097787497" CI_START="-0.30088295902212503" EFFECT_SIZE="-0.2" ESTIMABLE="YES" MEAN_1="-0.2" MEAN_2="0.0" MODIFIED="2016-06-16 19:21:52 +0100" MODIFIED_BY="[Empty name]" ORDER="16" SD_1="0.3" SD_2="0.3" SE="0.05147184326746662" STUDY_ID="STD-Ryan-2006" TOTAL_1="66" TOTAL_2="70" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.0389254071401253" CI_START="-0.23892540714012522" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.4" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.06" MODIFIED="2017-02-10 14:15:44 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.219808426014516" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="66" TOTAL_2="70" UNITS="" WEIGHT="100.0" Z="1.2270377497197928">
<NAME>Working memory measured by Spatial working memory test</NAME>
<GROUP_LABEL_1>Rosiglitazone</GROUP_LABEL_1>
<GROUP_LABEL_2>Glibenclamide (glyburide)</GROUP_LABEL_2>
<GRAPH_LABEL_1>Rosiglitazone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Glibenclamide (glyburide)</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.0389254071401253" CI_START="-0.23892540714012522" EFFECT_SIZE="0.4" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="0.6" MODIFIED="2016-06-16 19:22:46 +0100" MODIFIED_BY="[Empty name]" ORDER="16" SD_1="1.9" SD_2="1.9" SE="0.32598834069395527" STUDY_ID="STD-Ryan-2006" TOTAL_1="66" TOTAL_2="70" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-7.694072754914577" CI_START="-15.705927245085421" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-11.7" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.07" MODIFIED="2017-02-10 14:16:41 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="1.0379249454248298E-8" Q="0.0" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="66" TOTAL_2="70" UNITS="" WEIGHT="100.0" Z="5.724412156324532">
<NAME>CANTAB Rapid visual information processing test</NAME>
<GROUP_LABEL_1>Rosiglitazone</GROUP_LABEL_1>
<GROUP_LABEL_2>Glibenclamide (glyburide)</GROUP_LABEL_2>
<GRAPH_LABEL_1>Rosiglitazone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Glibenclamide (glyburide)</GRAPH_LABEL_2>
<CONT_DATA CI_END="-7.694072754914577" CI_START="-15.705927245085421" EFFECT_SIZE="-11.7" ESTIMABLE="YES" MEAN_1="-15.4" MEAN_2="-3.7" MODIFIED="2016-06-16 19:23:28 +0100" MODIFIED_BY="[Empty name]" ORDER="16" SD_1="12.2" SD_2="11.6" SE="2.0438779879036884" STUDY_ID="STD-Ryan-2006" TOTAL_1="66" TOTAL_2="70" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="11.83918580915075" CI_START="6.760814190849251" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="9.3" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.08" MODIFIED="2017-02-10 14:17:44 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="7.04560927537147E-13" Q="0.0" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="66" TOTAL_2="70" UNITS="" WEIGHT="100.00000000000001" Z="7.178547151032989">
<NAME>CANTAB Reaction time test</NAME>
<GROUP_LABEL_1>Rosiglitazone</GROUP_LABEL_1>
<GROUP_LABEL_2>Glibenclamide (glyburide)</GROUP_LABEL_2>
<GRAPH_LABEL_1>Rosiglitazone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Glibenclamide (glyburide)</GRAPH_LABEL_2>
<CONT_DATA CI_END="11.83918580915075" CI_START="6.760814190849251" EFFECT_SIZE="9.3" ESTIMABLE="YES" MEAN_1="13.0" MEAN_2="3.7" MODIFIED="2016-06-16 19:23:58 +0100" MODIFIED_BY="[Empty name]" ORDER="16" SD_1="8.7" SD_2="6.1" SE="1.2955267694608283" STUDY_ID="STD-Ryan-2006" TOTAL_1="66" TOTAL_2="70" WEIGHT="100.00000000000001"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.10260950938683977" CI_START="-0.5026095093868401" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.20000000000000018" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.09" MODIFIED="2017-02-10 14:18:37 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.19519089372077683" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="67" TOTAL_2="70" UNITS="" WEIGHT="100.0" Z="1.2953750121808247">
<NAME>Episodic memory measured by RAVLT (immediate)</NAME>
<GROUP_LABEL_1>Rosiglitazone</GROUP_LABEL_1>
<GROUP_LABEL_2>Glibenclamide (glyburide)</GROUP_LABEL_2>
<GRAPH_LABEL_1>Rosiglitazone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Glibenclamide (glyburide)</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.10260950938683977" CI_START="-0.5026095093868401" EFFECT_SIZE="-0.20000000000000018" ESTIMABLE="YES" MEAN_1="1.4" MEAN_2="1.6" MODIFIED="2016-06-16 19:24:49 +0100" MODIFIED_BY="[Empty name]" ORDER="16" SD_1="0.8" SD_2="1.0" SE="0.15439544388253312" STUDY_ID="STD-Ryan-2006" TOTAL_1="67" TOTAL_2="70" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-1.0974493377267567" CI_START="-1.7025506622732431" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.4" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.10" MODIFIED="2017-02-10 14:19:35 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="1.1968652171671566E-19" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="67" TOTAL_2="69" UNITS="" WEIGHT="100.0" Z="9.069388768608697">
<NAME>Speed measured by DSST</NAME>
<GROUP_LABEL_1>Rosiglitazone</GROUP_LABEL_1>
<GROUP_LABEL_2>Glibenclamide (glyburide)</GROUP_LABEL_2>
<GRAPH_LABEL_1>Rosiglitazone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Glibenclamide (glyburide)</GRAPH_LABEL_2>
<CONT_DATA CI_END="-1.0974493377267567" CI_START="-1.7025506622732431" EFFECT_SIZE="-1.4" ESTIMABLE="YES" MEAN_1="0.3" MEAN_2="1.7" MODIFIED="2016-06-16 19:25:32 +0100" MODIFIED_BY="[Empty name]" ORDER="16" SD_1="0.9" SD_2="0.9" SE="0.15436541929327494" STUDY_ID="STD-Ryan-2006" TOTAL_1="67" TOTAL_2="69" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.0389254071401253" CI_START="-0.23892540714012522" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.4" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.11" MODIFIED="2017-02-10 14:20:34 +0000" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="0.219808426014516" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="66" TOTAL_2="70" UNITS="" WEIGHT="100.0" Z="1.2270377497197928">
<NAME>Working memory measured by Spatial working memory test</NAME>
<GROUP_LABEL_1>Rosiglitazone</GROUP_LABEL_1>
<GROUP_LABEL_2>Glibenclamide (glyburide)</GROUP_LABEL_2>
<GRAPH_LABEL_1>Rosiglitazone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Glibenclamide (glyburide)</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.0389254071401253" CI_START="-0.23892540714012522" EFFECT_SIZE="0.4" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="0.6" MODIFIED="2016-11-28 11:28:05 +0000" MODIFIED_BY="[Empty name]" ORDER="113" SD_1="1.9" SD_2="1.9" SE="0.32598834069395527" STUDY_ID="STD-Ryan-2006" TOTAL_1="66" TOTAL_2="70" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2017-06-06 13:38:23 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2017-06-06 13:38:23 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAZIAAAWkCAYAAADv7odZAACAAElEQVR42uydf0Rf7///3yQvSSaS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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2017-06-03 18:35:16 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAAEZCAMAAABxStv9AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD/gADAwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID///8AAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///9BjlLGAAAgF0lEQVR42u1dfXAcZ3l/ZGu/7k6625U0sTBjbEvQP8wfQJo0diwD
pziJSyHADNMMIQEyU9EAA2XaAZJ2aJjO4BAIM2kKA246aYDQMGFSHD5sEvuAnM2H0nGHac0w4WQL
B+ucStqVLJ327vYk9f3ar/uQTtLd+WQ/P3/c7rvv8z7P7v32fd/d298+AAhE09ABOh4ERJNgbcFj
gGgekF4IpBcC6YVAIL0QSC8E0guBQHohrhg68RA0FhYegsCdeqTXtTAetDamEg6OCJx7IZBeCATS
C4H0QiC9Ng3MlhsimkSvJIEcyVbddKX2bXsN33pslQhrGCar1142kEZN771SqdQlaaCt9m0viapa
32T/YX2G7p6WrZds7O1aMTga50sAfZqskNM5mVBl8jEaUegtXCcqRx1aqMhP2KqUZtVtSVHTdJsU
c2hNVU/yroH8MyNK1GQGik22qbRJUQas1QSp5MR4q/FDsu21k4yrIoYk+0PLeS3X7zN2D9iyojHf
MrUBry1HHfYNI0rEj4H51VhLAL2arJL9Ssuy2gvSwgDyqBVzr90SwFy0GM2R5aWJGPlIqtlFstJz
tCj30MLsyY/2T1weZrW7Y4UXbiHbMg7dlvzJRKAT2DFbOK4zg5k4wNu1cdsvA7hBzi7RVq2iQluF
p052e+3A1gmYjxZncqSXYf1Mz1FeDq7fT51ivp+nvmd4XKwtupTQfrPgGupKQd3hxcD8Xszw2jmz
GFkAGI4VX5gHOFVEHjWbXnTuVZoByE+BeTNZHzfoRyljTJOVwltgLE8+p42hvecMbT+zUJz0ngLZ
1g8m+XD2GIEfE0oSDGmsFVq5NNZv+2UA2jneqsQs4bwxNOS1AxkD7CnQbnabulP4Pu/6XdxDfBe5
b9ECW7IK1NNU3othDDIlLwYKy+jntW2N7aRU6N1Dqu8pIY9qoFFKoWQKbOMy6b2md5eW9qboOv0n
F9kHXSOLopD9I4RK3PVk9yQbDsn5LzleTfrBC921lDul5h3FyBGvkny8isn07sVFHoMwVgoBvzQm
6rtrKmATsIaAYSBoCLRk7los7UvB9A6nY7yfx+PCwt8cS3ozDoam/C35/wMwdTnAXhPo3Oa0WeVi
X8o9FJkjXyq5KCBf+AFeU9wWOM0LBU4zY7/sm7wutTzuVTrlm3wAJv2Lw1PE93LQ75DJfc8HmxTW
HYEwadBDoYgdMD8oLi3lF+mImrukfYAE/CR2Uy3g9czjZLZ88gW7xy/KD0AvHQcHYUAtr66mjefI
xEztAz0K8JLGap62Tcp90pc9oXk1OwezGiuzeSP2bughEyjVgRMRvzneDsXJKbvgsVIt9/2rs6TQ
Zr6VrGtD2tJJW78a6FMZI2kMGgz+OhRxHLSn2cLS7zK38D34Adnls/jYSUu6zdmDJswe6A+0+VJR
7aBzroJcnC6v3XVQZiOZLecJecZ7FVpzJr7t3+nFf1y+z+8EZxZ2kS88lZD1Od7nFhTqYzohPRL1
Kol2WBxdLIbObVDNt0xmUl0G9/1614a0dRNp66f2ZUIy+Tp2A6JHtsM3IWbVPt5S5F7mIHZQGZ4F
2C8jj5o892rUBK7umyC2vV4v5l3f7mlk1M67njJw7lV97rUVtPY5ChOL9dX7u//auvjzf12vly9O
537RyKjj2c8H1vIdbdmJtBJLWuBg4DsmGgp8GDrwMLSFs9JmHVoE4AM5CKQXAumFQCC9EK0ETu3x
yrGJlzdIr/YdDzbryIIyWgTOvRBILwQC6YVAeiGQXs2GeeWbRmHZ5qWXkaRPaiVrymu3b0x4u5Lt
5/iH/egqNp9bk4w2ZiON2odexdHeFbevrGHdEH7L+yZ97+r11iCjvaBjb9c29DIdq+R9HSZXqjoa
1cFmNVk94WpYzYismZ4aF5g81/b1uHFNTrt2oqxPUxReNakrI7atSnZAaUvrJ3nHc0a5EQxF1mym
x43wYMyoTJeymmL7+ltZ6HJlrr+FvgiLyfNly5KWBkNGGW0ttPxp1Qdji+rfS7DrPP37VWW+68tF
iMsz8RL89syWrm+Wzu9K0S0PdeW6yZZdF1/5eo49w7qF1dGlXFQrwK7shUPJJWGnW9D1iV/AUmxu
fssia/jiHz/ambjw599dhM+8ADGyjdenTRM8++MnYCmS6z6Ygf/46dcvP9LB/C1A6k864MuxSMei
CIH4ijBfr1BfBLteuXDkc6y28BWNLMw9U4ITTzr+/jXwadWOTcqpwNOqLe+9jsgge7JAJwMZ8tUU
z0l5gGMaWPvcLeoY2yLUuATvZ3UKY3DOV85yO6qFfYzpd12567QxtfecMUTWHpPAesyrz/H+PQCd
pp05RvzfCBpXEWlco/uRc5MFt17YF7ClSV5b+PpSybapjNbBbqrmGdLaxyvN9y0DnM4aFUpVsmnn
h47sS62kYYWy4pC81uktHSikAlLcWnJcKqM1X7u4HJ8sk9GmndVltLxA+Bp9WwlS+5m21oOFvzk2
R0ZbF7RfplKprWfFGlWqdriCxO1bvj3n1RNbIFgAXBNbUcYVsHGYeq7C3amQHNe/72AsZGOXgzJa
uuS4CkdhW6H97XVjEr5uXLgUHcb7GG10hlCVKqhnxNrDZ2FQApB2O6R4ScrQ5zfSo3QL1bBKQUNe
Rx2E3Wp5GVfTlkL6XXeMdTxtLSUMG8VkMggeMthVgDQKhhjuuG5XHnAUt94nQr7YHQ14A38DhfCl
GcYE6Yw1fOykXehVypD/Mp8RJ/zdtyn5CwC/L8ReAIjOf5Z+5wqbQF3oYVt88DrnCyPOdFnZdEJ6
J6HQ7Df7n61wN50YyftCbom9GuD71wG8ZEu5GeLl7cr7hTI3rlDdrmV/bMatd7ggOWHtb0az+eNc
wtfztpwgVa87ijxqk7lXG8DsT9/YyPacWLY5MtqrYO51LeocjUKukc09+vng5Avpda3Tq6nAh6FR
RtuKQ4sAfCAHgfRCIL0QCKQXopXAqT1eOTbx8gbphSfsWlDPC/6WcXBE4NwLgfRCIJBeCKQXAul1
9cFcZR1xhelF86HRBIkV6thacll9uUphWu5el/PQR32VQ0t3ldW5a20yWvwVu+m9Vyp16Qe38qWK
TdX6i3y1JHXDJy9vJIR1WxYq19cgo7Xy2Ns1f3A0bln0+qv4IZnnejVEgc7UsKamJvi5PyBJkDQU
bTSYUza5/x8DuWNZGliRuzYdkdWE126fJj/h2VE4qsgSK+qlJUXjUnA3N67rXxE9zWhEToDbBhXN
ujlxaQ0hoyV1aHzCtrYfSUIZbQvmXrr/UDs8dfJbAD3HLrl91OJEbB7gu8rEEl8v0ixPpax6A0Cn
VTzGssg+RbPAurljt07QNLAnRO7aW39S1GyvXfsH8ft8O4LHJzS+JOp9K1Z4/r2s4C9FblzhX8uK
u843qJdEPlvSBvN7gfl9uzpuu9lob1CLND6RV3cFP/KDyKMm04tMvt7sT6fOG0MZMsa80RgXBeOG
uR/gezyLLMFNLwNVu45RoY8EB0QWWYK8yB1L1/zctfYQWDd77RbfMpn37QiuN0QOWVHvO469h0t1
/8XPjUua+VTG9a9m3Hy2oo07e1he2pvG+r1stGoGaHzEqVDy1vLz8qeRRzXQoIehqcI0uysfEKCS
f1RdGioQuWkB3Nyz9LNS6RrIHSv+jR5008tWS07r24h6TqK4pWuKDWd9TmVuXN9/WEZ7ulAho5Wc
qtloy/zIASmlhb85LjdFRtu/VHnBPxrmsidM3WKyzebWcqXr6fLcsQwHOuTApP9UUD3LZlhus6Ke
lHuV5poliC9PxQJdted/q5/P1pfRFlxhrh9K+PDU8GN2YDfV/LnXCamsQDkDt4QK8rthJ3/ZTCfV
ae+CAZkpXV/0Z235/62StxaWucJWQD7Tp4bscnBWCdajuWbvYQUlnpdWwB6AnaIJniW3wNtIm6BM
s7njw4NZla1T8pyFgXwojBp+zj6MPGr63Et+V6SsbPrdytZQwUtFZQt3+BWqle1QiuNMBXvYF1KX
DlXJWwvRP90WyIauPXLZCtn9TL19OlivS5eH72YFs13v2xL2L+aCBZUulRIybUPZBtOvk20S/0cX
dllsnfbstymF8NNbNfzsx6l9k+de9d++yC+wYXP7ZSmZujoOodN90cC5V/W5V0vp1Z3v2HKZD6G6
M68Uro4jvtwTktEivZavkM6RTYeF48p75Zt2AAjftC/hkOgDH4ZuMPAHyCZdOSIQSC8E0guB9EIg
cGrfWqCMFmW0eMKuFyijReDcC4H0QiCQXgikFwLp1VCYDaqDuDrolUwmJSrgqlsLy2Eoy1XLXxOw
qmW+feXoNpCWVpga0Srb7BoR19dkeVCPGkijunqvVOpVlT+jXpcWViA3U/1Z830Bq1rme5u8e+bC
K1VK49GNPB1fvi97F7APrnNwNKx7vP4qoY6wXK8jrhY2oSg2zROrnuAnMM8lm7z5HczCHolOA/R9
nOtWEyNCjMryuzJzm2V+TbOcs5A8oYr8sLYsf5w/gN/3cYXbCj/Ki6K7eJHnrI2ORHmCWmJzO7WZ
jsrUJ2/Ls4u6GWYJzsgGcSxHHK+cmCf3v4lmu+VrI5DURxQjPUIT2/ZqyojO6tBAHPZ/oL2sFuHZ
aEU9ntP2RvkM8qjOudeJZ7zF5Ym74wD3yw+5z74vZWdIwU554jhf36EWlB2u6BTUh6TDAHNPF6O0
A+x4SJQfVrrFbwRqViVLX3i+qJF6cHxidpjZxqPF6w+yCnNPF5gt96OrWTeB3l9kqbq6Z+aIspOG
PEFsjlObXXJR8try7GYKX93p7sMdr1LaXlI6/fKOCep1x1eLJHYaJyHQQzP5dzw0S2znny/spZLZ
pQkqvk082r0Qau+Ri5EdbEHUy0WK5nsBXn038qgeepHJ1xdCWliaz3XMcH9GG2eS1uI54zBfdzIw
5iditYxzPCcsFazCmDsh+ca5SSG3KRkZFeDYEFjUxwOGyB0rP5i+g9dwbbkfLWM8INrgets7JTDv
BKawlbgNzRf7mN+WsJPgw56wzbFZZGOKX84jc+7gsdM1y9Bu4rb5Ifgwb4kqZ0vvo6EH2jtsTPH9
FfU6TcM+RqZymI22FoLP2lNtRe98vqr01S9wFbAQziUrVpw+R+SEDVhBQJVq7hz5l33BCk7C6Rjv
Z1+5l0+2uh/wlK6OXuzomqqSm7Y8r6xQ8jL1q19emWpW/HP6SqV9VeS6aSe8v6KeuX0JuidRRluG
FWS0U/eUFXyoPCfrFq5AhfKMsWTlQ0y3Gs4J6+d35arU7R3/9GKogpS79KNdfMYdsvX9kE9qKZSu
zGb+0o/IMDpoVrmzIfLKcnxQyHXLyyuz3TJ0L0+eh2CdsF3W1dWKeoadjbwH766sYe6VeKr8iO+G
naECZTfcf4p/yUdhwJfO7oQz3aGcsCL360Cf4lY4SpaWZPuGAPkcqkVVuL67dCKYT1Z5Bu4Xi/fD
gM0SxrpvSRE23Vp5vljw8spyPDUI9PmQAaWsvCx279ycsh/x1zqPUrluwG4QztrBeodso+NJUiwj
j+qbe0nOTFmFw85IWAs7XlAe5+f9hY/JBT9j7Fbp3WSuNHvAywnLc7pq+feIJp9VPj5Oc85uC9wn
InWoFvUkW5l9azCf7Pin1MfF4r8pRYtpXvNjvKBLV6jN4b7yfLHg5ZXlOEp1O4ZMa4XKaezhbLcM
J7v6H/fXZu6bi4TsItptVrDeA4aUi5LAJORRHXOvumHYduU9x9VEsetXzW5Ab2u+Zq7pct3RAxMo
o60x91o7vZY/8qSrhQ1i5MgqdutXzW5Eb2sf+WRw4t0MxCY1QHo1il6IFYEPQ2M22lYcWgTgAzkI
pBcC6YVAIL0QrQRO7fHKsYmXN0ivTT4etOHwU8LBEYFzLwTSC4FAeiGQXgikV+NhXmE/mI22WVj/
ExNJgFNbuib9h9K9DamVntCyuz/55fIyzW7Nzgo/ujMv4qzhn6xX2wNRVr6p7L32eGOi1JCUVanU
JW2OL1Vsqm31ycsV7Gq6mDbsx7T/sIr/vWvKRluysbdrCvkNa8ntyJIJlrPVibB8r6KAZaRVvsFF
t06UZX7NMNGtE1GEIlXkfu07JNtuHSqIlZ9Ic3sv52yvJlOdZFqW1V5XwUq1tlRaa8vSobS3Lakr
ivEEzz/Lt3OFbZLr95+Re9w4ib+YyEbL/TjqsOFnoxW6W6bOpRjVRDZaEsuwF4u0gNlom9O3Gv5z
mjxnq666+V5heeLkMECPlB3h6z1Hi3KPK7rVlYK6w+8OUmD/Mpdw61BB7MmPvpPbW0WF6ztyZjGy
ADAcK74wzxSsGqHPjtnCcfI9x3/sPHvQ2wZmNpr/GxaP2E4VtgnX96dkL86ejBuT8JPQfrPg1kuK
GLk6l+KGi1NeLP9te/76isijxtMrmUy+yTcXylMv36tQ4RbOGS/x9YLIM8sHlDHIhMSnzjmp4Oei
5Xlomb3EssTSSZvGEstKhfQeUqXTMTI2U1EMEYp3Dtt23tsGlmHexHPIiu1UYXuz62rxZS/OQr/b
uvBTGpuqiHHcFfxSva0fyz7P38uY56UJU3squp0rrCK6dXWs1UW3VdS2Zblo/Zyz5q5FKl2d3sFU
t+ZrFz/4n5PuZrK2HJ90t1Wah3SxNEY3Tghmoz1VrMhGG1DaBqMLx8IUvzi1b/DUnmCq/EVGHb72
VWDUvcw/HdS80pUhsZ1BZJityEXr54vdDjLV3/bkLmkfIMPyQvaZy1zjWmRr37jsbQvgdCjVLceQ
6cXpty6WOsqy0Q6FLB13D8KxmHjzsDnk17eWFeR5llcfyq2gc9GtMhjIMytpMPhr8qUa5i2cVfJu
RwFQB8tz0aoOnODa2aXfZWhdNW1kySxeMwwqtiT9hq2ytTsJLbW08YN0yFxshyCH36V5capZpswl
5cLPrwaocpbXe5jHGEAcNMWNhWqBhb+z+NhJU+Zecv7nZWUvFdWwtH7akYUIcLoQyDOb6pFtMtTE
cv2UoPI2sPKxE2V1uFVCeoS/AS5ybz8NNnZQiZ8EeN5mCtZUQtbnyNqfyfEYQPSgMjwbvonAtwvI
LMvsg6oX5/TrmTKXlAs/P7UvR9x6e3vkfPgmxKzaN84Wovf20wFA+NuPKu3Gz73q7+KKubbaZSqt
bWR709tDMlqce5Vap3NcviXdOdtmInnd7GhkczEp+IQq0quV9LrmgA9Do4y2FYcWAfhADgLphUB6
IRBIL0QrgVN7vHJs4uUN0uuaGA8aFhRmo0XguYZAeiEQSC8E0guB9GpHmOvatFYTM7gJhWWNwlbQ
WukueX7NFf+5tlAiN7rB1oytRb/80ZJbl7RbLVBRVr4pFnrgKN/Rjl9zw4KqK42vR6l8+/deK2hs
f7vB1syFC4HyfXwpxdpdg4z2go69XfsMjsm4xvSxmtDNxqgy9YSiPGHznLJpVzfLla1M4xqV3DJR
H1z5raNRba2pKZFRqp+VFaO3LCct2UbvIqcjEqlJTbI8Hy7Bbtnwy1l7cU20m/Q1vTxeir6IxrW/
fRrLm2vIkpYGQ9mNPGqjudfF2SQV0uZohlm52EmVqcezJ+7rn6DlcOiSzLWqPVZRvp9rXDOO0NK6
9UU3kiLNxG4C2KEVVGprXprJF8ty0u74GlPMHpx2Ilwhe69Z1N7ByfpqoJyJZ7deFO1yX1KPFy9F
4Y8x/nvHXLQwMw8wH3HMgwA/xHShbUSv84Y2RJPaSiKfLFWmPmAM7TvHyuGCMXYn/zIlsB5jS3f2
8zy0fn0PzrmpYywvLlO8+nll/Ryyzh1MMZvnKlyCYxpYfInmqvXLKTKBp+ZdXzxeHvkklx3lp4A6
+VKJqXf3IL1qz/la+nhlsjzVa0VSWF+rGta4ni5U1l+pGXBzyArF7OjBRZFo1tz5oSP7vFy1fnmy
LIluVRmtyEbL8+aOvq0Eqf3hnFoW/ua4rF/5g3Ha081W3CIQJb7G1c9D69c3g81U5pb1c8hu4SZv
7ZCFIm37lm/P+Xcg/PJyVMbW53qJA8ube+PCpegw3sdox/te0m5HZbrZ8nyyPHcsMAWtHiV90Cgo
fW4eWlE/nTbpxOqUA9JA7yHS2FkYDMuR/Byy9gBLp7vYmenknFmSMuI5kc7BYPlpjyY8j25lbAvw
Bh6ayLmrGcYEVe/iYydtR6/fF2IvUN3sSHk+WcNV0k4nRvKEVMp+OL/g5qEV9S8Ps7y1Ugys982R
pQu3KWW5Za24LHLIWkWV1j2RY8pX+bMQnf+smGHRXLV++cP9HvVZHt3zFbFlNHucLcx+k/k/Z8sJ
UvW6o8ij9ph71TU7axnM17x448ZbKctGi3OvwNyrxXft67hrsdg6X1+ce/Pxjbfyxme+EhyV8a59
4K49ymgbDHwYGmW0rTi0CMAHchBILwTSC4FAeiFaCZza45VjEy9vkF7XxHiAMloEnmsIBNILgfRC
IL0QiGuDXmYLLDZmh2hnejkxeXjZV8YmyzZvryxaBXfVsHgiti67ZPW4Yvgr9qagV7zz0jOJG2pu
XjlHbDUUqluY96XWZSdQvsnKY2+3GehVOmcYsyrVr0qxoJIWHFVxc8SqDoxqgRy1yYTi1k8aijYa
UL8eEnLYZFyVeF7cBO94dss3rsuOxCGy0aYjspoAsCVF6wVJwmy0m4Fe8k6jj/YcPRccoaTttIrH
yNLXtC43R6z8c7hVdsspnst69UtZlfR9nXLxKP0tYutTKbejmbjM8+IeFix5dX128LWJ49zrrT8p
0lTL3bHC83MkpgeRR5uAXtZIflY9BXBnj5sjVpXgAFn6tJ8j9tXnoPRDt5zijYZXf9oYo+KjMeim
eh5fEXueCWsL54zrBb3+Z312sNcY4nHYQ0yJqzjpPaSBlz+NPKqBNnsY2hyw865qtmqOWLO/MHIk
kKOWiVy9+jR/Y1WlrZ8oFzxh7ZrtfIWv0N46emFL1xRv0DtH8DfHdpDRVoFigmEthVSzXEnrKxDB
kOJPBxW2FG59E8ytVZW5/ETyyt2Us2u187PRHuDaW2n+1cg8gNmB3dQmGByVXaaZINMfZRoMoZp1
4EWy1DmQPeTmiP3+9Z1euWsn6u+EAZkMZhqcEQPnYJAvym43Ly5Vz67HDuJwlstolyeZ9la1jefu
ATj7MPJoE9Br/K+2bXN+RuZCr5MXeAba6YR8mOWI3flrgL9mOWK7T2W8cgG3/halOE4m6r3yHeId
cd/ZFmh92pGP8CXp3vXZwc/U27muNvqubbSsS5eH7wbYj1P7TTL32ghWF+CKvLjma4K61/rtasDp
vogy2hpzr6uIXkphxc0xZ7lzjOv8jUJuXXY1jmZPcCxFel2l9GqTuyt4CFBG24JDiwB8IAeB9EIg
vRAIpBeilcCpPV45NvHyBumF40Gj966EgyMCzzUE0guBQHohkF4IpNc1AdSWIb2agLSqaDR7Yy3N
bg0pLQLpVQecW2KF6C19K+bApUjhoUJ6rR2J6BRMRf6B62jtEZnltb2d5rVNJnj6qqwW4Rlpe7Xb
R3QAQ5Gp5BGB9FodpQz57/8+zTW71z00y/LaHmd5bTsmWI1HLkZ2sIX554/vzQHkIkXtvXjgagCf
Vg1PrVwhJNU5fs+gH2oe6D+6Riv8RBJaR1E9Ot8TTGHbpg9Dt7Q7KunXyMFYM35Brxhd3SJnzb5k
MrnorYHkvprWScRoaqZXIrn+PjxwODjWAyaBHAzpFv28tnzuBSY/Zt3Lk3+krLOzkffggUN61QMt
1wu9uesBTnnvGfPz2jIMwlk+k1+csumrTQ7ZRseTeOCQXvVgsmteyXXtJ9Ov/W7RS3FF5LVliGi3
8Ue6Tnb1P04+HjCkXBQPHE7tWwOc2uPUHtGquSweggZjCfcO6dU04FwDp/YIpBcC6YVAIL0QSC8E
0guBQHohkF4IpBdiTbCusH17NYD0QmDvhUB6IRBlwOe92mzudTUAXzzegmO7Tnpu9HRvgwZwcETg
3AuB9EIgcGqPuBLXOTi1b8a1o84+9PqnyZ4N+1yTqT+d1tfn25+O63VHwDf5UddyivRqOLv4QWZ/
62aX+8XoYq1+09AF63p8++YW1BuBVbanNZ3i3KuNbmas/5aApTfsvGioN+y9mtyRrWdcXYepVX7D
be2+9boj0OveYaRXszoki/616r5ycsdG8rlWU/As1+m7op11RVDNBunVzAFPzEzWOEauw1TfsO+N
RlDdBude7TE2Whsc2jY+Lusbn81V2iC92oiJ6/85vFE/pDf6B3m8rdp4qgTvEtR3eAN3ndZqGna6
gQb0tQRf7b5XFRsL6YVo4pmGgyOiiUB6IZBeCKQXAoH0QiC9EFcFAj8KocYF0SDoVeiFd8AQjYGF
gyMC514IpBcCgfRCIL0QVxc6V575b75rSoy97elV3qctbeI9Km2m2DvCq8s4OCIQSC9Em9PLqnNr
RT3L8kuv0A9PVlXn1qbYHy/2WiG186FvlBBttdcRbLa5ahvuj74JD/3aB0fLEmeSd2ZY7I/YEjzj
eE2r7EwS1fzaLe3GXOfBvXE/rLbeH+4LQvG3+6Ffc+9V7U0Elh7eElx332rhCSzDL75oOb90/29l
MH6s7bk/1E/Iebsf+nUOjrol/pT1u3pFn1zRN+tXtL/Wq/rWw5/ttT9W2ZGvDLB9D30DXwKgB15S
tfrh0q22mImtMO9tl/2pQ2Hbtoe+s7HHgZ49q7yawAq8pOzK80sPxbRp96ddQ13vfS+dvUdFX8+d
i8BFQcuOvlUxcFir3LVo1/2xNnLTqOWHvnONO6bX7ln9LZx34Zq65W3kW1o6OJZ5CwZDl0RMbb8/
VeNs50MfeAmAf3aXa7eXNtPPwuW/OW6m2Mt/c9RXu5nVpvuh1/gyEO39vcEme4oC6bWZsOke0KlO
r6VN/BWUNnHsy1fb+dB5VZwkGHubAh/IQSC9EEgvBALphUB6IZBeCMTKCN6YwDcwIZpHL3z/EgIH
RwTSC4FAeiGQXgikFwKB9EIgvRAIBGJ1/D+keK9qTxTPjwAAAABJRU5ErkJggg==
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2017-06-03 18:35:16 +0100" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAWUAAAInCAIAAADPn98WAAAb/klEQVR42u3dv64dSb3F8SMhIQIH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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2017-06-06 14:01:45 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2017-06-06 14:01:45 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2016-06-29 11:11:01 +0100" MODIFIED_BY="[Empty name]">Update searches from May 2011 to November 2015</TITLE>
<APPENDIX_BODY MODIFIED="2017-06-06 14:01:45 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="3" ROWS="13">
<TR>
<TH VALIGN="TOP">
<P>Source</P>
<P> </P>
</TH>
<TH VALIGN="TOP">
<P>Search strategy</P>
</TH>
<TH VALIGN="TOP">
<P>Hits retrieved</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>1. ALOIS (www.medicine.ox.ac.uk/alois)</P>
<P>[Last searched for this review on 15 October 2016]</P>
</TD>
<TD VALIGN="TOP">
<P>Keyword search: diabetic OR diabetes OR &#8220;type 2&#8221; OR &#8220;type II&#8221;</P>
</TD>
<TD VALIGN="TOP">
<P>May 2011:</P>
<P>87</P>
<P>Oct 2014: 5</P>
<P>Nov 2015: 9</P>
<P>October 2016: 3</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>2. MEDLINE In-process and other non-indexed citations and MEDLINE 1950-present (Ovid SP)</P>
<P>[Last searched for this review on 15 October 2016]</P>
</TD>
<TD VALIGN="TOP">
<P>1. exp Diabetes Mellitus, Type 2/</P>
<P>2. (diabet* adj2 ("2" or "type II")).ti,ab.</P>
<P>3. (DM2 or NIDDM or IIDM).ti,ab.</P>
<P>4. or/1-3</P>
<P>5. (cognit* or memor* or QOL or "quality of life").ti,ab.</P>
<P>6. 4 and 5</P>
<P>7. randomized controlled trial.pt.</P>
<P>8. controlled clinical trial.pt.</P>
<P>9. randomized.ab.</P>
<P>10. placebo.ab.</P>
<P>11. drug therapy.fs.</P>
<P>12. randomly.ab.</P>
<P>13. trial.ab.</P>
<P>14. groups.ab.</P>
<P>15. or/7-14</P>
<P>16. (animals not (humans and animals)).sh.</P>
<P>17. 15 not 16</P>
<P>18. 6 and 17</P>
<P>19. (2008* or 2009* or 2010* or 2011*).ed.</P>
<P>20. 18 and 19</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>May 2011: 470</P>
<P>Oct 2014: 803</P>
<P>Nov 2015: 294</P>
<P>October 2016: 481</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>3. Embase</P>
<P>1980 to 2011 week 20 (Ovid SP)</P>
<P>[Last searched for this review on 15 October 2016]</P>
</TD>
<TD VALIGN="TOP">
<P>1. exp *non insulin dependent diabetes mellitus/</P>
<P>2. diabetic obesity/</P>
<P>3. (diabet* adj2 ("type II" or diabetic obesity)).ti,ab.</P>
<P>4. (DM2 or NIDDM or IIDM).ti,ab.</P>
<P>5. "diabetes mellitus".ti,ab.</P>
<P>6. or/1-5</P>
<P>7. (cogni* or dement* or alzheimer* or memor* or QOL or "quality of life").ti,ab.</P>
<P>8. 6 and 7</P>
<P>9. clinical trial/</P>
<P>10. double blind procedure/</P>
<P>11. single blind procedure/</P>
<P>12. (random* adj3 (assign* or alloc*)).ti,ab.</P>
<P>13. ((singl* or double* or trebl* or tripl*) and (blind* or mask*)).ti,ab.</P>
<P>14. or/9-13</P>
<P>15. 8 and 14</P>
<P>16. (2008* or 2009* or 2010* or 2011*).em.</P>
<P>17. 15 and 16</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>May 2011: 358</P>
<P>Oct 2014: 417</P>
<P>Nov 2015: 147</P>
<P>October 2016: 260</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>4. PsycINFO</P>
<P>1806 to May week 3 2011 (Ovid SP)</P>
<P>[Last searched for this review on 15 October 2016]</P>
</TD>
<TD VALIGN="TOP">
<P>1. *Diabetes Mellitus/</P>
<P>2. ("type 2" or "type II").ti,ab.</P>
<P>3. 1 and 2</P>
<P>4. (DM2 or NIDDM ir IIDM).ti,ab.</P>
<P>5. ("diabetes mellitus" and "type 2").ti,ab.</P>
<P>6. ("diabetes mellitus" and "type II").ti,ab.</P>
<P>7. ("type 2 diabet*" or "type II diabet*").ti,ab.</P>
<P>8. or/3-7</P>
<P>9. (cogn* or dement* or alzheimer* or QOL or "quality of life").ti,ab.</P>
<P>10. 8 and 9</P>
<P>11. (random* and (alloc* or assign*)).ti,ab.</P>
<P>12. ((doubl* or singl* or trebl* or tripl*) adj2 (blind* or mask*)).ti,ab.</P>
<P>13. randomi?ed.ti,ab.</P>
<P>14. "controlled trial*".ti,ab.</P>
<P>15. placebo*.ti,ab.</P>
<P>16. or/11-15</P>
<P>17. 10 and 16</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>May 2011: 53</P>
<P>Oct 2014: 59</P>
<P>Nov 2015: 13</P>
<P>October 2016: 21</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5. CINAHL (EBSCOhost)</P>
<P>[Last searched for this review on 15 October 2016]</P>
</TD>
<TD VALIGN="TOP">
<P>S1 (MM "Diabetes Mellitus, Non-Insulin-Dependent") </P>
<P>S2 TX DM2 OR NIDDM OR IIDM </P>
<P>S3 TX "diabetes mellitus type 2" </P>
<P>S4 TX "diabetes mellitus type II"</P>
<P>S5 TX "type 2 diabet*" OR "typ II diabet*" </P>
<P>S6 S1 or S2 or S3 or S4 or S5 </P>
<P>S7 TX cogni* OR dement* OR alzheimer* OR memor* OR QOL OR "quality of life"</P>
<P>S8 S6 and S7 </P>
<P>S9 EM 2008 </P>
<P>S10 EM 2009 </P>
<P>S11 EM 2010 </P>
<P>S12 EM 2011 </P>
<P>S13 S9 or S10 or S11 or S12 </P>
<P>S14 S8 and S13 </P>
<P>S15 TX random* alloc*</P>
<P>S16 TX placebo*</P>
<P>S17 (MH "Clinical Trials") OR (MH "Randomized Controlled Trials") </P>
<P>S18 TX trial OR RCT </P>
<P>S19 S15 or S16 or S17 or S18 </P>
<P>S20 S14 and S19 </P>
</TD>
<TD VALIGN="TOP">
<P>May 2011: 119</P>
<P>Oct 2014: 140</P>
<P>Nov 2015: 123</P>
<P>October 2016: 61</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>6. Web of Science (1945 to present); plus conference proceedings</P>
<P>[Last searched for this review on 15 October 2016]</P>
</TD>
<TD VALIGN="TOP">
<P>Topic=(diabet* OR DM2) AND Topic=(cognit* OR dement*) AND Topic=(random* OR trial OR placebo OR "double-blind*" OR RCT) AND Year Published=(2008-2011)</P>
<P>Timespan=All Years.</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>May 2011:367</P>
<P>Oct 2014: 89</P>
<P>Nov 2015: 502</P>
<P>October 2016: 508</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>7. LILACS (BIREME)</P>
<P>[Last searched for this review on 15 October 2016]</P>
</TD>
<TD VALIGN="TOP">
<P>diabet$ [Words] and demen$ OR memor$ OR alzheimer$ OR cogn$ [Words] and random$ OR trial OR placebo OR blind$ OR mask$ [Words]</P>
</TD>
<TD VALIGN="TOP">
<P>May 2011: 17</P>
<P>Oct 2014: 0</P>
<P>Nov 2015: 0</P>
<P>October 2016: 4</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>8. CENTRAL (the Cochrane Library)</P>
<P>[Last searched for this review on 15 October 2016]</P>
</TD>
<TD VALIGN="TOP">
<P>#1 diabet*</P>
<P>#2 MeSH descriptor Diabetes Mellitus, Type 2, this term only</P>
<P>#3 NIDDM OR &#8220;II DM&#8221; OR DM2</P>
<P>#4  #1 OR #2 OR #3</P>
<P>#5 dement* OR alzheim* OR cognit* OR memor*</P>
<P>#6  (#4 AND #5), from 2008 to 2011</P>
</TD>
<TD VALIGN="TOP">
<P>May 2011: 111</P>
<P>Oct 2014: 253</P>
<P>Nov 2015: 153</P>
<P>October 2016: 167</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>9. Clinicaltrials.gov (<A HREF="http://www.clinicaltrials.gov/">www.clinicaltrials.gov</A>)</P>
<P>[Last searched for this review on 15 October 2016]</P>
</TD>
<TD VALIGN="TOP">
<P>cognition OR cognitive OR memory OR dementia OR alzheimers OR alzheimer | Interventional Studies | diabetes OR DMII OR DM2 OR diabetic | Adult, Senior | received from 01/01/2008 to 06/01/2011</P>
</TD>
<TD VALIGN="TOP">
<P>May 2011: 54</P>
<P>Oct 2014: 22</P>
<P>Nov 2015: 6</P>
<P>October 2016: 48</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>10. ICTRP Search Portal (<A HREF="http://apps.who.int/trialsearch">http://apps.who.int/trialsearch</A>) [includes: Australian New Zealand Clinical Trials Registry; ClinicalTrilas.gov; ISRCTN; Chinese Clinical Trial Registry; Clinical Trials Registry &#8211; India; Clinical Research Information Service &#8211; Republic of Korea; German Clinical Trials Register; Iranian Registry of Clinical Trials; Japan Primary Registries Network; Pan African Clinical Trial Registry; Sri Lanka Clinical Trials Registry; The Netherlands National Trial Register]</P>
<P>[Last searched for this review on 15 October 2016]</P>
</TD>
<TD VALIGN="TOP">
<P>#1 Diabetes AND dementia = 4</P>
<P>#2 diabetes AND cognition = 29</P>
<P>#3 diabetes AND memory = 9</P>
</TD>
<TD VALIGN="TOP">
<P>May 2011: 42</P>
<P>Oct 2014: 26</P>
<P>Nov 2015: 24</P>
<P>October 2016: 5</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN="TOP">
<P>TOTAL before de-duplication</P>
</TD>
<TD VALIGN="TOP">
<P>May 2011: 1678</P>
<P>Oct 2014: 1206</P>
<P>Nov 2015: 1271</P>
<P>October 2016: 1558</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN="TOP">
<P>TOTAL after de-dupe and first-assess</P>
</TD>
<TD VALIGN="TOP">
<P>May 2011:43</P>
<P>Oct 2014: 171</P>
<P>Nov 2015: 286</P>
<P>October 2016: 255</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2017-06-03 15:22:16 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2011-06-18 09:58:58 +0100" MODIFIED_BY="[Empty name]">Original search: 2008</TITLE>
<APPENDIX_BODY MODIFIED="2017-06-03 15:22:16 +0100" MODIFIED_BY="[Empty name]">
<P>On 20 January 2008 the following databases were searched:</P>
<P>
<B>CENTRAL (the Cochrane Library)</B>: issue 4/2007<BR/>Search strategy:<BR/>1 DIABETES-MELLITUS-NON-INSULIN-DEPENDENT*:ME<BR/>2 OBESITY-IN-DIABETES*:ME<BR/>3 ((NIDDM or II DM) or DM2)<BR/>4 ((#1 or #2 or #3)<BR/>5 (COGN* or DEMENT* or MEMOR*)<BR/>6 (#4 and #5)</P>
<P>
<B>MEDLINE</B>: 1966-2008/01<BR/>Search strategy:<BR/>1 explode "Diabetes-Mellitus-Type-2"/ all subheadings<BR/>2 diabet* near ("2" or "type II")<BR/>3 DM2 or NIDDM or IIDM<BR/>4 #1 or #2 or #3<BR/>5 cognit* or memor* or QOL or "quality of life"<BR/>6 #4 and #5<BR/>7 (randomized-controlled-trial in PT) or (controlled-trial in PT)<BR/>8 "Randomized-Controlled-Trials"/ all subheadings<BR/>9 random* and (allocat* or assign*)<BR/>10 (doubl* or singl* or trebl* or tripl*) near (blind* or mask*)<BR/>11 placebo*<BR/>12 "Double-Blind-Method" in MIME,MJME<BR/>13 cross-over or crossover<BR/>14 #7 or #8 or #9 or #10 or #11 or #12 or #13<BR/>* 15 #6 and #14 
<BR/>

<BR/>
<B>Embase</B>: 1985-2008/01 week 3<BR/>Search strategy:<BR/>1 "non-insulin-dependent-diabetes-mellitus"/ all subheadings<BR/>2 "diabetic-obesity"/ all subheadings<BR/>3 "diabetes mellitus" and ("type 2" or "type II")<BR/>4 DM2 or NIDDM or IIDM<BR/>5 (typ* "2" or typ* "II") near (diabet* or DM)<BR/>6 "diabetes type 2" or "diabetes type II"<BR/>7 #1 or #2 or #3 or #4 or #5 or #6<BR/>8 cogn* or dement* or alzheimer* or memor* or QOL or "quality of life"<BR/>9 #7 and #8<BR/>10 explode "clinical-trial"/ all subheadings<BR/>11 "double-blind-procedure"/ all subheadings<BR/>12 "single-blind-procedure"/ all subheadings<BR/>13 alloc*<BR/>14 random* and (assign* or alloc*)<BR/>15 (singl* or double* or trebl* or tripl*) and (blind* or mask*)<BR/>16 #10 or #11 or #12 or #13 or #14 or #15<BR/>17 #9 and #16</P>
<P>
<B>PsycINFO</B>: 1872-2008/01 week 2<BR/>search strategy:<BR/>1 "Diabetes-Mellitus" in DE<BR/>2 #1 and ("type 2" or "type II")<BR/>3 DM2 or NIDDM ir IIDM<BR/>4 "diabetes mellitus type 2"<BR/>5 "diabetes mellitus type II"<BR/>6 ("type 2" or "type II") near (diab* or DM)<BR/>7 "diabetes type 2" or "diabetes type II"<BR/>8 #2 or #3 or #4 or #5 or #6 or #7<BR/>9 cogn* or dement* or alzheimer* or QOL or "quality of life"<BR/>10 #8 and #9<BR/>11 random* and (alloc* or assign*)<BR/>12 (doubl* or singl* or trebl* or tripl*) near (blind* or mask*)<BR/>13 randomi?ed<BR/>14 "controlled trial*"<BR/>15 placebo*<BR/>16 #11 or #12 or #13 or #14 or #15<BR/>17 #10 and #16</P>
<P>
<B>CINAHL</B>: 1982-2007/12 week 1<BR/>Search strategy:<BR/>1 "Diabetes-Mellitus-Non-Insulin-Dependent"/ all topical subheadings / all age subheadings<BR/>2 DM2 or NIDDM or IIDM<BR/>3 "diabetes mellitus type 2" or "diabetes mellitus type II"<BR/>4 "diabetes type 2" or "diabetes type II"<BR/>5 ("type 2" or "type II") near (diab* or DM)<BR/>6 #1 or #2 or #3 or #4 or #5<BR/>7 cogn* or dement* or alzheimer* or memor* or QOL or "quality of life"<BR/>8 #6 and #7<BR/>9 random* near (assign* or alloc*)<BR/>10 randomi?ed<BR/>11(singl* or doubl* or trebl* or tripl*) near (blind* or mask*)<BR/>12 placebo*<BR/>13 "controlled trial"<BR/>14 #9 or #10 or #11 or #12 or #13<BR/>15 #8 and #14</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2017-06-03 15:25:40 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2017-05-05 12:08:39 +0100" MODIFIED_BY="[Empty name]">Hierarchy used to select from instruments measuring the same outcome</TITLE>
<APPENDIX_BODY MODIFIED="2017-06-03 15:25:40 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Hierarchy used to select from instruments measuring the same outcome</B>
</P>
<P>For each outcome described in the protocol, we will apply an outcome specific hierarchy.</P>
<P>For example, if a given study reports 3 different instruments to measure executive function, we will apply the hierarchy to choose the single instrument of which we would extract / pool outcome data. For example, if a study reports data on Stroop Color and Word Test, Raven&#8217;s Progressive Matrices and the Hong Kong list learning test, we will only extract the data from the Stroop Color and Word Test, which is highest on our hierarchy on executive function. Validated versions of a test in alternative languages will be treated as the same test.</P>
<P>We recognise that the outcomes of interest may be measured with multiple other instruments. Instruments which do not appear on the list were not identified more than once in the sample papers. Data from other instruments will be extracted if no instrument from the list is used in a study. If a study uses more than one such instrument, then we have no a priori preference and reviewers&#8217; judgment will be used.</P>
<P>
<B>Primary outcome: Global cognitive function</B>
</P>
<P>Explanation: the hierarchy is based on the frequencies found below.</P>
<TABLE COLS="3" ROWS="6">
<TR>
<TD VALIGN="TOP">
<P>
<B>Hierarchy</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Instruments</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Frequency of use in sample papers</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>1</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>MMSE or modified MMSE</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>24</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>2</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>modified Telephone Interview for Cognitive Status (TICS-m)</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>8</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>3</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>ADAS-Cog</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>4</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>4</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Clinical Dementia Rating (CDR) or Clinical Dementia Rating sum of boxes (CDR-SOB)</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>5</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Hasegawa&#8217;s dementia scale (HDS-R) / modified HDS</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
</TR>
</TABLE>
<P/>
<P>
<B>Secondary outcome: Executive function</B>
</P>
<TABLE COLS="3" ROWS="7">
<TR>
<TD>
<P>
<B>Hierarchy</B>
</P>
</TD>
<TD>
<P>
<B>Instruments </B>
</P>
</TD>
<TD>
<P>
<B>Frequency of use in sample papers </B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>1</B>
</P>
</TD>
<TD>
<P>Stroop Color and Word Test, referred to as:· Modified Stroop test· Victoria version of Stroop Test· California Older Adult Stroop Test (COAST)· Stroop Color and Word Test</P>
</TD>
<TD>
<P>24</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>2</B>
</P>
</TD>
<TD>
<P>Trail Making Test B</P>
</TD>
<TD>
<P>22</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>3</B>
</P>
</TD>
<TD>
<P>WAIS-III Similarities task (WAIS = Wechsler Adult Intelligence Scale)</P>
</TD>
<TD>
<P>4</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>4</B>
</P>
</TD>
<TD>
<P>WAIS-III Matrices or Matrix Reasoning task</P>
</TD>
<TD>
<P>3</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>4</B>
</P>
</TD>
<TD>
<P>Task Switching</P>
</TD>
<TD>
<P>3</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>5</B>
</P>
</TD>
<TD>
<P>Raven&#8217;s Progressive Matrices</P>
</TD>
<TD>
<P>2</P>
</TD>
</TR>
</TABLE>
<P/>
<P>
<B>Secondary outcome: Speed</B>
</P>
<TABLE COLS="3" ROWS="11">
<TR>
<TD>
<P>
<B>Hierarchy</B>
</P>
</TD>
<TD>
<P>
<B>Instruments </B>
</P>
</TD>
<TD>
<P>
<B>Frequency of use in sample papers </B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>1</P>
</TD>
<TD>
<P>Trail Making Test, A</P>
</TD>
<TD>
<P>20</P>
</TD>
</TR>
<TR>
<TD>
<P>2</P>
</TD>
<TD>
<P>Digit symbol substitution test (DSST)</P>
</TD>
<TD>
<P>8</P>
</TD>
</TR>
<TR>
<TD>
<P>3</P>
</TD>
<TD>
<P>WAIS-R referred to as (for example):· the Digit Symbol Subtest of the WAIS-R· Digit Symbol and Similarities in Wechsler Adult Intelligence Scale 3rd edition· composite score of the Digit-Symbol Coding subtest of the WAIS-III· Symbol Search subtest of WAIS-III</P>
</TD>
<TD>
<P>5</P>
</TD>
</TR>
<TR>
<TD>
<P>4</P>
</TD>
<TD>
<P>Symbol Digit Modalities Test (SDMT)</P>
</TD>
<TD>
<P>4</P>
</TD>
</TR>
<TR>
<TD>
<P>5</P>
</TD>
<TD>
<P>Choice reaction time</P>
</TD>
<TD>
<P>3</P>
</TD>
</TR>
<TR>
<TD>
<P>5</P>
</TD>
<TD>
<P>Cancellation test</P>
</TD>
<TD>
<P>3</P>
</TD>
</TR>
<TR>
<TD>
<P>5</P>
</TD>
<TD>
<P>Finger Tapping Test</P>
</TD>
<TD>
<P>3</P>
</TD>
</TR>
<TR>
<TD>
<P>6</P>
</TD>
<TD>
<P>2-choice reaction time test</P>
</TD>
<TD>
<P>2</P>
</TD>
</TR>
<TR>
<TD>
<P>6</P>
</TD>
<TD>
<P>a subtest of the Leistungs-Prüf-System 50</P>
</TD>
<TD>
<P>2</P>
</TD>
</TR>
<TR>
<TD>
<P>6</P>
</TD>
<TD>
<P>Simple Reaction Time</P>
</TD>
<TD>
<P>2</P>
</TD>
</TR>
</TABLE>
<P/>
<P>
<B>Secondary outcome: Episodic memory</B>
</P>
<P>
<B>If</B> instruments occurred with the same frequency, then we preferred verbal over visual memory tests. If an instrument includes several episodic memory outcomes, then we preferred recall over recognition and delayed over immediate recall.</P>
<TABLE COLS="3" ROWS="13">
<TR>
<TD>
<P>
<B>Hierarchy</B>
</P>
</TD>
<TD>
<P>
<B>Instruments </B>
</P>
</TD>
<TD>
<P>
<B>Frequency of use in sample papers </B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>1</B>
</P>
</TD>
<TD>
<P>Rey Auditory Verbal Learning Test (RAVLT)</P>
</TD>
<TD>
<P>9</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>4</B>
</P>
</TD>
<TD>
<P>Logical Memory subtest of the Wechsler Memory Scale 3rd Edition (WMS-III)</P>
</TD>
<TD>
<P>5</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>5</B>
</P>
</TD>
<TD>
<P>Visual Reproduction II from Wechsler Memory Scale&#8211;Revised (WMS-R)</P>
</TD>
<TD>
<P>4</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>5</B>
</P>
</TD>
<TD>
<P>Benton Visual Retention Test-Revised 5th Edition (BVRT-R)</P>
</TD>
<TD>
<P>4</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>6</B>
</P>
</TD>
<TD>
<P>delayed recall of the TICS 10-word list</P>
</TD>
<TD>
<P>3</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>6</B>
</P>
</TD>
<TD>
<P>California Verbal Learning Test</P>
</TD>
<TD>
<P>3</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>6</B>
</P>
</TD>
<TD>
<P>Visual Reproduction I from Wechsler Memory Scale&#8211;Revised (WMS-R)</P>
</TD>
<TD>
<P>3</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>7</B>
</P>
</TD>
<TD>
<P>RivermeadBehavioural Memory Test (RBMT)</P>
</TD>
<TD>
<P>2</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>7</B>
</P>
</TD>
<TD>
<P>Hopkins Verbal Learning Test</P>
</TD>
<TD>
<P>2</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>7</B>
</P>
</TD>
<TD>
<P>Buschke Selective Reminding test</P>
</TD>
<TD>
<P>2</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>7</B>
</P>
</TD>
<TD>
<P>Paragraph Recall Test</P>
</TD>
<TD>
<P>2</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>7</B>
</P>
</TD>
<TD>
<P>Rey Complex Figure Test (RCFT )</P>
</TD>
<TD>
<P>2</P>
</TD>
</TR>
</TABLE>
<P/>
<P>
<B>Secondary outcome: Working memory</B>
</P>
<TABLE COLS="3" ROWS="7">
<TR>
<TD>
<P>
<B>Hierarchy</B>
</P>
</TD>
<TD>
<P>
<B>Instruments </B>
</P>
</TD>
<TD>
<P>
<B>Frequency of use in sample papers </B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>1*</P>
</TD>
<TD>
<P>Digit Span Test of WAIS-III (composite score calculated as difference betweenForward and Backward)</P>
</TD>
<TD>
<P>2</P>
</TD>
</TR>
<TR>
<TD>
<P>2</P>
</TD>
<TD>
<P>Digit Span Test of WAIS-III (Backward Component)</P>
</TD>
<TD>
<P>16</P>
</TD>
</TR>
<TR>
<TD>
<P>3</P>
</TD>
<TD>
<P>Digit Span Test of WAIS-III (Forward Component)</P>
</TD>
<TD>
<P>14</P>
</TD>
</TR>
<TR>
<TD>
<P>4</P>
</TD>
<TD>
<P>&#8220;d2&#8221; - Test of Attention</P>
</TD>
<TD>
<P>2</P>
</TD>
</TR>
<TR>
<TD>
<P>4</P>
</TD>
<TD>
<P>Self Ordered Pointing Test (SOPT)</P>
</TD>
<TD>
<P>2</P>
</TD>
</TR>
<TR>
<TD>
<P>4</P>
</TD>
<TD>
<P>Letter Number Sequencing (LNS) test</P>
</TD>
<TD>
<P>2</P>
</TD>
</TR>
</TABLE>
<P>* The WAIS &#8211;III composite instrument is preferred over the single components</P>
<P>
<B>Secondary outcome: Verbal fluency</B>
</P>
<TABLE COLS="3" ROWS="3">
<TR>
<TD>
<P>
<B>Hierarchy</B>
</P>
</TD>
<TD>
<P>
<B>Instruments </B>
</P>
</TD>
<TD>
<P>
<B>Frequency of use in sample papers </B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>1</B>
</P>
</TD>
<TD>
<P>Verbal fluency test</P>
</TD>
<TD>
<P>27</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>2</B>
</P>
</TD>
<TD>
<P>COWAT (Controlled Oral Word Association)</P>
</TD>
<TD>
<P>3</P>
</TD>
</TR>
</TABLE>
<P/>
<P>
<B>Secondary outcome: Semantic memory</B>
</P>
<TABLE COLS="3" ROWS="2">
<TR>
<TD>
<P>
<B>Hierarchy</B>
</P>
</TD>
<TD>
<P>
<B>Instruments </B>
</P>
</TD>
<TD>
<P>
<B>Frequency of use in sample papers </B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>1</P>
</TD>
<TD>
<P>Boston naming Test</P>
</TD>
<TD>
<P>7</P>
</TD>
</TR>
</TABLE>
<P/>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="AFF_z1411101445529436440705715292412_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="z1411101445529436440705715292412">
<ADDRESS>
<DEPARTMENT>Faculty of Medicine and Dentistry</DEPARTMENT>
<ORGANISATION>Universidad de Antofagasta</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Antofagasta</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="CL">Chile</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="AFF_z1411101445529436440705715292412_2" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="z1411101445529436440705715292412">
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Servicio de Salud Antofagasta</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Antofagasta</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="CL">Chile</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;4 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;11 studies included:&lt;/p&gt;&lt;p&gt;7 studies included in qualitative synthesis&lt;/p&gt;&lt;p&gt;4 studies ongoing&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;34 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;844 records screened by author team&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;Total after first assess by CDCIG info specialists&lt;/p&gt;&lt;p&gt;2008: 89 [did not perform one]&lt;/p&gt;&lt;p&gt;2011: 43&lt;/p&gt;&lt;p&gt;2014: 171&lt;/p&gt;&lt;p&gt;2015: 286&lt;/p&gt;&lt;p&gt;2016: 255 &lt;/p&gt;&lt;p&gt;TOTAL: 844&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;Total after duplicates removed:&lt;/p&gt;&lt;p&gt;2008: 89&lt;/p&gt;&lt;p&gt;2011: 1290&lt;/p&gt;&lt;p&gt;2014: 1206&lt;/p&gt;&lt;p&gt;2015: 1110&lt;/p&gt;&lt;p&gt;2016: 1183&lt;/p&gt;&lt;p&gt;TOTAL: 4878&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;2008: 181&lt;/p&gt;&lt;p&gt;2011: 1678&lt;/p&gt;&lt;p&gt;2014: 1814&lt;/p&gt;&lt;p&gt;2015: 1271&lt;/p&gt;&lt;p&gt;2016: 1558&lt;/p&gt;&lt;p&gt;TOTAL: 4944&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;1 additional records identified through other sources&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;810 records excluded by author team at title and abstract stage&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;23 full-text articles excluded, with reasons; &lt;span&gt;12 wrong intervention, 5 wrong outcome, 3 wrong design, 2 wrong participants, wrong setting 1&lt;/span&gt;&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>